MIME-Version: 1.0
Content-Type: multipart/related; boundary="----=_NextPart_01D75BA1.F8BC9610"

This document is a Single File Web Page, also known as a Web Archive file.  If you are seeing this message, your browser or editor doesn't support Web Archive files.  Please download a browser that supports Web Archive.

------=_NextPart_01D75BA1.F8BC9610
Content-Location: file:///C:/C467A08E/Ovaleap_clean.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="windows-1252"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:dt=3D"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-125=
2">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 15">
<meta name=3DOriginator content=3D"Microsoft Word 15">
<link rel=3DFile-List href=3D"Ovaleap_clean_files/filelist.xml">
<title>Ovaleap, INN-follitropin alfa</title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Subject>EPAR</o:Subject>
  <o:Author>CHMP</o:Author>
  <o:Keywords>Ovaleap, INN-follitropin alfa</o:Keywords>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>Manish Kumar</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>0</o:TotalTime>
  <o:LastPrinted>2013-03-18T07:36:00Z</o:LastPrinted>
  <o:Created>2021-06-07T08:05:00Z</o:Created>
  <o:LastSaved>2021-06-07T08:05:00Z</o:LastSaved>
  <o:Pages>1</o:Pages>
  <o:Words>10604</o:Words>
  <o:Characters>60443</o:Characters>
  <o:Company>PharmaLex GmbH</o:Company>
  <o:Lines>503</o:Lines>
  <o:Paragraphs>141</o:Paragraphs>
  <o:CharactersWithSpaces>70906</o:CharactersWithSpaces>
  <o:Version>16.00</o:Version>
 </o:DocumentProperties>
 <o:CustomDocumentProperties>
  <o:DM_Status dt:dt=3D"string"></o:DM_Status>
  <o:DM_Authors dt:dt=3D"string"></o:DM_Authors>
  <o:DM_Keywords dt:dt=3D"string"></o:DM_Keywords>
  <o:DM_Subject dt:dt=3D"string">General-EMA/423415/2010</o:DM_Subject>
  <o:DM_Title dt:dt=3D"string"></o:DM_Title>
  <o:DM_Language dt:dt=3D"string"></o:DM_Language>
  <o:DM_Owner dt:dt=3D"string">Espinasse Claire</o:DM_Owner>
  <o:DM_emea_cc dt:dt=3D"string"></o:DM_emea_cc>
  <o:DM_emea_message_subject dt:dt=3D"string"></o:DM_emea_message_subject>
  <o:DM_emea_doc_number dt:dt=3D"string">423415</o:DM_emea_doc_number>
  <o:DM_emea_received_date dt:dt=3D"string">nulldate</o:DM_emea_received_da=
te>
  <o:DM_emea_resp_body dt:dt=3D"string"></o:DM_emea_resp_body>
  <o:DM_emea_revision_label dt:dt=3D"string"></o:DM_emea_revision_label>
  <o:DM_emea_to dt:dt=3D"string"></o:DM_emea_to>
  <o:DM_emea_bcc dt:dt=3D"string"></o:DM_emea_bcc>
  <o:DM_emea_doc_category dt:dt=3D"string">General</o:DM_emea_doc_category>
  <o:DM_emea_from dt:dt=3D"string"></o:DM_emea_from>
  <o:DM_emea_internal_label dt:dt=3D"string">EMA</o:DM_emea_internal_label>
  <o:DM_emea_legal_date dt:dt=3D"string">nulldate</o:DM_emea_legal_date>
  <o:DM_emea_year dt:dt=3D"string">2010</o:DM_emea_year>
  <o:DM_emea_sent_date dt:dt=3D"string">nulldate</o:DM_emea_sent_date>
  <o:DM_emea_doc_lang dt:dt=3D"string"></o:DM_emea_doc_lang>
  <o:DM_emea_meeting_status dt:dt=3D"string"></o:DM_emea_meeting_status>
  <o:DM_emea_meeting_action dt:dt=3D"string"></o:DM_emea_meeting_action>
  <o:DM_emea_meeting_hyperlink dt:dt=3D"string"></o:DM_emea_meeting_hyperli=
nk>
  <o:DM_emea_meeting_title dt:dt=3D"string"></o:DM_emea_meeting_title>
  <o:DM_emea_meeting_ref dt:dt=3D"string"></o:DM_emea_meeting_ref>
  <o:DM_emea_meeting_flags dt:dt=3D"string"></o:DM_emea_meeting_flags>
  <o:DM_Version dt:dt=3D"string">CURRENT,1.1</o:DM_Version>
  <o:DM_Name dt:dt=3D"string">Hqrdtemplatecleanen</o:DM_Name>
  <o:DM_Creation_Date dt:dt=3D"string">13/07/2011 15:43:34</o:DM_Creation_D=
ate>
  <o:DM_Modify_Date dt:dt=3D"string">13/07/2011 15:43:34</o:DM_Modify_Date>
  <o:DM_Creator_Name dt:dt=3D"string">Espinasse Claire</o:DM_Creator_Name>
  <o:DM_Modifier_Name dt:dt=3D"string">Espinasse Claire</o:DM_Modifier_Name>
  <o:DM_Type dt:dt=3D"string">emea_document</o:DM_Type>
  <o:DM_DocRefId dt:dt=3D"string">EMA/555113/2011</o:DM_DocRefId>
  <o:DM_Category dt:dt=3D"string">Product Information</o:DM_Category>
  <o:DM_Path dt:dt=3D"string">/13. Projects/02-004-00014-PIM Implementation=
/Implementation/DES 2.8 Construction/QRD Template</o:DM_Path>
  <o:DM_emea_doc_ref_id dt:dt=3D"string">EMA/555113/2011</o:DM_emea_doc_ref=
_id>
  <o:DM_Modifer_Name dt:dt=3D"string">Espinasse Claire</o:DM_Modifer_Name>
  <o:DM_Modified_Date dt:dt=3D"string">13/07/2011 15:43:34</o:DM_Modified_D=
ate>
  <o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_Enabled dt:dt=3D"strin=
g">true</o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_Enabled>
  <o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_SetDate dt:dt=3D"strin=
g">2021-05-18T11:50:43Z</o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_=
SetDate>
  <o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_Method dt:dt=3D"string=
">Standard</o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_Method>
  <o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_Name dt:dt=3D"string">=
0eea11ca-d417-4147-80ed-01a58412c458</o:MSIP_Label_0eea11ca-d417-4147-80ed-=
01a58412c458_Name>
  <o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_SiteId dt:dt=3D"string=
">bc9dc15c-61bc-4f03-b60b-e5b6d8922839</o:MSIP_Label_0eea11ca-d417-4147-80e=
d-01a58412c458_SiteId>
  <o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_ActionId dt:dt=3D"stri=
ng">cd646b8d-4426-4d72-8ee3-dd04a1a3bc36</o:MSIP_Label_0eea11ca-d417-4147-8=
0ed-01a58412c458_ActionId>
  <o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_ContentBits dt:dt=3D"s=
tring">2</o:MSIP_Label_0eea11ca-d417-4147-80ed-01a58412c458_ContentBits>
  <o:ContentTypeId dt:dt=3D"string">0x010100726F91DD1AE57B44B1BCEB7F1056F5D=
0</o:ContentTypeId>
 </o:CustomDocumentProperties>
 <o:OfficeDocumentSettings>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=3DdataStoreItem href=3D"Ovaleap_clean_files/item0001.xml"
target=3D"Ovaleap_clean_files/props002.xml">
<link rel=3DdataStoreItem href=3D"Ovaleap_clean_files/item0003.xml"
target=3D"Ovaleap_clean_files/props004.xml">
<link rel=3DdataStoreItem href=3D"Ovaleap_clean_files/item0005.xml"
target=3D"Ovaleap_clean_files/props006.xml">
<link rel=3DthemeData href=3D"Ovaleap_clean_files/themedata.thmx">
<link rel=3DcolorSchemeMapping href=3D"Ovaleap_clean_files/colorschememappi=
ng.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:HyphenationZone>21</w:HyphenationZone>
  <w:DisplayHorizontalDrawingGridEvery>0</w:DisplayHorizontalDrawingGridEve=
ry>
  <w:DisplayVerticalDrawingGridEvery>0</w:DisplayVerticalDrawingGridEvery>
  <w:UseMarginsForDrawingGridOrigin/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-GB</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>AR-SA</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <w:DocumentVariables>
   <w:Registered>-1</w:Registered>
   <w:Version>0</w:Version>
  </w:DocumentVariables>
  <m:mathPr>
   <m:mathFont m:val=3D"Cambria Math"/>
   <m:brkBin m:val=3D"before"/>
   <m:brkBinSub m:val=3D"&#45;-"/>
   <m:smallFrac m:val=3D"off"/>
   <m:dispDef/>
   <m:lMargin m:val=3D"0"/>
   <m:rMargin m:val=3D"0"/>
   <m:defJc m:val=3D"centerGroup"/>
   <m:wrapIndent m:val=3D"1440"/>
   <m:intLim m:val=3D"subSup"/>
   <m:naryLim m:val=3D"undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState=3D"false" DefUnhideWhenUsed=3D"false"
  DefSemiHidden=3D"false" DefQFormat=3D"false" LatentStyleCount=3D"376">
  <w:LsdException Locked=3D"false" QFormat=3D"true" Name=3D"Normal"/>
  <w:LsdException Locked=3D"false" QFormat=3D"true" Name=3D"heading 1"/>
  <w:LsdException Locked=3D"false" QFormat=3D"true" Name=3D"heading 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   QFormat=3D"true" Name=3D"heading 3"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   QFormat=3D"true" Name=3D"heading 4"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   QFormat=3D"true" Name=3D"heading 5"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   QFormat=3D"true" Name=3D"heading 6"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   QFormat=3D"true" Name=3D"heading 7"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   QFormat=3D"true" Name=3D"heading 8"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   QFormat=3D"true" Name=3D"heading 9"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"index 1"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"index 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"index 3"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"index 4"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"index 5"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"index 6"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"index 7"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"index 8"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"index 9"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"toc 1"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"toc 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"toc 3"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"toc 4"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"toc 5"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"toc 6"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"toc 7"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"toc 8"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"toc 9"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Normal Indent"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"footnote text"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"annotation text"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"header"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"footer"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"index heading"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   QFormat=3D"true" Name=3D"caption"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"table of figures"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"envelope address"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"envelope return"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"footnote reference"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"annotation reference"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"line number"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"page number"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"endnote reference"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"endnote text"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"table of authorities"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"toa heading"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"List"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"List 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"List 3"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"List 4"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"List 5"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"List Bullet 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"List Bullet 3"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"List Bullet 4"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"List Bullet 5"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"List Number 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"List Number 3"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"List Number 4"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"List Number 5"/>
  <w:LsdException Locked=3D"false" QFormat=3D"true" Name=3D"Title"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Closing"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Signature"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" SemiHidden=3D"true"
   UnhideWhenUsed=3D"true" Name=3D"Default Paragraph Font"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Body Text"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Body Text Indent"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"List Continue"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"List Continue 2"/>
  <w:LsdException Locked=3D"false" QFormat=3D"true" Name=3D"Subtitle"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Salutation"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Date"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Body Text First Indent"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Body Text First Indent 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Note Heading"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Body Text 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Body Text 3"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Body Text Indent 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Body Text Indent 3"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Block Text"/>
  <w:LsdException Locked=3D"false" Priority=3D"99" SemiHidden=3D"true"
   UnhideWhenUsed=3D"true" Name=3D"Hyperlink"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"FollowedHyperlink"/>
  <w:LsdException Locked=3D"false" QFormat=3D"true" Name=3D"Strong"/>
  <w:LsdException Locked=3D"false" QFormat=3D"true" Name=3D"Emphasis"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Document Map"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Plain Text"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"E-mail Signature"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"HTML Top of Form"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"HTML Bottom of Form"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Normal (Web)"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"HTML Acronym"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"HTML Address"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"HTML Cite"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"HTML Code"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"HTML Definition"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"HTML Keyboard"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"HTML Preformatted"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"HTML Sample"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"HTML Typewriter"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"HTML Variable"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Normal Table"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"annotation subject"/>
  <w:LsdException Locked=3D"false" Priority=3D"99" SemiHidden=3D"true"
   UnhideWhenUsed=3D"true" Name=3D"No List"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Outline List 1"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Outline List 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Outline List 3"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Simple 1"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Simple 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Simple 3"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Classic 1"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Classic 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Classic 3"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Classic 4"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Colorful 1"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Colorful 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Colorful 3"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Columns 1"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Columns 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Columns 3"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Columns 4"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Columns 5"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Grid 1"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Grid 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Grid 3"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Grid 4"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Grid 5"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Grid 6"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Grid 7"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Grid 8"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table List 1"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table List 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table List 3"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table List 4"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table List 5"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table List 6"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table List 7"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table List 8"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table 3D effects 1"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table 3D effects 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table 3D effects 3"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Contemporary"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Elegant"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Professional"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Subtle 1"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Subtle 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Web 1"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Web 2"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Web 3"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Balloon Text"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"true" UnhideWhenUsed=3D"tr=
ue"
   Name=3D"Table Theme"/>
  <w:LsdException Locked=3D"false" Priority=3D"99" SemiHidden=3D"true"
   Name=3D"Placeholder Text"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" QFormat=3D"true" Name=3D"=
No Spacing"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"99" SemiHidden=3D"true" Name=
=3D"Revision"/>
  <w:LsdException Locked=3D"false" Priority=3D"34" QFormat=3D"true"
   Name=3D"List Paragraph"/>
  <w:LsdException Locked=3D"false" Priority=3D"29" QFormat=3D"true" Name=3D=
"Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"30" QFormat=3D"true"
   Name=3D"Intense Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"19" QFormat=3D"true"
   Name=3D"Subtle Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"21" QFormat=3D"true"
   Name=3D"Intense Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"31" QFormat=3D"true"
   Name=3D"Subtle Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"32" QFormat=3D"true"
   Name=3D"Intense Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"33" QFormat=3D"true" Name=3D=
"Book Title"/>
  <w:LsdException Locked=3D"false" Priority=3D"37" SemiHidden=3D"true"
   UnhideWhenUsed=3D"true" Name=3D"Bibliography"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" SemiHidden=3D"true"
   UnhideWhenUsed=3D"true" QFormat=3D"true" Name=3D"TOC Heading"/>
  <w:LsdException Locked=3D"false" Priority=3D"41" Name=3D"Plain Table 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"42" Name=3D"Plain Table 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"43" Name=3D"Plain Table 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"44" Name=3D"Plain Table 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"45" Name=3D"Plain Table 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"40" Name=3D"Grid Table Light=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"46" Name=3D"Grid Table 1 Lig=
ht"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"Grid Table 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"Grid Table 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"Grid Table 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"Grid Table 5 Dar=
k"/>
  <w:LsdException Locked=3D"false" Priority=3D"51" Name=3D"Grid Table 6 Col=
orful"/>
  <w:LsdException Locked=3D"false" Priority=3D"52" Name=3D"Grid Table 7 Col=
orful"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"Grid Table 1 Light Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"Grid Table 2 Acc=
ent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"Grid Table 3 Acc=
ent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"Grid Table 4 Acc=
ent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"Grid Table 5 Dar=
k Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"Grid Table 6 Colorful Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"Grid Table 7 Colorful Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"Grid Table 1 Light Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"Grid Table 2 Acc=
ent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"Grid Table 3 Acc=
ent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"Grid Table 4 Acc=
ent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"Grid Table 5 Dar=
k Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"Grid Table 6 Colorful Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"Grid Table 7 Colorful Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"Grid Table 1 Light Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"Grid Table 2 Acc=
ent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"Grid Table 3 Acc=
ent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"Grid Table 4 Acc=
ent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"Grid Table 5 Dar=
k Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"Grid Table 6 Colorful Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"Grid Table 7 Colorful Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"Grid Table 1 Light Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"Grid Table 2 Acc=
ent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"Grid Table 3 Acc=
ent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"Grid Table 4 Acc=
ent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"Grid Table 5 Dar=
k Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"Grid Table 6 Colorful Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"Grid Table 7 Colorful Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"Grid Table 1 Light Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"Grid Table 2 Acc=
ent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"Grid Table 3 Acc=
ent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"Grid Table 4 Acc=
ent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"Grid Table 5 Dar=
k Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"Grid Table 6 Colorful Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"Grid Table 7 Colorful Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"Grid Table 1 Light Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"Grid Table 2 Acc=
ent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"Grid Table 3 Acc=
ent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"Grid Table 4 Acc=
ent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"Grid Table 5 Dar=
k Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"Grid Table 6 Colorful Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"Grid Table 7 Colorful Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"46" Name=3D"List Table 1 Lig=
ht"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"List Table 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"List Table 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"List Table 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"List Table 5 Dar=
k"/>
  <w:LsdException Locked=3D"false" Priority=3D"51" Name=3D"List Table 6 Col=
orful"/>
  <w:LsdException Locked=3D"false" Priority=3D"52" Name=3D"List Table 7 Col=
orful"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"List Table 1 Light Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"List Table 2 Acc=
ent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"List Table 3 Acc=
ent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"List Table 4 Acc=
ent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"List Table 5 Dar=
k Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"List Table 6 Colorful Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"List Table 7 Colorful Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"List Table 1 Light Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"List Table 2 Acc=
ent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"List Table 3 Acc=
ent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"List Table 4 Acc=
ent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"List Table 5 Dar=
k Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"List Table 6 Colorful Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"List Table 7 Colorful Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"List Table 1 Light Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"List Table 2 Acc=
ent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"List Table 3 Acc=
ent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"List Table 4 Acc=
ent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"List Table 5 Dar=
k Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"List Table 6 Colorful Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"List Table 7 Colorful Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"List Table 1 Light Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"List Table 2 Acc=
ent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"List Table 3 Acc=
ent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"List Table 4 Acc=
ent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"List Table 5 Dar=
k Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"List Table 6 Colorful Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"List Table 7 Colorful Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"List Table 1 Light Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"List Table 2 Acc=
ent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"List Table 3 Acc=
ent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"List Table 4 Acc=
ent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"List Table 5 Dar=
k Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"List Table 6 Colorful Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"List Table 7 Colorful Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"46"
   Name=3D"List Table 1 Light Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"47" Name=3D"List Table 2 Acc=
ent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"48" Name=3D"List Table 3 Acc=
ent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"49" Name=3D"List Table 4 Acc=
ent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"50" Name=3D"List Table 5 Dar=
k Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"51"
   Name=3D"List Table 6 Colorful Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"52"
   Name=3D"List Table 7 Colorful Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"99" SemiHidden=3D"true"
   UnhideWhenUsed=3D"true" Name=3D"Mention"/>
  <w:LsdException Locked=3D"false" Priority=3D"99" SemiHidden=3D"true"
   UnhideWhenUsed=3D"true" Name=3D"Smart Hyperlink"/>
  <w:LsdException Locked=3D"false" Priority=3D"99" SemiHidden=3D"true"
   UnhideWhenUsed=3D"true" Name=3D"Hashtag"/>
  <w:LsdException Locked=3D"false" Priority=3D"99" SemiHidden=3D"true"
   UnhideWhenUsed=3D"true" Name=3D"Unresolved Mention"/>
  <w:LsdException Locked=3D"false" Priority=3D"99" SemiHidden=3D"true"
   UnhideWhenUsed=3D"true" Name=3D"Smart Link"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;
	mso-font-alt:"\FF2D\FF33 \660E\671D";
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-536870145 1791491579 134217746 0 131231 0;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:\5B8B\4F53;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 680460288 22 0 262145 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536869121 1107305727 33554432 0 415 0;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1610610945 1073750107 16 0 415 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520081665 -1073717157 41 0 66047 0;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536869121 1107305727 33554432 0 415 0;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-alt:"Times New Roman";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 680460288 22 0 262145 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;
	mso-font-charset:128;
	mso-generic-font-family:modern;
	mso-font-pitch:fixed;
	mso-font-signature:-536870145 1791491579 134217746 0 131231 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
h1
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 1 Char";
	mso-style-next:Normal;
	margin:0in;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	tab-stops:.5in;
	font-size:14.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Arial",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-font-kerning:0pt;
	mso-ansi-language:X-NONE;
	mso-fareast-language:X-NONE;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
h2
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	tab-stops:28.35pt;
	font-size:14.0pt;
	font-family:"Arial",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-weight:bold;
	font-style:italic;}
h3
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	tab-stops:28.35pt;
	font-size:13.0pt;
	font-family:"Arial",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-weight:bold;}
h4
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:4;
	tab-stops:28.35pt;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-weight:bold;}
h5
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:5;
	tab-stops:28.35pt;
	font-size:13.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-weight:bold;
	font-style:italic;}
h6
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:6;
	tab-stops:28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:7;
	tab-stops:28.35pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:8;
	tab-stops:28.35pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:9;
	tab-stops:28.35pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{mso-style-update:auto;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:35.4pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-link:"Comment Text Char";
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-unhide:no;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt center 207.65pt right 415.3pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-unhide:no;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt center 3.15in right 415.3pt;
	font-size:8.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Arial",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	mso-no-proof:yes;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:"Index 1";
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Arial",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-next:Normal;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.05pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	mso-element:frame;
	mso-element-frame-width:3.0in;
	mso-element-frame-height:1.5in;
	mso-element-frame-hspace:7.05pt;
	mso-element-wrap:auto;
	mso-element-anchor-horizontal:page;
	mso-element-left:center;
	mso-element-top:bottom;
	mso-height-rule:exactly;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{mso-style-unhide:no;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
span.MsoCommentReference
	{mso-style-unhide:no;
	mso-style-parent:"";
	mso-ansi-font-size:8.0pt;
	mso-bidi-font-size:8.0pt;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToa, li.MsoToa, div.MsoToa
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-parent:"";
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:24.0pt 48.0pt 1.0in 96.0pt 120.0pt 2.0in 168.0pt 192.0pt 3.0in;
	font-size:10.0pt;
	font-family:"Courier New";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l9 level1 lfo15;
	tab-stops:list .25in left 28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l8 level1 lfo20;
	tab-stops:list .25in left 28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoList2, li.MsoList2, div.MsoList2
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoList3, li.MsoList3, div.MsoList3
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoList4, li.MsoList4, div.MsoList4
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoList5, li.MsoList5, div.MsoList5
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l7 level1 lfo16;
	tab-stops:28.35pt list 32.15pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l6 level1 lfo17;
	tab-stops:28.35pt list 46.3pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l5 level1 lfo18;
	tab-stops:28.35pt list 60.45pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l4 level1 lfo19;
	tab-stops:28.35pt list 74.6pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l3 level1 lfo21;
	tab-stops:28.35pt list 32.15pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l2 level1 lfo22;
	tab-stops:28.35pt list 46.3pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l1 level1 lfo23;
	tab-stops:28.35pt list 60.45pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	mso-pagination:widow-orphan;
	mso-list:l0 level1 lfo24;
	tab-stops:28.35pt list 74.6pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	mso-pagination:widow-orphan;
	mso-outline-level:1;
	tab-stops:28.35pt;
	font-size:16.0pt;
	font-family:"Arial",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-font-kerning:14.0pt;
	mso-ansi-language:EN-GB;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-unhide:no;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	color:green;
	mso-ansi-language:EN-GB;
	font-style:italic;
	mso-bidi-font-style:normal;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	background:#CCCCCC;
	mso-shading:windowtext;
	mso-pattern:gray-20 auto;
	border:none;
	mso-border-alt:solid windowtext .75pt;
	padding:0in;
	mso-padding-alt:1.0pt 1.0pt 1.0pt 1.0pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	mso-pagination:widow-orphan;
	mso-outline-level:2;
	tab-stops:28.35pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-unhide:no;
	mso-style-next:Normal;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-unhide:no;
	mso-style-next:Normal;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIn=
dent
	{mso-style-unhide:no;
	mso-style-parent:"Body Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirst=
Indent2
	{mso-style-unhide:no;
	mso-style-parent:"Body Text Indent";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-unhide:no;
	mso-style-next:Normal;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:200%;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:200%;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{mso-style-unhide:no;
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
a:link, span.MsoHyperlink
	{mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-parent:"";
	color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-noshow:yes;
	color:purple;
	mso-themecolor:followedhyperlink;
	text-decoration:underline;
	text-underline:single;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	background:navy;
	font-size:10.0pt;
	font-family:"Tahoma",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-unhide:no;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:10.0pt;
	font-family:"Courier New";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-unhide:no;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p
	{mso-style-unhide:no;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
address
	{mso-style-unhide:no;
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-style:italic;}
pre
	{mso-style-unhide:no;
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:10.0pt;
	font-family:"Courier New";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-unhide:no;
	mso-style-parent:"Comment Text";
	mso-style-link:"Comment Subject Char";
	mso-style-next:"Comment Text";
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{mso-style-priority:1;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-parent:"";
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:35.4pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-priority:29;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Quote Char";
	mso-style-next:Normal;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	color:black;
	mso-ansi-language:EN-GB;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-priority:30;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Intense Quote Char";
	mso-style-next:Normal;
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	border:none;
	mso-border-bottom-alt:solid #4F81BD .5pt;
	padding:0in;
	mso-padding-alt:0in 0in 4.0pt 0in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	color:#4F81BD;
	mso-ansi-language:EN-GB;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{mso-style-noshow:yes;
	mso-style-priority:37;
	mso-style-next:Normal;
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{mso-style-noshow:yes;
	mso-style-priority:39;
	mso-style-qformat:yes;
	mso-style-parent:"Heading 1";
	mso-style-next:Normal;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	tab-stops:28.35pt;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-font-kerning:16.0pt;
	mso-ansi-language:EN-GB;
	font-weight:bold;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	mso-style-unhide:no;
	mso-style-next:Normal;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	mso-line-height-alt:6.0pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Arial",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-variant:small-caps;
	mso-ansi-language:EN-GB;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	mso-style-unhide:no;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-US;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-unhide:no;
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	mso-fareast-font-family:Verdana;
	mso-bidi-font-family:Verdana;
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-GB;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Body text \(Agency\)";
	mso-ansi-font-size:9.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	mso-ascii-font-family:Verdana;
	mso-fareast-font-family:Verdana;
	mso-hansi-font-family:Verdana;
	mso-bidi-font-family:Verdana;
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-GB;
	mso-bidi-language:AR-SA;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-unhide:no;
	mso-style-link:"Drafting Notes \(Agency\) Char";
	mso-style-next:"Body text \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:11.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Courier New";
	mso-fareast-font-family:Verdana;
	mso-bidi-font-family:"Times New Roman";
	color:#339966;
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-GB;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Drafting Notes \(Agency\)";
	mso-ansi-font-size:11.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-fareast-font-family:Verdana;
	mso-hansi-font-family:"Courier New";
	color:#339966;
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-GB;
	mso-bidi-language:AR-SA;
	font-style:italic;
	mso-bidi-font-style:normal;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-unhide:no;
	mso-style-parent:"";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	mso-fareast-font-family:Verdana;
	mso-bidi-font-family:Verdana;
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-GB;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAg=
ency
	{mso-style-name:"Table heading rows \(Agency\)";
	mso-style-unhide:no;
	mso-style-parent:"Body text \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	tab-stops:.5in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:Verdana;
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-GB;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	mso-style-unhide:no;
	margin:0in;
	line-height:14.0pt;
	mso-line-height-rule:exactly;
	mso-pagination:widow-orphan;
	tab-stops:.5in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:Verdana;
	mso-ansi-language:EN-GB;
	mso-fareast-language:ZH-CN;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Normal \(Agency\)";
	mso-ansi-font-size:9.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	mso-ascii-font-family:Verdana;
	mso-fareast-font-family:Verdana;
	mso-hansi-font-family:Verdana;
	mso-bidi-font-family:Verdana;
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-GB;
	mso-bidi-language:AR-SA;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	mso-style-unhide:no;
	margin:0in;
	text-align:center;
	mso-pagination:widow-orphan;
	tab-stops:-1.0in -.5in 28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-weight:bold;
	mso-bidi-font-weight:normal;
	mso-no-proof:yes;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	mso-pagination:widow-orphan;
	tab-stops:28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	font-weight:bold;
	mso-bidi-font-weight:normal;
	mso-no-proof:yes;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Comment Text";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-US;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"Comment Text Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-US;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Heading 1";
	mso-ansi-font-size:14.0pt;
	font-family:"Arial",sans-serif;
	mso-ascii-font-family:Arial;
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:Arial;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-priority:30;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Intense Quote";
	mso-ansi-font-size:11.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	color:#4F81BD;
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-US;
	font-weight:bold;
	font-style:italic;}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-priority:29;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:Quote;
	mso-ansi-font-size:11.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	color:black;
	mso-ansi-language:EN-GB;
	mso-fareast-language:EN-US;
	font-style:italic;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	font-size:10.0pt;
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	mso-fareast-font-family:SimSun;
	mso-ansi-language:DE;
	mso-fareast-language:DE;}
 /* Page Definitions */
 @page
	{mso-footnote-separator:url("Ovaleap_clean_files/header.htm") fs;
	mso-footnote-continuation-separator:url("Ovaleap_clean_files/header.htm") =
fcs;
	mso-endnote-separator:url("Ovaleap_clean_files/header.htm") es;
	mso-endnote-continuation-separator:url("Ovaleap_clean_files/header.htm") e=
cs;
	mso-endnote-numbering-style:arabic;}
@page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;
	mso-header-margin:36.85pt;
	mso-footer-margin:36.85pt;
	mso-title-page:yes;
	mso-footer:url("Ovaleap_clean_files/header.htm") f1;
	mso-first-footer:url("Ovaleap_clean_files/header.htm") ff1;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;
	mso-endnote-numbering-style:arabic;}
 /* List Definitions */
 @list l0
	{mso-list-id:-132;
	mso-list-type:simple;
	mso-list-template-ids:-597397526;}
@list l0:level1
	{mso-level-style-link:"List Number 5";
	mso-level-tab-stop:74.6pt;
	mso-level-number-position:left;
	margin-left:74.6pt;
	text-indent:-.25in;}
@list l1
	{mso-list-id:-131;
	mso-list-type:simple;
	mso-list-template-ids:-1082883932;}
@list l1:level1
	{mso-level-style-link:"List Number 4";
	mso-level-tab-stop:60.45pt;
	mso-level-number-position:left;
	margin-left:60.45pt;
	text-indent:-.25in;}
@list l2
	{mso-list-id:-130;
	mso-list-type:simple;
	mso-list-template-ids:1260806880;}
@list l2:level1
	{mso-level-style-link:"List Number 3";
	mso-level-tab-stop:46.3pt;
	mso-level-number-position:left;
	margin-left:46.3pt;
	text-indent:-.25in;}
@list l3
	{mso-list-id:-129;
	mso-list-type:simple;
	mso-list-template-ids:1552727864;}
@list l3:level1
	{mso-level-style-link:"List Number 2";
	mso-level-tab-stop:32.15pt;
	mso-level-number-position:left;
	margin-left:32.15pt;
	text-indent:-.25in;}
@list l4
	{mso-list-id:-128;
	mso-list-type:simple;
	mso-list-template-ids:-74663058;}
@list l4:level1
	{mso-level-number-format:bullet;
	mso-level-style-link:"List Bullet 5";
	mso-level-text:\F0B7;
	mso-level-tab-stop:74.6pt;
	mso-level-number-position:left;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-family:Symbol;}
@list l5
	{mso-list-id:-127;
	mso-list-type:simple;
	mso-list-template-ids:-1586449596;}
@list l5:level1
	{mso-level-number-format:bullet;
	mso-level-style-link:"List Bullet 4";
	mso-level-text:\F0B7;
	mso-level-tab-stop:60.45pt;
	mso-level-number-position:left;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-family:Symbol;}
@list l6
	{mso-list-id:-126;
	mso-list-type:simple;
	mso-list-template-ids:54140078;}
@list l6:level1
	{mso-level-number-format:bullet;
	mso-level-style-link:"List Bullet 3";
	mso-level-text:\F0B7;
	mso-level-tab-stop:46.3pt;
	mso-level-number-position:left;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-family:Symbol;}
@list l7
	{mso-list-id:-125;
	mso-list-type:simple;
	mso-list-template-ids:542273296;}
@list l7:level1
	{mso-level-number-format:bullet;
	mso-level-style-link:"List Bullet 2";
	mso-level-text:\F0B7;
	mso-level-tab-stop:32.15pt;
	mso-level-number-position:left;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-family:Symbol;}
@list l8
	{mso-list-id:-120;
	mso-list-type:simple;
	mso-list-template-ids:-1742151574;}
@list l8:level1
	{mso-level-style-link:"List Number";
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;}
@list l9
	{mso-list-id:-119;
	mso-list-type:simple;
	mso-list-template-ids:-5206224;}
@list l9:level1
	{mso-level-number-format:bullet;
	mso-level-style-link:"List Bullet";
	mso-level-text:\F0B7;
	mso-level-tab-stop:.25in;
	mso-level-number-position:left;
	margin-left:.25in;
	text-indent:-.25in;
	font-family:Symbol;}
@list l10
	{mso-list-id:-2;
	mso-list-type:simple;
	mso-list-template-ids:-1;}
@list l10:level1
	{mso-level-start-at:0;
	mso-level-text:*;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:0in;
	text-indent:0in;}
@list l11
	{mso-list-id:163859649;
	mso-list-type:hybrid;
	mso-list-template-ids:2146616686 134807553 134807555 134807557 134807553 1=
34807555 134807557 134807553 134807555 134807557;}
@list l11:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l11:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l11:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:1.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l11:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:2.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l11:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:2.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l11:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:3.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l11:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:3.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l11:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:4.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l11:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:4.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l12
	{mso-list-id:592786408;
	mso-list-type:hybrid;
	mso-list-template-ids:-1014440800 67567617 67567619 67567621 67567617 6756=
7619 67567621 67567617 67567619 67567621;}
@list l12:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l12:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l12:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l12:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l12:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l12:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l12:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l12:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l12:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l13
	{mso-list-id:639768276;
	mso-list-type:hybrid;
	mso-list-template-ids:1120817764 67567617 67567619 67567621 67567617 67567=
619 67567621 67567617 67567619 67567621;}
@list l13:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l13:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l13:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l13:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l13:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l13:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l13:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l13:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l13:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l14
	{mso-list-id:1065109409;
	mso-list-type:hybrid;
	mso-list-template-ids:-468659802 67567617 67567619 67567621 67567617 67567=
619 67567621 67567617 67567619 67567621;}
@list l14:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:110.2pt;
	text-indent:-.25in;
	font-family:Symbol;}
@list l14:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:146.2pt;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l14:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:182.2pt;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l14:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:218.2pt;
	text-indent:-.25in;
	font-family:Symbol;}
@list l14:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:254.2pt;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l14:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:290.2pt;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l14:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:326.2pt;
	text-indent:-.25in;
	font-family:Symbol;}
@list l14:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:362.2pt;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l14:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:398.2pt;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l15
	{mso-list-id:1082068650;
	mso-list-type:hybrid;
	mso-list-template-ids:443193708 67567617 67567619 67567621 67567617 675676=
19 67567621 67567617 67567619 67567621;}
@list l15:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l15:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l15:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l15:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l15:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l15:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l15:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l15:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l15:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l16
	{mso-list-id:1187330242;
	mso-list-type:hybrid;
	mso-list-template-ids:1166604464 67567617 67567619 67567621 67567617 67567=
619 67567621 67567617 67567619 67567621;}
@list l16:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l16:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l16:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l16:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l16:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l16:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l16:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l16:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l16:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l17
	{mso-list-id:1225944973;
	mso-list-type:hybrid;
	mso-list-template-ids:-2820380 67567617 67567619 67567621 67567617 6756761=
9 67567621 67567617 67567619 67567621;}
@list l17:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l17:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l17:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l17:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l17:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l17:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l17:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l17:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l17:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l18
	{mso-list-id:1293752539;
	mso-list-type:hybrid;
	mso-list-template-ids:7106256 67567617 67567619 67567621 67567617 67567619=
 67567621 67567617 67567619 67567621;}
@list l18:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l18:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l18:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l18:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l18:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l18:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l18:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l18:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l18:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l19
	{mso-list-id:1747220272;
	mso-list-type:simple;
	mso-list-template-ids:1620494122;}
@list l19:level1
	{mso-level-start-at:5;
	mso-level-tab-stop:28.5pt;
	mso-level-number-position:left;
	margin-left:28.5pt;
	text-indent:-28.5pt;}
@list l20
	{mso-list-id:1871919056;
	mso-list-type:hybrid;
	mso-list-template-ids:-1228372506 67698689 67698691 67698693 67698689 6769=
8691 67698693 67698689 67698691 67698693;}
@list l20:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l20:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l20:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:1.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l20:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:2.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l20:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:2.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l20:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:3.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l20:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:3.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l20:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:4.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l20:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:4.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l21
	{mso-list-id:1890921793;
	mso-list-type:hybrid;
	mso-list-template-ids:1733441246 67567617 67567619 67567621 67567617 67567=
619 67567621 67567617 67567619 67567621;}
@list l21:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l21:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l21:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l21:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l21:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l21:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l21:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l21:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l21:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l22
	{mso-list-id:2047872296;
	mso-list-type:hybrid;
	mso-list-template-ids:798277818 -42433902 1788004580 336330779 336330767 3=
36330777 336330779 336330767 336330777 336330779;}
@list l22:level1
	{mso-level-number-format:alpha-upper;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:283.5pt;
	text-indent:-283.5pt;
	mso-ansi-font-weight:bold;}
@list l22:level2
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:82.5pt;
	text-indent:-28.5pt;
	mso-ansi-font-weight:bold;
	mso-ansi-font-style:normal;}
@list l22:level3
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;}
@list l22:level4
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l22:level5
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l22:level6
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;}
@list l22:level7
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l22:level8
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l22:level9
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;}
@list l23
	{mso-list-id:2132508293;
	mso-list-type:hybrid;
	mso-list-template-ids:626979406 67567617 67567619 67567621 67567617 675676=
19 67567621 67567617 67567619 67567621;}
@list l23:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l23:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l23:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l23:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l23:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l23:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l23:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;}
@list l23:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l23:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;}
@list l10:level1 lfo1
	{mso-level-start-at:1;
	mso-level-number-format:bullet;
	mso-level-numbering:continue;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:.25in;
	mso-level-legacy-space:0in;
	margin-left:.25in;
	text-indent:-.25in;}
@list l10:level1 lfo2
	{mso-level-start-at:1;
	mso-level-number-format:bullet;
	mso-level-numbering:continue;
	mso-level-text:-;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:.25in;
	mso-level-legacy-space:0in;
	margin-left:.25in;
	text-indent:-.25in;}
@list l20:level1 lfo12
	{mso-level-start-at:0;}
@list l11:level1 lfo13
	{mso-level-start-at:0;}
ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-ansi-language:DE;
	mso-fareast-language:DE;}
table.MsoTableGrid
	{mso-style-name:"Table Grid";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-unhide:no;
	border:solid black 1.0pt;
	mso-border-alt:solid black .5pt;
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-border-insideh:.5pt solid black;
	mso-border-insidev:.5pt solid black;
	mso-para-margin:0in;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	mso-ansi-language:DE;
	mso-fareast-language:DE;}
table.TablegridAgencyblack
	{mso-style-name:"Table grid \(Agency\) black";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	border:solid windowtext 1.0pt;
	mso-border-alt:solid windowtext .5pt;
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-border-insideh:.75pt solid windowtext;
	mso-border-insidev:.75pt solid windowtext;
	mso-para-margin:0in;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Verdana",sans-serif;
	mso-ansi-language:DE;
	mso-fareast-language:DE;}
table.TablegridAgencyblackFirstRow
	{mso-style-name:"Table grid \(Agency\) black";
	mso-table-condition:first-row;
	mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-tstyle-border-top:.5pt solid windowtext;
	mso-tstyle-border-left:.5pt solid windowtext;
	mso-tstyle-border-bottom:.5pt solid windowtext;
	mso-tstyle-border-right:.5pt solid windowtext;
	mso-tstyle-diagonal-down:cell-none;
	mso-tstyle-diagonal-up:cell-none;
	mso-tstyle-border-insideh:.75pt solid windowtext;
	mso-tstyle-border-insidev:.75pt solid windowtext;
	font-size:9.0pt;
	mso-ansi-font-size:9.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Malgun Gothic",sans-serif;
	mso-ascii-font-family:"Malgun Gothic";
	mso-hansi-font-family:"Malgun Gothic";
	color:windowtext;
	mso-ansi-font-weight:bold;
	mso-ansi-font-style:normal;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext=3D"edit" spidmax=3D"2049"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext=3D"edit">
  <o:idmap v:ext=3D"edit" data=3D"1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=3DEN-US link=3Dblue vlink=3Dpurple style=3D'tab-interval:.5in;wo=
rd-wrap:
break-word'>

<div class=3DWordSection1>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-paginati=
on:none;
tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-paginati=
on:widow-orphan no-line-numbers;
tab-stops:-1.0in -.5in 28.35pt'><b style=3D'mso-bidi-font-weight:normal'><s=
pan
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>ANHANG&n=
bsp;I</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-paginati=
on:widow-orphan no-line-numbers;
tab-stops:-1.0in -.5in 28.35pt'><span lang=3DDE style=3D'mso-bidi-font-size=
:12.0pt;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DTitleA><span lang=3DDE style=3D'mso-ansi-language:DE'>ZUSAMMENFA=
SSUNG DER
MERKMALE DES ARZNEIMITTELS<o:p></o:p></span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;tab-stops:-1=
.0in -.5in 28.35pt'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<span lang=3DDE style=3D'font-size:11.0pt;font-family:"Times New Roman",ser=
if;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:DE;mso-fareast-=
language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span>

<p class=3DMsoNormal style=3D'mso-pagination:no-line-numbers'><b style=3D'm=
so-bidi-font-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>1.<span
style=3D'mso-tab-count:1'> </span>BEZEICHNUNG DES ARZNEIMITTELS<o:p><=
/o:p></span></b></p>

<p class=3DMsoNormal style=3D'mso-pagination:none'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Ovaleap 300&nbsp;I.E./0,5&nbsp;ml =
Injektionslsung<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Ovaleap 450&nbsp;I.E./0,75&nbsp;ml=
 Injektionslsung<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Ovaleap 900&nbsp;I.E./1,5&nbsp;ml
Injektionslsung<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE;mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE;mso-bidi-font-style:italic'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:no-line-numbers'><b style=3D'm=
so-bidi-font-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>2.<span
style=3D'mso-tab-count:1'> </span>QUALITATIVE UND QUANTITATIVE
ZUSAMMENSETZUNG</span></b><span lang=3DDE style=3D'mso-bidi-font-size:12.0p=
t;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Jeder ml Lsung enthlt 600&nbsp;I=
.E. (entspricht
44&nbsp;Mikrogramm) Follitropin alfa*.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><u><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Ovaleap
300&nbsp;I.E./0,5&nbsp;ml Injektionslsung<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Jede Patrone enthlt 300&nbsp;I.E.=
 (entspricht
22&nbsp;Mikrogramm) Follitropin alfa in 0,5&nbsp;ml Injektionslsung.<o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><u><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Ovaleap
450&nbsp;I.E./0,75&nbsp;ml Injektionslsung<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Jede Patrone enthlt 450&nbsp;I.E.
(entspricht 33&nbsp;Mikrogramm) Follitropin alfa in 0,75&nbsp;ml
Injektionslsung.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><u><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Ovaleap
900&nbsp;I.E./1,5&nbsp;ml Injektionslsung<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Jede Patrone enthlt 900&nbsp;I.E.
(entspricht 66&nbsp;Mikrogramm) Follitropin alfa in 1,5&nbsp;ml
Injektionslsung.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:none;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>*Folli=
tropin
alfa<span style=3D'mso-bidi-font-weight:bold'> (</span></span><span lang=3D=
DE
style=3D'mso-ansi-language:DE'>rekombinantes humanes Follikel-stimulierendes
Hormon [r-hFSH])</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
color:black;mso-ansi-language:DE;mso-bidi-font-weight:bold'> </span><span
lang=3DDE style=3D'mso-ansi-language:DE'>wird mittels rekombinanter DNA-Tec=
hnologie
aus Ovarialzellen des Chinesischen Hamsters </span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-bid=
i-font-weight:
bold'>(CHO&nbsp;DHFR<sup>-</sup>)</span><span lang=3DDE style=3D'mso-ansi-l=
anguage:
DE'> gewonnen. </span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
color:black;mso-ansi-language:DE;mso-bidi-font-weight:bold'><o:p></o:p></sp=
an></p>

<p class=3DMsoNormal style=3D'mso-pagination:none;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-bid=
i-font-weight:
bold'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:none;tab-stops:.5in'><u><span =
lang=3DDE
style=3D'mso-ansi-language:DE'>Sonstige(r) Bestandteil(e) mit bekannter Wir=
kung:</span></u><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE;
mso-bidi-font-weight:bold'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-fo=
nt-size:
11.0pt;color:black;mso-ansi-language:DE;mso-no-proof:yes'>Ovaleap enthlt
0,02&nbsp;mg pro ml </span><span lang=3DDE style=3D'mso-bidi-font-size:11.0=
pt;
mso-ansi-language:DE'>Benzalkoniumchlorid.<span style=3D'color:black;mso-no=
-proof:
yes'><o:p></o:p></span></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-fo=
nt-size:
11.0pt;color:black;mso-ansi-language:DE;mso-no-proof:yes'>Ovaleap enthlt</=
span><span
lang=3DDE style=3D'color:black;mso-themecolor:text1;mso-ansi-language:DE'>
10,0&nbsp;mg pro ml </span><span lang=3DDE style=3D'mso-bidi-font-size:11.0=
pt;
mso-ansi-language:DE'>Benzylalkohol.</span><span lang=3DDE style=3D'color:#=
1F497D;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:none;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-bid=
i-font-weight:
bold'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan no-line-numbers;
mso-outline-level:1'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso=
-ansi-language:
DE'>Vollstndige Auflistung der sonstigen Bestandteile, siehe Abschnitt&nbs=
p;6.1.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan no-line-numbers'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>3.<span
style=3D'mso-tab-count:1'> </span>DARREICHUNGSFORM</span></b><span la=
ng=3DDE
style=3D'mso-bidi-font-size:12.0pt;text-transform:uppercase;mso-ansi-langua=
ge:
DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Injektionslsung (Injektion).<o:p>=
</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Klare, farblose Lsung.<o:p></o:p>=
</span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Der pH-Wert der Lsung betrgt 6,8=
&#8209;7,2.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan no-line-numbers;page-break-after:avoid'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;text-transform:u=
ppercase;
mso-ansi-language:DE'>4.<span style=3D'mso-tab-count:1'> </span>KLINI=
SCHE
ANGABEN</span></b><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;text-t=
ransform:
uppercase;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan no-line-numbers;
page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan no-line-numbers;page-break-after:avoid;mso-outline-level:1'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>4.1<span style=3D'mso-tab-count:1'> </span=
>Anwendungsgebiete</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;tab-stops:.5in'><span =
lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-1.15pt;page-break-after:avoid'>=
<u
style=3D'text-underline:black'><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Erwachsene
Frauen</span></u><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p></o:p>=
</span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.15pt;margin-bo=
ttom:
0in;margin-left:5.95pt;margin-bottom:.0001pt;page-break-after:avoid'><span
lang=3DDE style=3D'mso-bidi-font-size:13.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;page=
-break-after:
avoid;mso-list:l14 level1 lfo3;tab-stops:.5in'><![if !supportLists]><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast=
-font-family:
Symbol;mso-bidi-font-family:Symbol;color:black;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
11.0pt;
color:black;mso-ansi-language:DE'>Anovulation (einschlielich polyzystisches
Ovarialsyndrom) bei Frauen, die auf eine Behandlung mit Clomifencitrat nicht
angesprochen haben.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;page=
-break-after:
avoid;mso-list:l14 level1 lfo3;tab-stops:.5in'><![if !supportLists]><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast=
-font-family:
Symbol;mso-bidi-font-family:Symbol;color:black;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
11.0pt;
color:black;mso-ansi-language:DE'>Stimulation einer multifollikulren
Entwicklung bei Frauen, die sich einer Superovulation zur Vorbereitung auf =
eine
Technik der assistierten Reproduktion (ART), wie <i style=3D'mso-bidi-font-=
style:
normal'>In-vitro</i>-Fertilisation (IVF), Intratubarem Gametentransfer oder
Intratubarem Zygotentransfer unterziehen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;page=
-break-after:
avoid;mso-list:l14 level1 lfo3;tab-stops:.5in'><![if !supportLists]><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast=
-font-family:
Symbol;mso-bidi-font-family:Symbol;color:black;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
11.0pt;
color:black;mso-ansi-language:DE'>Ovaleap wird zusammen mit luteinisierendem
Hormon (LH) zur Stimulation der Follikelreifung bei Frauen angewendet, die
einen schweren LH- und FSH-Mangel aufweisen. In klinischen Studien wurden d=
iese
Patientinnen durch einen endogenen LH-Serumspiegel &lt;&nbsp;1,2&nbsp;I.E./=
l definiert.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-1.15pt;page-break-after:avoid'>=
<u
style=3D'text-underline:black'><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Erwachsene
Mnner</span></u><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p></o:p>=
</span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.15pt;margin-bo=
ttom:
0in;margin-left:5.95pt;margin-bottom:.0001pt;page-break-after:avoid;tab-sto=
ps:
28.35pt 34.0pt'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:bl=
ack;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;page=
-break-after:
avoid;mso-list:l14 level1 lfo3;tab-stops:.5in'><![if !supportLists]><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast=
-font-family:
Symbol;mso-bidi-font-family:Symbol;color:black;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
11.0pt;
color:black;mso-ansi-language:DE'>Ovaleap wird zusammen mit humanem
Choriongonadotropin (hCG) zur Stimulation der Spermatogenese bei Mnnern
angewendet, die an angeborenem oder erworbenem hypogonadotropem Hypogonadis=
mus
leiden.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan lines-together no-line-numbers;page-break-after:avoid;mso-outl=
ine-level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
12.0pt;mso-ansi-language:DE'>4.2<span style=3D'mso-tab-count:1'> </span=
>Dosierung
und Art der Anwendung<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;mso-outline-level:1;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;mso-outline-level:1;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Die
Behandlung mit Follitropin alfa sollte unter der Aufsicht eines Arztes
eingeleitet werden, der in der Behandlung von Fertilittsstrungen erfahren
ist.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><u><span lang=3DDE style=3D'mso-bidi=
-font-size:
11.0pt;color:black;mso-ansi-language:DE;mso-bidi-font-style:italic'>Dosieru=
ng<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><i><u><span lang=3DDE style=3D'mso-b=
idi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p><span style=3D'text-decoratio=
n:
 none'>&nbsp;</span></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Die
Dosisempfehlungen fr Follitropin alfa entsprechen den fr urinres FSH
gebruchlichen Dosierungen. Klinische Untersuchungen von Follitropin alfa
zeigen, dass sich die tgliche Dosis, Anwendungsschemata und
Therapieberwachung nicht von den fr urinres FSH blichen Methoden
unterscheiden. Es wird angeraten, sich an die nachfolgend aufgefhrten,
empfohlenen Anfangsdosen zu halten.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Klinis=
che
Vergleichsstudien haben gezeigt, dass die Patienten mit Follitropin alfa im
Vergleich zu urinrem FSH durchschnittlich eine niedrigere Gesamtdosis und =
eine
krzere Behandlungsdauer bentigen. Deshalb wird es als gerechtfertigt ange=
sehen,
eine niedrigere Gesamtdosis von Follitropin alfa zu geben, als normalerweise
bei urinrem FSH gebruchlich ist, nicht nur, um die Entwicklung der Follik=
el
zu optimieren, sondern auch, um das Risiko einer unerwnschten ovariellen
Hyperstimulation zu minimieren (siehe Abschnitt&nbsp;5.1).<o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;tab-stops:.5in'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DDE style=3D'mso-bidi-f=
ont-size:
11.0pt;color:black;mso-ansi-language:DE'>Frauen mit Anovulation (einschlie=
lich
polyzystisches Ovarialsyndrom)<o:p></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Follit=
ropin
alfa wird ber einen bestimmten Zeitraum tglich injiziert. Bei Frauen mit
Menstruation sollte die Behandlung innerhalb der ersten 7&nbsp;Tage des
Menstruationszyklus beginnen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>blich=
erweise
wird die Therapie mit 75&#8209;150 I.E. FSH tglich begonnen. Die Dosis kan=
n um
37,5&nbsp;I.E. oder 75&nbsp;I.E. in 7- oder vorzugsweise 14-tgigen Interva=
llen
gesteigert werden, sofern dies fr eine adquate, nicht berschieende
Stimulation des Follikelwachstums erforderlich ist. Die Behandlung sollte d=
er
individuellen Reaktion der Patientin angepasst werden, die durch Bestimmung=
 der
Follikelgre im Ultraschall und/oder durch Messungen des strogenspiegels
beurteilt werden kann. Die maximale Tagesdosis liegt blicherweise bei Gaben
bis zu 225&nbsp;I.E. FSH. Falls nach 4-wchiger Behandlung kein Erfolg zu
verzeichnen ist, sollte die Stimulation in diesem Zyklus abgebrochen und die
Patientin weiteren Untersuchungen unterzogen werden; anschlieend kann ein
neuer Zyklus mit hherer Anfangsdosierung begonnen werden.<o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DDE style=3D'mso-bidi-font=
-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></i></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Nach
erfolgreicher Stimulation werden 24&#8209;48&nbsp;Stunden nach der letzten
Follitropin-alfa-Injektion einmalig 250&nbsp;Mikrogramm rekombinantes
Choriongonadotropin alfa (r-hCG) oder 5.000&#8209;10.000&nbsp;I.E. hCG
injiziert. Der Patientin wird empfohlen, am Tag der hCG-Injektion und am da=
rauf
folgenden Tag Geschlechtsverkehr zu haben. Alternativ kann eine intrauterine
Insemination (IUI) durchgefhrt werden.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Bei
berschieender ovarieller Reaktion ist die Behandlung zu beenden und kein =
hCG
zu verabreichen (siehe Abschnitt&nbsp;4.4). Die Behandlung sollte im nchst=
en
Zyklus mit einer niedrigeren Dosis wieder aufgenommen werden.<o:p></o:p></s=
pan></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><i><u><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
color:black;mso-ansi-language:DE'>Stimulationstherapie zur Erreichung einer
mehrfachen Follikelreifung bei Frauen vor In&#8209;vitro&#8209;Fertilisation
oder anderen ART-Methoden <o:p></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:bl=
ack;
mso-ansi-language:DE'>Die Behandlung fr die Superovulation beginnt gewhnl=
ich
am 2. oder 3.&nbsp;Zyklustag mit der Anwendung von tglich 150&#8209;225&nb=
sp;I.E.
Follitropin alfa. Die Behandlung wird fortgesetzt, bis eine ausreichende
Follikelreifung (beurteilt durch Monitoring der Serum-strogenspiegel und/o=
der
Ultraschalluntersuchung) erzielt ist, wobei die Dosis der ovariellen Reakti=
on
der Patientin angepasst wird (blicherweise bis maximal 450&nbsp;I.E. tgli=
ch).
Im Allgemeinen wird etwa am zehnten Behandlungstag eine ausreichende
Follikelentwicklung erzielt (Spanne: 5 bis 20&nbsp;Tage).<o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Um die
Endreifung der Follikel zu induzieren, werden 250&nbsp;Mikrogramm r&#8209;h=
CG
oder 5.000&nbsp;I.E. bis 10.000&nbsp;I.E. hCG einmalig 24&#8209;48&nbsp;Stu=
nden
nach der letzten Follitropin-alfa-Injektion verabreicht.<o:p></o:p></span><=
/p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Eine g=
ngige
Behandlung zur Unterdrckung des endogenen LH-Peaks und zur Kontrolle der
tonischen LH-Werte ist die Downregulation mit einem GnRH-Agonisten oder
-Antagonisten (GnRH ist Gonadotropin freisetzendes Hormon). Bei einer
Downregulation wird mit der Anwendung von Follitropin alfa blicherweise et=
wa 2&nbsp;Wochen
nach Beginn der Agonist-Verabreichung begonnen. Die Behandlung mit beiden
Prparaten wird fortgefhrt bis eine ausreichende Follikelentwicklung erzie=
lt
ist. Beispielsweise werden nach einer zweiwchigen Vorbehandlung mit einem
Agonisten whrend der ersten 7&nbsp;Tage 150&#8209;225&nbsp;I.E. Follitropin
alfa pro Tag verabreicht. Danach wird die Dosis der ovariellen Reaktion
angepasst.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Die
Erfahrungen mit IVF zeigen, dass im Allgemeinen die Erfolgschancen der
Behandlung whrend der ersten 4&nbsp;Behandlungsversuche stabil bleiben und
danach allmhlich abnehmen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><i><span =
lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></i></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;tab-stops:.5in'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DDE style=3D'mso-bidi-f=
ont-size:
11.0pt;color:black;mso-ansi-language:DE'>Frauen mit Anovulation aufgrund ei=
nes schweren
LH- und FSH-Mangels<o:p></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Bei Fr=
auen,
die an LH- und FSH-Mangel (hypogonadotropem Hypogonadismus) leiden, ist das
Ziel der Anwendung von Follitropin alfa zusammen mit Lutropin alfa die
Entwicklung eines einzelnen reifen Graafschen Follikels, aus dem nach Gabe=
 von
hCG die Eizelle freigesetzt wird. Follitropin alfa muss ber einen bestimmt=
en
Zeitraum tglich zusammen mit Lutropin alfa injiziert werden. Da diese
Patientinnen unter einer Amenorrhoe leiden und ihre endogene strogensekret=
ion
niedrig ist, kann jederzeit mit der Behandlung begonnen werden.<o:p></o:p><=
/span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>blich=
erweise
wird die Therapie mit tglich 75&nbsp;I.E. Lutropin alfa und 75&#8209;150&n=
bsp;I.E.
FSH begonnen. Die Behandlung sollte der individuellen Reaktion der Patientin
angepasst werden, die durch Bestimmung der Follikelgre im Ultraschall und
durch Messungen des strogenspiegels beurteilt werden kann.<o:p></o:p></spa=
n></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Wenn e=
ine
Erhhung der FSH-Dosis angezeigt ist, sollte die Anpassung der Dosierung
vorzugsweise in Intervallen von 7&#8209;14 Tagen und in Schritten von 37,5&=
#8209;75&nbsp;I.E.
erfolgen. Es ist mglich, die Stimulationsdauer in jedem beliebigen Zyklus =
auf
bis zu 5&nbsp;Wochen auszudehnen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Nach
erfolgreicher Stimulation werden 24&#8209;48 Stunden nach der letzten Injek=
tion
von Follitropin alfa und Lutropin alfa einmalig 250&nbsp;Mikrogramm r&#8209=
;hCG
oder 5.000&nbsp;I.E. bis 10.000&nbsp;I.E. hCG injiziert. Der Patientin wird
empfohlen, am Tag der Injektion von hCG und am darauf folgenden Tag
Geschlechtsverkehr zu haben. Alternativ kann eine IUI durchgefhrt werden.<=
o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Eine
Untersttzung der Lutealphase kann in Betracht gezogen werden, da nach der
Ovulation ein Mangel an luteotropen Substanzen (LH/hCG) zu einer frhen
Corpus-Luteum-Insuffizienz fhren kann.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Bei
berschieender Reaktion ist die Behandlung zu beenden und kein hCG zu
verabreichen. Die Behandlung sollte im nchsten Zyklus mit einer niedrigeren
FSH-Dosis wieder aufgenommen werden.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;tab-stops:.5in'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DDE style=3D'mso-bidi-f=
ont-size:
11.0pt;color:black;mso-ansi-language:DE'>Mnner mit hypogonadotropem
Hypogonadismus<o:p></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Follit=
ropin
alfa soll ber einen Zeitraum von mindestens 4&nbsp;Monaten dreimal pro Woc=
he
in einer Dosis von 150&nbsp;I.E. zusammen mit hCG angewendet werden. Wenn d=
er
Patient nach dieser Zeit keine erwnschte Reaktion zeigt, kann die
Kombinationstherapie fortgesetzt werden. Klinische Erfahrungen zeigen, dass
eine Behandlung von 18&nbsp;Monaten und lnger erforderlich sein kann, um d=
ie
Spermatogenese zu induzieren.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><i><span =
lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></i></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><i style=3D'mso-bidi-font-style:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Besond=
ere
Patientengruppen<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><u><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color=
:black;
mso-ansi-language:DE;mso-bidi-font-style:italic'>ltere Patienten<o:p></o:p=
></span></u></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Es gibt
keinen relevanten Nutzen von Follitropin alfa bei lteren Patienten. Die Si=
cherheit
und Wirksamkeit von Follitropin alfa bei lteren Patienten ist nicht erwies=
en.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.0pt;margin-bot=
tom:
0in;margin-left:5.95pt;margin-bottom:.0001pt'><span lang=3DDE style=3D'mso-=
ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><u><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color=
:black;
mso-ansi-language:DE;mso-bidi-font-style:italic'>Einschrnkung der Leber- o=
der
Nierenfunktion<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Die Si=
cherheit,
Wirksamkeit und Pharmakokinetik von Follitropin alfa bei Patienten mit
eingeschrnkter Leber- oder Nierenfunktion ist nicht erwiesen.<o:p></o:p></=
span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><u><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color=
:black;
mso-ansi-language:DE;mso-bidi-font-style:italic'>Kinder und Jugendliche<o:p=
></o:p></span></u></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Es gibt
keinen relevanten Nutzen von Follitropin alfa bei Kindern und Jugendlichen.=
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><i style=3D'mso-bidi-font-style:normal'><u><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Art de=
r Anwendung<o:p></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:bl=
ack;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Ovalea=
p wird
subkutan angewendet. Die erste Injektion muss unter direkter rztlicher
Aufsicht erfolgen. Die Selbstinjektion sollte nur durch solche Patienten er=
folgen,
die motiviert und ausreichend geschult sind und die Mglichkeit haben, fach=
kundigen
Rat einzuholen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Da die
Mehrfachdosis-Patrone fr mehrere Injektionen vorgesehen ist, sollten die
Patienten klare Anweisungen erhalten, um einen Fehlgebrauch des Arzneimitte=
ls
zu vermeiden.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Die
Ovaleap-Patrone ist ausschlielich fr die Anwendung mit dem Ovaleap-Pen
bestimmt, der separat erhltlich ist. Hinweise zur Anwendung mit dem
Ovaleap-Pen siehe Abschnitt&nbsp;6.6.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>4.3<span style=3D'mso-tab-count:1'> </span=
>Gegenanzeigen</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1'><=
span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l14 level1 lfo3;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;color:black;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
12.0pt;
mso-ansi-language:DE'>berempfindlichkeit gegen den Wirkstoff Follitropin a=
lfa,
FSH oder einen der in Abschnitt&nbsp;6.1 genannten sonstigen Bestandteile;<=
/span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l14 level1 lfo3;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;color:black;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Tumoren
des Hypothalamus oder der Hypophyse</span><span lang=3DDE style=3D'mso-bidi=
-font-size:
11.0pt;color:black;mso-ansi-language:DE'>;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l14 level1 lfo3;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;color:black;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Vergrerung
der Ovarien oder Ovarialzysten, die nicht auf einem polyzystischen
Ovarialsyndrom beruhen</span><span lang=3DDE style=3D'mso-bidi-font-size:11=
.0pt;
color:black;mso-ansi-language:DE'>;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l14 level1 lfo3;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;color:black;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>gynkologische
Blutungen unbekannter Ursache</span><span lang=3DDE style=3D'mso-bidi-font-=
size:
11.0pt;color:black;mso-ansi-language:DE'>;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l14 level1 lfo3;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;color:black;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Ovarial-,
Uterus- oder Mammakarzinom</span><span lang=3DDE style=3D'mso-bidi-font-siz=
e:11.0pt;
color:black;mso-ansi-language:DE'>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;tab-=
stops:
.5in'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Ovaleap darf nicht angewendet werd=
en,
wenn abzusehen ist, dass das Therapieziel nicht erreicht werden kann, wie z=
um
Beispiel bei:<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l14 level1 lfo3;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;color:black;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>primrer
Ovarialinsuffizienz</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
color:black;mso-ansi-language:DE'>;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l14 level1 lfo3;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;color:black;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Missbildungen
der Sexualorgane, die eine Schwangerschaft unmglich machen</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'>;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l14 level1 lfo3;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;color:black;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>fibrsen
Tumoren der Gebrmutter, die eine Schwangerschaft unmglich machen</span><s=
pan
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'>;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l14 level1 lfo3;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;color:black;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>primrer
testikulrer Insuffizienz</span><span lang=3DDE style=3D'mso-bidi-font-size=
:11.0pt;
color:black;mso-ansi-language:DE'>.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>4.4<span style=3D'mso-tab-count:1'> </span=
>Besondere
Warnhinweise und Vorsichtsmanahmen fr die Anwendung<o:p></o:p></span></b>=
</p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:bl=
ack;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:none;mso-layout-grid-align:non=
e;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><u><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Nachverfolgbarkeit=
<o:p></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi=
-language:
DE'>Um die Nachverfolgbarkeit biologischer Arzneimittel zu verbessern, sind=
 der
Handelsname sowie die Chargennummer des angewendeten Arzneimittels in der
Patientenakte auf eindeutige Art und Weise aufzuzeichnen.<o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:bl=
ack;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><i style=3D'mso-bidi-font-style:normal'><u><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Allgem=
eines<o:p></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Follitropin alfa ist eine stark wi=
rkende
gonadotrope Substanz, die leichte bis schwere Nebenwirkungen verursachen ka=
nn.
Sie darf nur von rzten angewendet werden, die mit Fertilittsproblemen und
deren Behandlung umfassend vertraut sind.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Die Gonadotropintherapie erfordert
einen gewissen zeitlichen Aufwand von rzten und medizinischem Personal sow=
ie
die Verfgbarkeit geeigneter medizinischer Einrichtungen zum Zyklus-Monitor=
ing.
Ein sicherer und wirksamer Einsatz von Follitropin alfa erfordert die
berwachung der ovariellen Reaktion der Frauen mittels Ultraschall,
vorzugsweise in Kombination mit regelmigen Messungen der stradiolwerte im
Serum. Die ovarielle Reaktion verschiedener Patientinnen auf die FSH-Gabe k=
ann
zu einem gewissen Grad variieren  manche Patientinnen zeigen eine
unzureichende ovarielle Reaktion auf FSH, andere eine bersteigerte Reaktio=
n.
Es sollte bei Mnnern wie Frauen jeweils die geringste wirksame Dosis zur
Erreichung des Behandlungsziels verwendet werden.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><i style=3D'mso-bidi-font-style:normal'><u><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Porphy=
rie<o:p></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Patienten, die an Porphyrie leiden
oder bei denen Porphyrieflle in der Familie bekannt sind, mssen whrend d=
er
Behandlung mit Follitropin alfa engmaschig berwacht werden. Eine
Verschlechterung oder erstes Auftreten einer Porphyrie kann ein Absetzen de=
r Behandlung
erforderlich machen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><i style=3D'mso-bidi-font-style:normal'><u><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Behand=
lung
von Frauen<o:p></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Bevor mit einer Behandlung begonnen
wird, mssen die Ursachen fr die Infertilitt des Paares genau abgeklrt u=
nd
mgliche Kontraindikationen fr eine Schwangerschaft festgestellt sein.
Insbesondere mssen die Patientinnen auf Hypothyreose,
Nebennierenrindeninsuffizienz und Hyperprolaktinmie untersucht und
entsprechend behandelt werden.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Unabhngig davon, ob die Stimulati=
on
des Follikelwachstums als Behandlung der anovulatorischen Infertilitt oder=
 als
assistierte Reproduktion durchgefhrt wird, kann bei Patientinnen eine
Vergrerung der Ovarien oder eine berstimulation auftreten. Durch Anwendu=
ng
der empfohlenen Follitropin-alfa-Dosis und des Behandlungsschemas sowie dur=
ch
eine sorgfltige berwachung der Therapie wird die Hufigkeit solcher
Vorkommnisse minimiert. Zur exakten Interpretation der Parameter der
Follikelentwicklung und Follikelreifung sollte der Arzt Erfahrung in der
Interpretation der relevanten Untersuchungsergebnisse besitzen.<o:p></o:p><=
/span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>In klinischen Studien wurde belegt,
dass die Sensitivitt der Ovarien auf Follitropin alfa erhht wird, wenn es
zusammen mit Lutropin alfa angewendet wird. Wenn eine Erhhung der FSH-Dosis
angezeigt ist, sollte die Anpassung der Dosis vorzugsweise in 7&#8209;14-t=
gigen
Intervallen und in Schritten von 37,5&#8209;75I.E. erfolgen.<o:p></o:p></sp=
an></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Es wurde kein direkter Vergleich v=
on
Follitropin alfa/LH mit humanem Menopausengonadotropin (hMG) durchgefhrt. =
Ein
Vergleich mit historischen Daten zeigt, dass die unter Follitropin alfa/LH
erreichte Ovulationsrate vergleichbar der unter hMG erreichten Ovulationsra=
te
ist.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><i style=3D'mso-bidi-font-style:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Ovarie=
lles
Hyperstimulationssyndrom (OHSS)<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Eine gewisse Vergrerung der Ovar=
ien
ist bei einer kontrollierten ovariellen Stimulation zu erwarten. Bei Frauen=
 mit
polyzystischem Ovarialsyndrom tritt dies hufiger auf und bildet sich fr
gewhnlich ohne Behandlung wieder zurck.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Im Gegensatz zu einer unkomplizier=
ten
Vergrerung der Ovarien ist ein OHSS ein Zustand, der sich in zunehmendem
Schweregrad manifestieren kann. Er umfasst eine deutliche Vergrerung der
Ovarien, hohe Sexualsteroidkonzentrationen im Serum und eine erhhte vaskul=
re
Permeabilitt, welche zu einer Flssigkeitsansammlung in den peritonealen,
pleuralen und selten auch in den perikardialen Krperhhlen fhren kann.<o:=
p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Folgende Symptomatik kann in schwe=
ren
Fllen eines OHSS beobachtet werden: Unterleibsschmerzen, aufgeblhter Bauc=
h,
gravierende Vergrerung der Ovarien, Gewichtszunahme, Dyspnoe, Oligurie und
gastrointestinale Symptome einschlielich belkeit, Erbrechen und Durchfall.
Bei einer klinischen Untersuchung knnen auch Hypovolmie, Hmokonzentratio=
n,
Strungen im Elektrolythaushalt, Aszites, Hmoperitoneum, Pleuraergsse,
Hydrothorax oder akute Atemnot festgestellt werden. Sehr selten knnen bei
einem schweren OHSS Komplikationen auftreten wie Ovarialtorsion oder
thromboembolische Ereignisse, z. B. Lungenembolie, ischmischer Schlaganfall
oder Herzinfarkt.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Unabhngige Risikofaktoren fr die
Entwicklung eines OHSS umfassen polyzystisches Ovarialsyndrom, hohe absolute
oder rasch ansteigende stradiolspiegel im Serum (z. B.
&gt;&nbsp;900&nbsp;pg/ml oder &gt;&nbsp;3.300&nbsp;pmol/l bei anovulatorisc=
hen
Patientinnen; &gt;&nbsp;3.000&nbsp;pg/ml oder &gt;&nbsp;11.000&nbsp;pmol/l =
bei
assistierter Reproduktion) und eine hohe Anzahl sich entwickelnder
Ovarialfollikel (z. B. &gt;&nbsp;3&nbsp;Follikel mit einem Durchmesser von
&#8805;&nbsp;14&nbsp;mm bei anovulatorischen Patientinnen;
&#8805;&nbsp;20&nbsp;Follikel mit einem Durchmesser von &#8805;&nbsp;12 mm =
bei
assistierter Reproduktion).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Durch Einhaltung der empfohlenen
Follitropin-alfa-Dosis und des empfohlenen Behandlungsschemas kann das Risi=
ko
einer ovariellen berstimulation minimiert werden (siehe Abschnitte&nbsp;4.2
und 4.8). Zur frhzeitigen Identifizierung von Risikofaktoren werden die
berwachung der Stimulationszyklen mittels Ultraschall sowie Bestimmungen d=
er
stradiolspiegel empfohlen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Es liegen Hinweise vor, dass hCG e=
ine
Schlsselrolle bei der Auslsung eines OHSS spielt und dass das Syndrom
schwerwiegender und langwieriger verlaufen kann, wenn eine Schwangerschaft
eintritt. Es ist deshalb empfehlenswert, bei Anzeichen einer ovariellen
berstimulation (z. B. ein stradiolspiegel im Serum von
&gt;&nbsp;5.500&nbsp;pg/ml oder &gt;&nbsp;20.200&nbsp;pmol/l und/oder insge=
samt
&#8805;&nbsp;40 Follikel) kein hCG zu geben und die Patientin anzuweisen, f=
r
mindestens 4&nbsp;Tage keinen Geschlechtsverkehr zu haben oder geeignete
Verhtungsmethoden (Barrieremethoden) anzuwenden. Ein OHSS kann sich rasch
(innerhalb von 24&nbsp;Stunden) oder innerhalb einiger Tage entwickeln und =
zu
einem schwerwiegenden medizinischen Ereignis werden. Es tritt zumeist nach
Beendigung der Hormonbehandlung auf und ist etwa 7 bis 10&nbsp;Tage nach der
Behandlung am strksten ausgeprgt. Deshalb sollten die Patientinnen ber e=
inen
Zeitraum von mindestens 2&nbsp;Wochen nach der hCG-Gabe unter Beobachtung
bleiben.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Bei der assistierten Reproduktion =
kann
durch Absaugen smtlicher Follikel vor der Ovulation die Wahrscheinlichkeit=
 fr
das Auftreten einer berstimulation verringert werden.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Ein leichtes oder mittelschweres O=
HSS
klingt normalerweise spontan ab. Wenn es zu einem schweren OHSS kommt, wird
empfohlen, eine noch laufende Gonadotropinbehandlung ggf. abzubrechen, die
Patientin zu hospitalisieren und mit einer geeigneten Therapie gegen OHSS zu
beginnen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><i style=3D'mso-bidi-font-style:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Mehrli=
ngsschwangerschaften<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Bei Patientinnen, die sich einer
Ovulationsinduktion unterziehen, ist die Wahrscheinlichkeit einer
Mehrlingsschwangerschaft im Vergleich zur natrlichen Konzeption erhht. Bei
den meisten Mehrlingsschwangerschaften handelt es sich um Zwillinge.
Mehrlingsschwangerschaften, insbesondere die hherer Ordnung, bergen ein
erhhtes Risiko fr maternale und perinatale Komplikationen.<o:p></o:p></sp=
an></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Um das Risiko einer
Mehrlingsschwangerschaft zu minimieren, wird die sorgfltige berwachung der
ovariellen Reaktion empfohlen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Bei Patientinnen, die sich einer
assistierten Reproduktion unterziehen, steht das Risiko einer
Mehrlingsschwangerschaft hauptschlich mit der Anzahl der bertragenen
Embryonen, ihrer Qualitt und dem Alter der Patientin im Zusammenhang.<o:p>=
</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Die Patientinnen mssen vor
Behandlungsbeginn ber das potenzielle Risiko einer Mehrlingsschwangerschaft
informiert werden.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><i style=3D'mso-bidi-font-style:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Fehlge=
burten<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Die Hufigkeit von Fehlgeburten od=
er
Schwangerschaftsabbrchen ist bei Patientinnen, die sich einer
Stimulationsbehandlung oder einer Technik der assistierten Reproduktion
unterziehen, hher als nach einer natrlichen Empfngnis.<o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><i style=3D'mso-bidi-font-style:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Ektope
Schwangerschaften<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Bei Frauen mit Eileitererkrankunge=
n in
der Anamnese besteht das Risiko einer ektopen Schwangerschaft, unabhngig
davon, ob die Schwangerschaft durch spontane Konzeption oder durch
Fertilittsbehandlungen eingetreten ist. Die Hufigkeit einer ektopen
Schwangerschaft nach Anwendung einer Technik der assistierten Reproduktion
liegt hher als in der Allgemeinbevlkerung.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><i style=3D'mso-bidi-font-style:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Neopla=
smen
der Fortpflanzungsorgane<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Bei Frauen, die sich mehrfachen
Behandlungszyklen zur Ovulationsinduktion unterzogen haben, wurde von
gutartigen wie auch von bsartigen Neoplasmen der Ovarien und anderer
Fortpflanzungsorgane berichtet. Bisher konnte noch nicht geklrt werden, ob
eine Behandlung mit Gonadotropinen Einfluss auf das Risiko unfruchtbarer Fr=
auen
fr diese Tumoren hat.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><i style=3D'mso-bidi-font-style:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Kongen=
itale
Missbildungen<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Die Hufigkeit kongenitaler
Missbildungen nach Anwendung von Techniken der assistierten Reproduktion k=
nnte
etwas hher liegen als nach spontaner Empfngnis. Es wird angenommen, dass =
dies
auf eine unterschiedliche Vorbelastung der Eltern (z.&nbsp;B. Alter der Mut=
ter,
Eigenschaften der Spermien) und Mehrlingsschwangerschaften zurckzufhren i=
st.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><i style=3D'mso-bidi-font-style:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Thromb=
oembolische
Ereignisse<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Bei Frauen mit krzlich aufgetrete=
nen
oder bestehenden thromboembolischen Erkrankungen oder bei Frauen mit
allgemeinen Risikofaktoren fr thromboembolische Ereignisse, wie eine eigene
oder familire Anamnese, kann eine Gonadotropinbehandlung das Risiko einer
Verschlechterung bzw. des Auftretens solcher Ereignisse weiter erhhen. Bei
diesen Patientinnen muss eine genaue Nutzen-Risiko-Abwgung erfolgen. Eine
Schwangerschaft bzw. ein OHSS bergen jedoch bereits an sich ein erhhtes Ri=
siko
fr thromboembolische Ereignisse.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><i style=3D'mso-bidi-font-style:normal'><u><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Behand=
lung
von Mnnern<o:p></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Erhhte endogene FSH-Spiegel deuten
auf eine primre testikulre Insuffizienz hin. Solche Patienten sprechen auf
eine Therapie mit Follitropin alfa/hCG nicht an. Follitropin alfa sollte ni=
cht
angewendet werden, wenn abzusehen ist, dass das Therapieziel nicht erreicht
werden kann.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Es wird empfohlen, 4 bis 6&nbsp;Mo=
nate
nach Beginn der Behandlung zur Beurteilung des Ansprechens eine
Spermauntersuchung durchzufhren.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><i style=3D'mso-bidi-font-style:norm=
al'><u><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-bidi-=
font-weight:
bold;mso-no-proof:yes'>Benzalkoniumchloridgehalt</span></u></i><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DDE style=3D'mso-bidi-f=
ont-size:
11.0pt;color:black;mso-ansi-language:DE;mso-no-proof:yes'><o:p></o:p></span=
></u></i></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-fo=
nt-size:
11.0pt;color:black;mso-ansi-language:DE;mso-no-proof:yes'>Ovaleap enthlt 0=
,02&nbsp;mg/ml
Benzalkoniumchlorid.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><i style=3D'mso-bidi-font-style:norm=
al'><u><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-bidi-=
font-weight:
bold;mso-no-proof:yes'><o:p><span style=3D'text-decoration:none'>&nbsp;</sp=
an></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><i style=3D'mso-bidi-font-style:norm=
al'><u><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-bidi-=
font-weight:
bold;mso-no-proof:yes'>Benzylalkoholgehalt</span></u></i><i style=3D'mso-bi=
di-font-style:
normal'><u><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;
mso-ansi-language:DE;mso-no-proof:yes'><o:p></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-fo=
nt-size:
11.0pt;color:black;mso-ansi-language:DE;mso-no-proof:yes'>Ovaleap enthlt 1=
0,0&nbsp;mg/ml
Benzylalkohol.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><u><span lang=3DDE style=3D'mso-bidi=
-font-size:
11.0pt;mso-ansi-language:DE;mso-bidi-font-weight:bold;mso-no-proof:yes'>Ben=
zylalkohol
kann allergische Reaktionen verursachen.<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-fo=
nt-size:
11.0pt;mso-ansi-language:DE;mso-bidi-font-weight:bold;mso-no-proof:yes'>Gro=
e
Mengen sollten wegen des Risikos der Akkumulation und Toxizitt
(&quot;metabolische Azidose&quot;) nur mit Vorsicht und wenn absolut ntig =
angewendet
werden, insbesondere bei Personen mit eingeschrnkter Leber- oder
Nierenfunktion sowie bei schwangeren oder stillenden Frauen.<o:p></o:p></sp=
an></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><u><span lang=3DDE style=3D'mso-bidi=
-font-size:
11.0pt;mso-ansi-language:DE;mso-bidi-font-weight:bold;mso-no-proof:yes'><o:=
p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><i style=3D'mso-bidi-font-style:norm=
al'><u><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-bidi-=
font-weight:
bold'>Natriumgehalt</span></u></i><i style=3D'mso-bidi-font-style:normal'><=
u><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'><o:p></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-fo=
nt-size:
11.0pt;color:black;mso-ansi-language:DE'>Ovaleap enthlt weniger als 1&nbsp=
;mmol
Natrium (23&nbsp;mg) pro Dosis, </span><span lang=3DDE style=3D'mso-ansi-la=
nguage:
DE'>d.h., es ist nahezu natriumfrei.</span><span lang=3DDE style=3D'mso-b=
idi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>4.5<span style=3D'mso-tab-count:1'> </span=
>Wechselwirkungen
mit anderen Arzneimitteln und sonstige Wechselwirkungen</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1'><=
span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-fo=
nt-size:
11.0pt;color:black;mso-ansi-language:DE'>Gleichzeitige Anwendung von
Follitropin alfa zusammen mit anderen Arzneimitteln zur ovariellen Stimulat=
ion
(z.&nbsp;B. hCG, Clomifencitrat) kann die follikulre Reaktion verstrken,
wohingegen bei gleichzeitiger Anwendung eines GnRH-Agonisten oder -Antagoni=
sten
zur hypophysren Desensibilisierung eine hhere Dosis von Follitropin alfa
erforderlich sein kann, um eine adquate ovarielle Reaktion zu erzielen.
Klinisch signifikante Wechselwirkungen mit anderen Arzneimitteln wurden bis=
her
bei einer Follitropin-alfa-Therapie nicht beobachtet.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan no-line-numbers;page-break-after:avoid;mso-outline-level:1'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>4.6<span style=3D'mso-tab-count:1'> </span=
>Fertilitt,
Schwangerschaft und Stillzeit</span></b><span lang=3DDE style=3D'mso-bidi-f=
ont-size:
12.0pt;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DDE style=3D'mso-bidi-font=
-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></i></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><i style=3D'mso-bidi-font-style:normal'><u><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-far=
east-language:
DE'>Schwangerschaft<o:p></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:bl=
ack;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Es gibt keine Indikation fr die
Anwendung von Ovaleap whrend einer Schwangerschaft. Daten ber eine begren=
zte
Anzahl von exponierten Schwangeren (weniger als 300&nbsp;Schwangerschaftsau=
sgnge)
deuten nicht auf ein Fehlbildungsrisiko oder eine fetale/neonatale Toxizitt
von Follitropin alfa hin.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>In tierexperimentellen Studien wur=
de
keine teratogene Wirkung beobachtet (siehe Abschnitt&nbsp;5.3). Es liegen k=
eine
ausreichenden Daten ber exponierte Schwangere vor, um eine teratogene Wirk=
ung
von Follitropin alfa auszuschlieen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><i style=3D'mso-bidi-font-style:normal'><u><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Stillz=
eit<o:p></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
tab-stops:.5in'><u><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color=
:black;
mso-ansi-language:DE'><o:p><span style=3D'text-decoration:none'>&nbsp;</spa=
n></o:p></span></u></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Ovaleap </span><span lang=3DDE
style=3D'mso-ansi-language:DE'>ist whrend der Stillzeit nicht indiziert</s=
pan><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;tab-stops:.5in'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DDE style=3D'mso-bidi-f=
ont-size:
11.0pt;color:black;mso-ansi-language:DE'>Fertilitt<o:p></o:p></span></u></=
i></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;tab-stops:.5in'><u><sp=
an
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Ovaleap </span><span lang=3DDE
style=3D'mso-ansi-language:DE'>ist zur Anwendung bei Infertilitt indiziert
(siehe Abschnitt&nbsp;4.1).</span><span lang=3DDE style=3D'mso-bidi-font-si=
ze:11.0pt;
color:black;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal><i style=3D'mso-bidi-font-style:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></i></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan no-line-numbers;page-break-after:avoid;mso-outline-level:1'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>4.7<span style=3D'mso-tab-count:1'> </span=
>Auswirkungen
auf die Verkehrstchtigkeit und die Fhigkeit zum Bedienen von Maschinen</s=
pan></b><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>Ovaleap </span><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-a=
nsi-language:
DE'>hat keinen oder einen zu vernachlssigenden Einfluss auf die
Verkehrstchtigkeit und die Fhigkeit zum Bedienen von Maschinen. </span><s=
pan
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan no-line-numbers;page-break-after:avoid;mso-outline-level:1'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>4.8<span style=3D'mso-tab-count:1'> </span=
>Nebenwirkungen<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;tab-stops:.5in'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DDE style=3D'mso-bidi-f=
ont-size:
11.0pt;color:black;mso-ansi-language:DE'>Zusammenfassung des Sicherheitspro=
fils<o:p></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;tab-stops:.5in'><span =
lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Die am hufigsten gemeldeten
Nebenwirkungen sind Kopfschmerzen, Ovarialzysten und lokale Reaktionen an d=
er
Injektionsstelle (z. B. Schmerzen, Rtung, Bluterguss, Schwellung und/oder
Reizung an der Injektionsstelle).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Hufig wurde ber ein OHSS leichten
oder mittleren Schweregrades berichtet, das als intrinsisches Risiko des
Stimulationsprozesses angesehen werden muss. Ein schweres OHSS tritt
gelegentlich auf (siehe Abschnitt&nbsp;4.4).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Sehr selten kann es zu einer
Thromboembolie kommen (siehe Abschnitt&nbsp;4.4).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;tab-stops:.5in'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DDE style=3D'mso-bidi-f=
ont-size:
11.0pt;color:black;mso-ansi-language:DE'>Tabellarische Auflistung der Neben=
wirkungen</span></u></i><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
ansi-language:
DE'>Die folgenden Definitionen beziehen sich auf die nachstehend verwendeten
Hufigkeitsangaben: </span><span lang=3DDE style=3D'mso-bidi-font-size:11.0=
pt;
color:black;mso-ansi-language:DE'>sehr hufig (&#8805;&nbsp;1/10), hufig (=
&#8805;&nbsp;1/100,
&lt;&nbsp;1/10), gelegentlich (&#8805;&nbsp;1/1.000, &lt;&nbsp;1/100), selt=
en (&#8805;&nbsp;1/10.000,
&lt;&nbsp;1/1.000), sehr selten (&lt;&nbsp;1/10.000), nicht bekannt (Hufig=
keit
auf Grundlage der verfgbaren Daten nicht abschtzbar). </span><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Innerhalb jeder
Hufigkeitsgruppe werden die Nebenwirkungen nach abnehmendem Schweregrad
angegeben.<span style=3D'color:black'><o:p></o:p></span></span></p>

<p class=3DMsoNormal style=3D'margin-left:85.05pt;text-indent:-85.05pt;tab-=
stops:
.5in'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><i style=3D'mso-bidi-font-style:norm=
al'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'>Behandlung
von Frauen<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><i><span lang=3DDE style=3D'mso-bidi=
-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></i></p>

<table class=3DMsoNormalTable border=3D1 cellspacing=3D0 cellpadding=3D0
 style=3D'border-collapse:collapse;border:none;mso-border-bottom-alt:solid =
windowtext .5pt;
 mso-yfti-tbllook:480;mso-padding-alt:0in 5.4pt 0in 5.4pt;mso-border-inside=
h:
 .5pt solid windowtext;mso-border-insidev:.5pt solid windowtext'>
 <tr style=3D'mso-yfti-irow:0;mso-yfti-firstrow:yes'>
  <td width=3D614 colspan=3D3 valign=3Dtop style=3D'width:460.6pt;border:no=
ne;
  border-bottom:solid windowtext 1.0pt;mso-border-bottom-alt:solid windowte=
xt .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><b style=3D'mso-bidi-font-weight:normal'><span la=
ng=3DDE
  style=3D'mso-ansi-language:DE'>Tabelle&nbsp;1: Nebenwirkungen bei Frauen<=
o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:1'>
  <td width=3D205 valign=3Dtop style=3D'width:153.5pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><b style=3D'mso-bidi-font-weight:normal'><span la=
ng=3DDE
  style=3D'mso-ansi-language:DE'>Systemorganklasse<o:p></o:p></span></b></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><b style=3D'mso-bidi-font-weight:normal'><span la=
ng=3DDE
  style=3D'mso-ansi-language:DE'>Hufigkeit<o:p></o:p></span></b></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><b style=3D'mso-bidi-font-weight:normal'><span la=
ng=3DDE
  style=3D'mso-ansi-language:DE'>Nebenwirkung<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:2'>
  <td width=3D205 valign=3Dtop style=3D'width:153.5pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid;tab-stops:.5in'><i style=3D'mso-bidi-font-style:no=
rmal'><span
  lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Erkran=
kungen
  des Immunsystems</span></i><i style=3D'mso-bidi-font-style:normal'><span
  lang=3DDE style=3D'mso-ansi-language:DE'><o:p></o:p></span></i></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Sehr selten</span><span lang=3DDE
  style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Leichte bis schwerwiegende
  berempfindlichkeitsreaktionen einschlielich anaphylaktischer Reaktionen=
 und
  Schock</span><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p></o:p></=
span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:3'>
  <td width=3D205 valign=3Dtop style=3D'width:153.5pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid;tab-stops:.5in'><i style=3D'mso-bidi-font-style:no=
rmal'><span
  lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Erkran=
kungen
  des Nervensystems<o:p></o:p></span></i></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Sehr hufig</span><span lang=3DDE
  style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid;tab-stops:28.35pt center 71.35pt'><span lang=3DDE
  style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Kopf=
schmerzen</span><span
  lang=3DDE style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:4'>
  <td width=3D205 valign=3Dtop style=3D'width:153.5pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid;tab-stops:.5in'><i><span lang=3DDE style=3D'mso-bi=
di-font-size:
  11.0pt;color:black;mso-ansi-language:DE'>Geferkrankungen</span></i><i
  style=3D'mso-bidi-font-style:normal'><span lang=3DDE style=3D'mso-bidi-fo=
nt-size:
  11.0pt;mso-ansi-language:DE'><o:p></o:p></span></i></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Sehr selten</span><span lang=3DDE
  style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></spa=
n></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid;tab-stops:28.35pt center 71.35pt'><span lang=3DDE
  style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Thro=
mboembolien
  </span><span lang=3DDE style=3D'mso-ansi-language:DE'>(sowohl in Zusammen=
hang mit
  als auch unabhngig von einem OHSS)</span><span lang=3DDE style=3D'mso-bi=
di-font-size:
  11.0pt;mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:5'>
  <td width=3D205 valign=3Dtop style=3D'width:153.5pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid;tab-stops:.5in'><i><span lang=3DDE style=3D'mso-bi=
di-font-size:
  11.0pt;color:black;mso-ansi-language:DE'>Erkrankungen der Atemwege, des
  Brustraums und Mediastinums</span></i><i style=3D'mso-bidi-font-style:nor=
mal'><span
  lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p><=
/o:p></span></i></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Sehr selten</span><span lang=3DDE
  style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Exazerbation oder Verstrkung von Asthm=
a</span><span
  lang=3DDE style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:6'>
  <td width=3D205 valign=3Dtop style=3D'width:153.5pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><i><span lang=3DDE style=3D'mso-bidi-font-size:11=
.0pt;
  color:black;mso-ansi-language:DE'>Erkrankungen des Gastrointestinaltrakts=
</span></i><i
  style=3D'mso-bidi-font-style:normal'><span lang=3DDE style=3D'mso-bidi-fo=
nt-size:
  11.0pt;mso-ansi-language:DE'><o:p></o:p></span></i></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Hufig</span><span lang=3DDE
  style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Bauchschmerzen, aufgeblhter Bauch,
  abdominale Beschwerden, belkeit, Erbrechen, Diarrhoe</span><span lang=3D=
DE
  style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:7'>
  <td width=3D205 rowspan=3D4 valign=3Dtop style=3D'width:153.5pt;border:so=
lid windowtext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><i><span lang=3DDE style=3D'mso-bidi-font-size:11=
.0pt;
  color:black;mso-ansi-language:DE'>Erkrankungen der Geschlechtsorgane und =
der
  Brustdrse<o:p></o:p></span></i></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Sehr hufig</span><span lang=3DDE
  style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Ovarialzysten</span><span lang=3DDE
  style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:8'>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-ansi-language:DE'>H=
ufig<o:p></o:p></span></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Leichtes oder mittelschweres OHSS
  (einschlielich der damit verbundenen Symptomatik)</span><span lang=3DDE
  style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:9'>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-ansi-language:DE'>Ge=
legentlich<o:p></o:p></span></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Schweres OHSS (einschlielich der damit
  verbundenen Symptomatik) (siehe Abschnitt&nbsp;4.4)</span><span lang=3DDE
  style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:10'>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Selten</span><span lang=3DDE
  style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Komplikationen in Zusammenhang mit einem
  schweren OHSS</span><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p><=
/o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:11;mso-yfti-lastrow:yes'>
  <td width=3D205 valign=3Dtop style=3D'width:153.5pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><i style=3D'mso-bidi-font-style:normal'><span lan=
g=3DDE
  style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Allgemeine
  Erkrankungen und Beschwerden am Verabreichungsort</span></i><i
  style=3D'mso-bidi-font-style:normal'><span lang=3DDE style=3D'mso-ansi-la=
nguage:
  DE'><o:p></o:p></span></i></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Sehr hufig</span><span lang=3DDE
  style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Reaktionen an der Injektionsstelle
  (z.&nbsp;B. Schmerzen, Rtung, Bluterguss, Schwellung und/oder Reizung an=
 der
  Injektionsstelle)</span><span lang=3DDE style=3D'mso-ansi-language:DE'><o=
:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=3DMsoNormal style=3D'margin-left:85.05pt;text-indent:-85.05pt;mso-=
pagination:
none;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:85.05pt;text-indent:-85.05pt;mso-=
pagination:
widow-orphan lines-together;page-break-after:avoid;tab-stops:.5in'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DDE style=3D'mso-bidi-font=
-size:
11.0pt;color:black;mso-ansi-language:DE'>Behandlung von Mnnern<o:p></o:p><=
/span></i></p>

<p class=3DMsoNormal style=3D'margin-left:85.05pt;text-indent:-85.05pt;mso-=
pagination:
widow-orphan lines-together;page-break-after:avoid;tab-stops:.5in'><i><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE;
mso-no-proof:yes'><o:p>&nbsp;</o:p></span></i></p>

<table class=3DMsoNormalTable border=3D1 cellspacing=3D0 cellpadding=3D0
 style=3D'border-collapse:collapse;border:none;mso-border-bottom-alt:solid =
windowtext .5pt;
 mso-yfti-tbllook:480;mso-padding-alt:0in 5.4pt 0in 5.4pt;mso-border-inside=
h:
 .5pt solid windowtext;mso-border-insidev:.5pt solid windowtext'>
 <tr style=3D'mso-yfti-irow:0;mso-yfti-firstrow:yes'>
  <td width=3D614 colspan=3D3 valign=3Dtop style=3D'width:460.6pt;border:no=
ne;
  border-bottom:solid windowtext 1.0pt;mso-border-bottom-alt:solid windowte=
xt .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><b style=3D'mso-bidi-font-weight:normal'><span la=
ng=3DDE
  style=3D'mso-ansi-language:DE'>Tabelle&nbsp;2: Nebenwirkungen bei Mnnern=
<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:1'>
  <td width=3D205 valign=3Dtop style=3D'width:153.5pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><b style=3D'mso-bidi-font-weight:normal'><span la=
ng=3DDE
  style=3D'mso-ansi-language:DE'>Systemorganklasse<o:p></o:p></span></b></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><b style=3D'mso-bidi-font-weight:normal'><span la=
ng=3DDE
  style=3D'mso-ansi-language:DE'>Hufigkeit<o:p></o:p></span></b></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><b style=3D'mso-bidi-font-weight:normal'><span la=
ng=3DDE
  style=3D'mso-ansi-language:DE'>Nebenwirkung<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:2'>
  <td width=3D205 valign=3Dtop style=3D'width:153.5pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid;tab-stops:.5in'><i style=3D'mso-bidi-font-style:no=
rmal'><span
  lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Erkran=
kungen
  des Immunsystems</span></i><i style=3D'mso-bidi-font-style:normal'><span
  lang=3DDE style=3D'mso-ansi-language:DE'><o:p></o:p></span></i></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Sehr selten</span><span lang=3DDE
  style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Leichte bis schwerwiegende
  berempfindlichkeitsreaktionen einschlielich anaphylaktischer Reaktionen=
 und
  Schock</span><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p></o:p></=
span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:3'>
  <td width=3D205 valign=3Dtop style=3D'width:153.5pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid;tab-stops:.5in'><i><span lang=3DDE style=3D'mso-bi=
di-font-size:
  11.0pt;color:black;mso-ansi-language:DE'>Erkrankungen der Atemwege, des
  Brustraums und Mediastinums</span></i><i style=3D'mso-bidi-font-style:nor=
mal'><span
  lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p><=
/o:p></span></i></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Sehr selten</span><span lang=3DDE
  style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Exazerbation oder Verstrkung von Asthm=
a</span><span
  lang=3DDE style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:4'>
  <td width=3D205 valign=3Dtop style=3D'width:153.5pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><i><span lang=3DDE style=3D'mso-bidi-font-size:11=
.0pt;
  color:black;mso-ansi-language:DE'>Erkrankungen der Haut und des
  Unterhautzellgewebes</span></i><i style=3D'mso-bidi-font-style:normal'><s=
pan
  lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p><=
/o:p></span></i></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Hufig</span><span lang=3DDE
  style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Akne</span><span lang=3DDE style=3D'mso=
-ansi-language:
  DE'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:5'>
  <td width=3D205 valign=3Dtop style=3D'width:153.5pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><i><span lang=3DDE style=3D'mso-bidi-font-size:11=
.0pt;
  color:black;mso-ansi-language:DE'>Erkrankungen der Geschlechtsorgane und =
der
  Brustdrse<o:p></o:p></span></i></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Hufig<o:p></o:p></span></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Gynkomastie, Varikozele<o:p></o:p></sp=
an></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:6'>
  <td width=3D205 valign=3Dtop style=3D'width:153.5pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><i style=3D'mso-bidi-font-style:normal'><span lan=
g=3DDE
  style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Allgemeine
  Erkrankungen und Beschwerden am Verabreichungsort</span></i><i
  style=3D'mso-bidi-font-style:normal'><span lang=3DDE style=3D'mso-ansi-la=
nguage:
  DE'><o:p></o:p></span></i></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Sehr hufig</span><span lang=3DDE
  style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Reaktionen an der Injektionsstelle
  (z.&nbsp;B. Schmerzen, Rtung, Bluterguss, Schwellung und/oder Reizung an=
 der
  Injektionsstelle)</span><span lang=3DDE style=3D'mso-ansi-language:DE'><o=
:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:7;mso-yfti-lastrow:yes'>
  <td width=3D205 valign=3Dtop style=3D'width:153.5pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><i><span lang=3DDE style=3D'mso-bidi-font-size:11=
.0pt;
  color:black;mso-ansi-language:DE'>Untersuchungen</span></i><i
  style=3D'mso-bidi-font-style:normal'><span lang=3DDE style=3D'mso-bidi-fo=
nt-size:
  11.0pt;mso-ansi-language:DE'><o:p></o:p></span></i></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Hufig<o:p></o:p></span></p>
  </td>
  <td width=3D205 valign=3Dtop style=3D'width:153.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
  color:black;mso-ansi-language:DE'>Gewichtszunahme<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=3DMsoNormal style=3D'margin-left:85.05pt;text-indent:-85.05pt;mso-=
pagination:
none;tab-stops:.5in'><i><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></i></p>

<p class=3DMsoNormal><u><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
mso-ansi-language:DE;mso-no-proof:yes'>Meldung des Verdachts auf Nebenwirku=
ngen</span></u><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE;mso-no-proof:yes'>Die Meldung des Verdachts auf Nebenwirkungen nach der
Zulassung ist von groer Wichtigkeit.</span><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'> <span style=3D'mso-no-proof:yes'>Sie ermglic=
ht
eine kontinuierliche berwachung des Nutzen-Risiko-Verhltnisses des
Arzneimittels.</span> </span><span lang=3DDE style=3D'mso-ansi-language:DE'=
>Angehrige
von Gesundheitsberufen</span><span lang=3DDE style=3D'mso-bidi-font-size:11=
.0pt;
mso-ansi-language:DE;mso-no-proof:yes'> sind aufgefordert, jeden Verdachtsf=
all
einer Nebenwirkung ber <span style=3D'background:lightgrey;mso-highlight:l=
ightgrey'>das
in </span></span><span lang=3DEN-GB><a
href=3D"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_fo=
rm/2013/03/WC500139752.doc"><span
lang=3DDE style=3D'background:lightgrey;mso-highlight:lightgrey;mso-ansi-la=
nguage:
DE'>Anhang&nbsp;V</span></a></span><span lang=3DDE style=3D'mso-bidi-font-s=
ize:
11.0pt;background:lightgrey;mso-highlight:lightgrey;mso-ansi-language:DE;
mso-no-proof:yes'> aufgefhrte nationale Meldesystem</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-no-proof:yes'>
anzuzeigen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan no-line-numbers;mso-outline-level:1'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>4.9<span
style=3D'mso-tab-count:1'> </span>berdosierung</span></b><span lang=3D=
DE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'margin-left:85.05pt;text-indent:-85.05pt;page=
-break-after:
avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language=
:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
ansi-language:
DE'>Die Auswirkungen einer berdosierung von </span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Follit=
ropin
alfa </span><span lang=3DDE style=3D'mso-ansi-language:DE'>sind nicht bekan=
nt, es
besteht jedoch die Mglichkeit fr das Auftreten eines OHSS (siehe Abschnit=
t&nbsp;4.4).</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'><o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan no-line-numbers'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>5.<span
style=3D'mso-tab-count:1'> </span>PHARMAKOLOGISCHE EIGENSCHAFTEN</spa=
n></b><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan no-line-numbers'>=
<span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan no-line-numbers;mso-outline-level:1'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>5.1<span
style=3D'mso-tab-count:1'> </span>Pharmakodynamische Eigenschaften</spa=
n></b><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-bidi-font-style=
:italic'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
12.0pt;mso-ansi-language:DE'>Pharmakotherapeutische Gruppe</span><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>: </sp=
an><span
lang=3DDE style=3D'mso-ansi-language:DE'>Sexualhormone und Modulatoren des
Genitalsystems, Gonadotropine</span><span lang=3DDE style=3D'mso-bidi-font-=
size:
11.0pt;color:black;mso-ansi-language:DE'>, ATC-Code: G03GA05.<o:p></o:p></s=
pan></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-pagination:widow-orpha=
n no-line-numbers;
mso-list:skip'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:bla=
ck;
mso-ansi-language:DE'>Ovaleap ist ein </span><span lang=3DDE style=3D'mso-b=
idi-font-size:
12.0pt;mso-ansi-language:DE;mso-no-proof:yes'>biologisch/biotechnologisch
hergestelltes Arzneimittel, das im Wesentlichen einem bereits zugelassenen =
Arzneimittel
gleicht</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:blac=
k;
mso-ansi-language:DE'>. </span><span lang=3DDE style=3D'mso-bidi-font-size:=
12.0pt;
mso-ansi-language:DE'>Ausfhrliche Informationen sind auf den Internetseiten
der Europischen Arzneimittel-Agentur </span><span lang=3DEN-GB><a
href=3D"http://www.ema.europa.eu/"><span lang=3DDE style=3D'mso-bidi-font-s=
ize:12.0pt;
mso-ansi-language:DE'>http://www.ema.europa.eu</span></a></span><span lang=
=3DDE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'> verfgbar.<o:p></=
o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:85.05pt;text-indent:-85.05pt;page=
-break-after:
avoid'><i style=3D'mso-bidi-font-style:normal'><u><span lang=3DDE style=3D'=
mso-bidi-font-size:
12.0pt;mso-ansi-language:DE'>Pharmakodynamische Wirkungen</span></u></i><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DDE style=3D'mso-bidi-f=
ont-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'margin-left:85.05pt;text-indent:-85.05pt;page=
-break-after:
avoid;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
12.0pt;mso-ansi-language:DE'>Bei Frauen besteht die Hauptwirkung von parent=
eral
appliziertem FSH in der Entwicklung reifer Graaf'scher Follikel. Bei
anovulatorischen Frauen ist das Ziel der Behandlung mit Follitropin alfa die
Entwicklung eines einzelnen reifen Graafschen Follikels, aus dem die Eizel=
le
nach Verabreichung von hCG freigesetzt wird.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:85.05pt;text-indent:-85.05pt;mso-=
pagination:
widow-orphan lines-together;page-break-after:avoid;tab-stops:.5in'><i
style=3D'mso-bidi-font-style:normal'><u><span lang=3DDE style=3D'mso-bidi-f=
ont-size:
12.0pt;mso-ansi-language:DE'>Klinische Wirksamkeit und Sicherheit</span></u=
></i><i><u><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'> bei
Frauen<o:p></o:p></span></u></i></p>

<p class=3DMsoNormal style=3D'margin-left:85.05pt;text-indent:-85.05pt;mso-=
pagination:
widow-orphan lines-together;page-break-after:avoid;tab-stops:.5in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;mso-outline-level:1;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>In
klinischen Studien wurden Patientinnen mit schwerem FSH- und LH-Mangel durch
endogene LH-Serumspiegel von &lt;&nbsp;1,2&nbsp;I.E./l definiert, welche in
einem Zentrallabor bestimmt wurden. Es sollte jedoch bercksichtigt werden,
dass es Unterschiede bei LH-Bestimmungen in verschiedenen Labors gibt.<o:p>=
</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>In
klinischen Studien, die r-hFSH (Follitropin alfa) und urinres FSH im Rahme=
n der
ART (siehe untenstehende Tabelle&nbsp;3) und zur Ovulationsinduktion
verglichen, war Follitropin alfa wirksamer als urinres FSH im Hinblick auf
eine niedrigere Gesamtdosis und eine krzere Behandlungsdauer, die bentigt
wurde, um eine Follikelreifung einzuleiten.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Bei
Anwendung von Follitropin alfa im Rahmen der ART wurden bei einer niedriger=
en
Gesamtdosis und bei krzerer Behandlungsdauer im Vergleich zu urinrem FSH =
mehr
Eizellen gewonnen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Tabell=
e&nbsp;3:
</span><span lang=3DDE style=3D'mso-ansi-language:DE'>Ergebnisse von Studie=
 GF 8407
(randomisierte Studie im Parallelgruppendesign zur Wirksamkeit und
Vertrglichkeit von </span><span lang=3DDE style=3D'mso-bidi-font-size:11.0=
pt;
color:black;mso-ansi-language:DE'>Follitropin alfa </span><span lang=3DDE
style=3D'mso-ansi-language:DE'>im Vergleich zu urinrem FSH im Rahmen von A=
RT)</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'><o:p></o:p></span></p>

<table class=3DMsoNormalTable border=3D1 cellspacing=3D0 cellpadding=3D0 wi=
dth=3D576
 style=3D'width:432.35pt;margin-left:5.4pt;border-collapse:collapse;border:=
none;
 mso-border-alt:solid windowtext .5pt;mso-yfti-tbllook:480;mso-padding-alt:
 0in 5.4pt 0in 5.4pt;mso-border-insideh:.5pt solid windowtext'>
 <tr style=3D'mso-yfti-irow:0;mso-yfti-firstrow:yes'>
  <td width=3D265 valign=3Dtop style=3D'width:198.45pt;border:solid windowt=
ext 1.0pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid;mso-outline-level:1;tab-stops:.5in'><span lang=3DDE
  style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p=
>&nbsp;</o:p></span></p>
  </td>
  <td width=3D142 valign=3Dtop style=3D'width:106.35pt;border:solid windowt=
ext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-pagina=
tion:widow-orphan lines-together;
  page-break-after:avoid;tab-stops:.5in;mso-layout-grid-align:none;text-aut=
ospace:
  none'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-=
ansi-language:
  DE;mso-fareast-language:DE;mso-bidi-font-weight:bold'>Follitropin alfa<o:=
p></o:p></span></p>
  <p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-pagina=
tion:widow-orphan lines-together;
  page-break-after:avoid;mso-outline-level:1;tab-stops:.5in'><span lang=3DDE
  style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-f=
areast-language:
  DE;mso-bidi-font-weight:bold'>(n =3D 130)</span><span lang=3DDE style=3D'=
mso-bidi-font-size:
  11.0pt;color:black;mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D170 valign=3Dtop style=3D'width:127.55pt;border:solid windowt=
ext 1.0pt;
  border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt:
  solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-pagina=
tion:widow-orphan lines-together;
  page-break-after:avoid;tab-stops:.5in;mso-layout-grid-align:none;text-aut=
ospace:
  none'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-=
ansi-language:
  DE;mso-fareast-language:DE;mso-bidi-font-weight:bold'>urinres FSH<o:p></=
o:p></span></p>
  <p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-pagina=
tion:widow-orphan lines-together;
  page-break-after:avoid;mso-outline-level:1;tab-stops:.5in'><span lang=3DDE
  style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-f=
areast-language:
  DE;mso-bidi-font-weight:bold'>(n =3D 116)</span><span lang=3DDE style=3D'=
mso-bidi-font-size:
  11.0pt;color:black;mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:1'>
  <td width=3D265 valign=3Dtop style=3D'width:198.45pt;border:solid windowt=
ext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid;mso-outline-level:1;tab-stops:.5in'><span lang=3DDE
  style=3D'mso-ansi-language:DE'>Anzahl der gewonnenen Eizellen</span><span
  lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-languag=
e:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D142 valign=3Dtop style=3D'width:106.35pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-pagina=
tion:widow-orphan lines-together;
  page-break-after:avoid;mso-outline-level:1;tab-stops:.5in'><span lang=3DDE
  style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-f=
areast-language:
  DE'>11,0  5,9</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
  color:black;mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D170 valign=3Dtop style=3D'width:127.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-pagina=
tion:widow-orphan lines-together;
  page-break-after:avoid;mso-outline-level:1;tab-stops:.5in'><span lang=3DDE
  style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-f=
areast-language:
  DE'>8,8  4,8</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
  color:black;mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:2'>
  <td width=3D265 valign=3Dtop style=3D'width:198.45pt;border:solid windowt=
ext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid;mso-outline-level:1;tab-stops:.5in'><span lang=3DDE
  style=3D'mso-ansi-language:DE'>Bentigte Tage fr FSH-Stimulation</span><=
span
  lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-languag=
e:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D142 valign=3Dtop style=3D'width:106.35pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-pagina=
tion:widow-orphan lines-together;
  page-break-after:avoid;mso-outline-level:1;tab-stops:.5in'><span lang=3DDE
  style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-f=
areast-language:
  DE'>11,7  1,9</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
  color:black;mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D170 valign=3Dtop style=3D'width:127.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-pagina=
tion:widow-orphan lines-together;
  page-break-after:avoid;mso-outline-level:1;tab-stops:.5in'><span lang=3DDE
  style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-f=
areast-language:
  DE'>14,5  3,3</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
  color:black;mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:3'>
  <td width=3D265 valign=3Dtop style=3D'width:198.45pt;border:solid windowt=
ext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid;mso-outline-level:1;tab-stops:.5in'><span lang=3DDE
  style=3D'mso-ansi-language:DE'>Erforderliche FSH-Gesamtdosis (Anzahl an F=
SH 75&nbsp;I.E.
  Ampullen) </span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color=
:black;
  mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D142 valign=3Dtop style=3D'width:106.35pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-pagina=
tion:widow-orphan lines-together;
  page-break-after:avoid;mso-outline-level:1;tab-stops:.5in'><span lang=3DDE
  style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-f=
areast-language:
  DE'>27,6  10,2</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
  color:black;mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D170 valign=3Dtop style=3D'width:127.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-pagina=
tion:widow-orphan lines-together;
  page-break-after:avoid;mso-outline-level:1;tab-stops:.5in'><span lang=3DDE
  style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-f=
areast-language:
  DE'>40,7  13,6</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
  color:black;mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:4;mso-yfti-lastrow:yes'>
  <td width=3D265 valign=3Dtop style=3D'width:198.45pt;border:solid windowt=
ext 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
  page-break-after:avoid;mso-outline-level:1;tab-stops:.5in'><span lang=3DDE
  style=3D'mso-ansi-language:DE'>Notwendigkeit, die Dosis zu erhhen (%)</s=
pan><span
  lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-languag=
e:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D142 valign=3Dtop style=3D'width:106.35pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-pagina=
tion:widow-orphan lines-together;
  page-break-after:avoid;mso-outline-level:1;tab-stops:.5in'><span lang=3DDE
  style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-f=
areast-language:
  DE'>56,2</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:b=
lack;
  mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
  <td width=3D170 valign=3Dtop style=3D'width:127.55pt;border-top:none;bord=
er-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1=
.0pt;
  mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid window=
text .5pt;
  mso-border-alt:solid windowtext .5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-pagina=
tion:widow-orphan lines-together;
  page-break-after:avoid;mso-outline-level:1;tab-stops:.5in'><span lang=3DDE
  style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-f=
areast-language:
  DE'>85,3</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:b=
lack;
  mso-ansi-language:DE'><o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-ansi-language:DE'>Die Unterschiede zwischen den zwei Gruppen w=
aren
fr alle aufgelisteten Kriterien statistisch signifikant
(p&nbsp;&lt;&nbsp;0,05).</span><span lang=3DDE style=3D'mso-bidi-font-size:=
11.0pt;
color:black;mso-ansi-language:DE;mso-fareast-language:DE'><o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-far=
east-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:85.05pt;text-indent:-85.05pt;page=
-break-after:
avoid;tab-stops:.5in'><i style=3D'mso-bidi-font-style:normal'><u><span lang=
=3DDE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Klinische Wirksamk=
eit
und Sicherheit</span></u></i><i><u><span lang=3DDE style=3D'mso-bidi-font-s=
ize:
11.0pt;color:black;mso-ansi-language:DE'> bei Mnnern<o:p></o:p></span></u>=
</i></p>

<p class=3DMsoNormal style=3D'margin-left:85.05pt;text-indent:-85.05pt;page=
-break-after:
avoid;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Bei M=
nnern
mit FSH-Mangel induziert Follitropin alfa bei gleichzeitiger Anwendung von =
hCG
ber mindestens 4&nbsp;Monate hinweg die Spermatogenese.<o:p></o:p></span><=
/p>

<p class=3DMsoNormal style=3D'mso-outline-level:1;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan lines-together no-line-numbers;page-break-after:avoid;mso-outl=
ine-level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
12.0pt;mso-ansi-language:DE'>5.2<span style=3D'mso-tab-count:1'> </span=
>Pharmakokinetische
Eigenschaften<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-left:85.05pt;text-indent:-85.05pt;mso-=
pagination:
widow-orphan lines-together;page-break-after:avoid;mso-list:skip'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-bidi-=
font-style:
italic'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-pagination:widow-orpha=
n lines-together;
page-break-after:avoid;mso-list:skip'><span lang=3DDE style=3D'mso-ansi-lan=
guage:
DE'>Nach intravenser Injektion wird Follitropin alfa im Extrazellularraum =
mit
einer initialen Halbwertszeit von 2 Stunden verteilt und mit einer terminal=
en
Halbwertszeit von etwa 1&nbsp;Tag aus dem Krper ausgeschieden. Das
Verteilungsvolumen im Steady-state betrgt 10&nbsp;l, die Gesamt-Clearance
liegt bei 0,6&nbsp;l/Stunde. Ein Achtel der eingesetzten Dosis von Follitro=
pin
alfa wird mit dem Urin ausgeschieden.</span><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;color:black;mso-ansi-language:DE;mso-fareast-language:DE'><o:p></o:p=
></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-far=
east-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-bid=
i-font-style:
italic'>Nach subkutaner Gabe betrgt die absolute Bioverfgbarkeit etwa 70&=
nbsp;%.
Bei wiederholter Gabe wird Follitropin alfa 3-fach akkumuliert und ein
Steady-state wird nach 3&#8209;4&nbsp;Tagen erreicht. Bei Frauen, deren
endogene Gonadotropinsekretion supprimiert wurde, hat Follitropin alfa trotz
LH-Spiegeln unter der Nachweisgrenze nachweislich die Follikelentwicklung u=
nd
Steroidgenese wirksam stimuliert.</span><span lang=3DDE style=3D'mso-bidi-f=
ont-size:
11.0pt;color:black;mso-ansi-language:DE;mso-fareast-language:DE'><o:p></o:p=
></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-bidi-font-style=
:italic'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan lines-together no-line-numbers;page-break-after:avoid;mso-outl=
ine-level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
12.0pt;mso-ansi-language:DE'>5.3<span style=3D'mso-tab-count:1'> </span=
>Prklinische
Daten zur Sicherheit</span></b><span lang=3DDE style=3D'mso-bidi-font-size:=
12.0pt;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:85.05pt;text-indent:-85.05pt;mso-=
pagination:
widow-orphan lines-together;page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-pagination:widow-orpha=
n lines-together;
page-break-after:avoid;mso-list:skip'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;color:black;mso-ansi-language:DE;mso-bidi-font-style:italic'>Basiere=
nd
auf den konventionellen Studien zur akuten Toxizitt, Toxizitt bei
wiederholter Gabe und Genotoxizitt lassen die prklinischen Daten keine
besonderen Gefahren fr den Menschen erkennen, welche sich zustzlich zu den
bereits in anderen Abschnitten dieser Zusammenfassung der Merkmale des
Arzneimittels erwhnten Eigenschaften ergeben wrden.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-bid=
i-font-style:
italic'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-bid=
i-font-style:
italic'>Eine Beeintrchtigung der Fertilitt wurde bei Ratten beobachtet, d=
enen
ber einen lngeren Zeitraum pharmakologische Dosierungen von Follitropin a=
lfa
(&#8805;&nbsp;40&nbsp;I.E./kg/Tag) verabreicht wurden.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-bid=
i-font-style:
italic'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE;mso-bid=
i-font-style:
italic'>Bei Gabe von hohen Dosen (&#8805;&nbsp;5&nbsp;I.E./kg/Tag) verursac=
hte
Follitropin alfa eine Abnahme der Anzahl lebensfhiger Ften ohne dabei
teratogen zu sein, sowie eine Wehenanomalie hnlich, wie sie nach Gabe von
humanem Menopausengonadotropin (hMG) aus Urin beobachtet wurde. Da die
Anwendung von </span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
mso-ansi-language:DE'>Ovaleap <span style=3D'mso-bidi-font-style:italic'>in=
 der
Schwangerschaft jedoch nicht indiziert ist, sind diese Daten von
untergeordneter klinischer Bedeutung.<o:p></o:p></span></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan no-line-numbers'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>6.<span
style=3D'mso-tab-count:1'> </span>PHARMAZEUTISCHE ANGABEN<o:p></o:p><=
/span></b></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan no-line-numbers'>=
<span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan no-line-numbers;mso-outline-level:1'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>6.1<span
style=3D'mso-tab-count:1'> </span>Liste der sonstigen Bestandteile</spa=
n></b><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:85.05pt;text-indent:-85.05pt;page=
-break-after:
avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language=
:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'colo=
r:black;
mso-ansi-language:DE'>Natriumdihydrogenphosphat-Dihydrat</span><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'colo=
r:black;
mso-ansi-language:DE'>Natriumhydroxid (2&nbsp;M) (zur pH-Einstellung)<o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Mannitol<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Methionin<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Polysorbat 20<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Benzylalkohol<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Benzalkoniumchlorid<o:p></o:p></sp=
an></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'colo=
r:black;
mso-ansi-language:DE'>Wasser fr Injektionszwecke</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p><=
/o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan no-line-numbers;mso-outline-level:1'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>6.2<span
style=3D'mso-tab-count:1'> </span>Inkompatibilitten</span></b><span la=
ng=3DDE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
12.0pt;mso-ansi-language:DE'>Da keine Kompatibilittsstudien durchgefhrt
wurden, darf dieses Arzneimittel nicht mit anderen Arzneimitteln gemischt w=
erden.</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'><o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan no-line-numbers;mso-outline-level:1'><b style=3D'mso-bidi-font=
-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>6.3<span
style=3D'mso-tab-count:1'> </span>Dauer der Haltbarkeit</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:red;mso-ansi-language:DE'>3</span><span lang=3DDE style=3D'mso=
-bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>&nbsp;Jahre.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;tab-stops:.5in'><u><sp=
an
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Dauer der
Haltbarkeit und Lagerungsbedingungen nach Anbruch<span style=3D'color:black=
'><o:p></o:p></span></span></u></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Die in den Pen eingelegte Patrone =
kann
hchstens 28&nbsp;Tage aufbewahrt werden. Nicht ber 25&nbsp;C lagern.</sp=
an><span
lang=3DDE style=3D'mso-ansi-language:DE'> Der Patient soll das Datum der er=
sten
Anwendung in dem Patiententagebuch notieren, das dem Ovaleap-Pen beiliegt.<=
/span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Die Kappe des Pens muss nach jeder
Injektion wieder auf den Pen aufgesetzt werden, um den Inhalt vor Licht zu
schtzen.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><b style=3D'mso-bidi-=
font-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>6.4<span
style=3D'mso-tab-count:1'> </span>Besondere Vorsichtsmanahmen fr die
Aufbewahrung<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Im Khlschrank lagern (2&nbsp;C&#=
8209;8&nbsp;C).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Nicht einfrieren.<o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Die Patrone im Umkarton aufbewahre=
n,
um den Inhalt vor Licht zu schtzen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Das Arzneimittel kann ungeffnet
innerhalb der Dauer der Haltbarkeit aus dem Khlschrank genommen und ohne
erneute Khlung bis zu 3 Monate aufbewahrt werden. Nicht ber 25&nbsp;C la=
gern.
Ist das Arzneimittel nach 3&nbsp;Monaten nicht verwendet worden, muss es ve=
rworfen
werden.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso=
-ansi-language:
DE'>Aufbewahrungsbedingungen nach Anbruch des Arzneimittels, siehe Abschnit=
t&nbsp;6.3.</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan lines-together no-line-numbers;page-break-after:avoid;mso-outl=
ine-level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
12.0pt;mso-ansi-language:DE'>6.5<span style=3D'mso-tab-count:1'> </span=
>Art
und Inhalt des Behltnisses<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-pagination:widow-orphan lines-together;page-break-after:avoid;mso-layou=
t-grid-align:
none;text-autospace:none'><u><span lang=3DDE style=3D'mso-bidi-font-size:11=
.0pt;
color:black;mso-ansi-language:DE'>Ovaleap 300&nbsp;I.E./0,5&nbsp;ml
Injektionslsung<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;mso-layout-grid-align:none;text-autospace:none'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'>Patrone
(Typ-I-Glas) mit einem Gummikolben (Brombutylgummi) und einer Brdelkappe (=
Aluminium)
mit Septum (Brombutylgummi); sie enthlt 0,5&nbsp;ml Lsung.<br>
Injektionsnadeln (Edelstahl; 0,33&nbsp;mm&nbsp;x&nbsp;12&nbsp;mm,
29&nbsp;G&nbsp;x&nbsp;&quot;).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;background:lightgrey;mso-highlight:lightgrey;mso-ansi-la=
nguage:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Packungsgre mit 1&nbsp;Patrone u=
nd 10&nbsp;Injektionsnadeln</span><span
lang=3DDE style=3D'mso-ansi-language:DE'>.</span><span lang=3DDE style=3D'm=
so-bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;color:black;background:lightgrey;mso-highlight:lightgrey;mso-ansi-la=
nguage:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso=
-ansi-language:
DE'>Es werden mglicherweise nicht alle Packungsgren in den Verkehr gebra=
cht.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><u><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Ovaleap
450&nbsp;I.E./0,75&nbsp;ml Injektionslsung<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:bl=
ack;
mso-ansi-language:DE'>Patrone (Typ-I-Glas) mit einem Gummikolben
(Brombutylgummi) und einer Brdelkappe (Aluminium) mit Septum (Brombutylgum=
mi);
sie enthlt 0,75&nbsp;ml Lsung.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:bl=
ack;
mso-ansi-language:DE'>Injektionsnadeln (Edelstahl;
0,33&nbsp;mm&nbsp;x&nbsp;12&nbsp;mm, 29&nbsp;G&nbsp;x&nbsp;&quot;).<o:p></=
o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Packungsgre mit 1&nbsp;Patrone u=
nd
10&nbsp;Injektionsnadeln</span><span lang=3DDE style=3D'mso-ansi-language:D=
E'>.</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;color:black;background:lightgrey;mso-highlight:lightgrey;mso-ansi-la=
nguage:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso=
-ansi-language:
DE'>Es werden mglicherweise nicht alle Packungsgren in den Verkehr gebra=
cht.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><u><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Ovaleap
900&nbsp;I.E./1,5&nbsp;ml Injektionslsung<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Patrone (Typ-I-Glas) mit einem
Gummikolben (Brombutylgummi) und einer Brdelkappe (Aluminium) mit Septum
(Brombutylgummi); sie enthlt 1,5&nbsp;ml Lsung.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Injektionsnadeln (Edelstahl;
0,33&nbsp;mm&nbsp;x&nbsp;12&nbsp;mm, 29&nbsp;G&nbsp;x&nbsp;&quot;).<o:p></=
o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Packungsgre mit 1&nbsp;Patrone u=
nd
20&nbsp;Injektionsnadeln</span><span lang=3DDE style=3D'mso-ansi-language:D=
E'>.</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'><o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso=
-ansi-language:
DE'>Es werden mglicherweise nicht alle Packungsgren in den Verkehr gebra=
cht.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan no-line-numbers;mso-outline-level:1'><a name=3D"OLE_LINK1"><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>6.6<span style=3D'mso-tab-count:1'> </span=
>Besondere
Vorsichtsmanahmen fr die Beseitigung und sonstige Hinweise zur Handhabung=
</span></b></a><span
style=3D'mso-bookmark:OLE_LINK1'><span lang=3DDE style=3D'mso-bidi-font-siz=
e:12.0pt;
mso-ansi-language:DE'><o:p></o:p></span></span></p>

<span style=3D'mso-bookmark:OLE_LINK1'></span>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
12.0pt;mso-ansi-language:DE'>Keine besonderen Anforderungen fr die
Beseitigung.</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color=
:black;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
ansi-language:
DE'>Die Lsung darf nicht angewendet werden, wenn sie Schwebstoffe enthlt =
oder
nicht klar ist. </span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
color:black;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Ovaleap ist nur fr die Anwendung =
mit
dem Ovaleap-Pen bestimmt. Die Anwendungshinweise fr den Pen mssen genau
eingehalten werden.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Jede Patrone darf nur von einem
einzigen Patienten verwendet werden.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Leere Patronen drfen nicht wieder
aufgefllt werden. Der Inhalt der Ovaleap-Patronen darf nicht mit anderen
Arzneimitteln in der Patrone gemischt werden.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
ansi-language:
DE'>Benutzte Injektionsnadeln sind nach der Injektion unverzglich zu entso=
rgen</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'>.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan no-line-numbers'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>7.<span
style=3D'mso-tab-count:1'> </span>INHABER DER ZULASSUNG</span></b><sp=
an
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>Theramex Ireland Limited<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DEN-GB style=3D'm=
so-bidi-font-family:
Verdana;color:black'>3<sup>rd</sup> Floor, </span><span lang=3DNL
style=3D'mso-ansi-language:NL'>Kilmore House,<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>Park Lane, Spencer Dock,<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>Dublin 1<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>D01 YE64<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
mso-ansi-language:DE;mso-no-proof:yes'>Irland</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan lines-together no-line-numbers;page-break-after:avoid'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>8.<span style=3D'mso-tab-count:1'> </spa=
n>ZULASSUNGSNUMMER(N)<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-pagination:widow-orphan lines-together;page-break-after:avoid;mso-layou=
t-grid-align:
none;text-autospace:none'><u><span lang=3DDE style=3D'mso-bidi-font-size:11=
.0pt;
color:black;mso-ansi-language:DE'>Ovaleap 300&nbsp;I.E./0,5&nbsp;ml
Injektionslsung<o:p></o:p></span></u></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>EU/1/13/871/001<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><u><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Ovaleap
450&nbsp;I.E./0,75&nbsp;ml Injektionslsung<o:p></o:p></span></u></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>EU/1/13/871/002<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><u><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Ovaleap
900&nbsp;I.E./1,5&nbsp;ml Injektionslsung<o:p></o:p></span></u></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>EU/1/13/871/003<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan no-line-numbers'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>9.<span
style=3D'mso-tab-count:1'> </span>DATUM DER ERTEILUNG DER ZULASSUNG/V=
ERLNGERUNG
DER ZULASSUNG</span></b><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
12.0pt;mso-ansi-language:DE'>Datum der Erteilung der Zulassung</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'>: 27.
September 2013.<i style=3D'mso-bidi-font-style:normal'><o:p></o:p></i></spa=
n></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>Datum d=
er letzten
Verlngerung der Zulassung: 16. Mai 2018.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan no-line-numbers'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>10.<span
style=3D'mso-tab-count:1'> </span>STAND DER INFORMATION<o:p></o:p></spa=
n></b></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-pagination:widow-orpha=
n no-line-numbers;
mso-list:skip'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-=
language:
DE'>Ausfhrliche Informationen zu diesem Arzneimittel sind auf den
Internetseiten der Europischen Arzneimittel-Agentur </span><span lang=3DEN=
-GB><a
href=3D"http://www.ema.europa.eu/"><span lang=3DDE style=3D'mso-bidi-font-s=
ize:12.0pt;
mso-ansi-language:DE'>http://www.ema.europa.eu</span></a></span><span lang=
=3DDE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'> verfgbar.</span>=
<span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;background:lightgrey;mso-highl=
ight:
lightgrey;mso-ansi-language:DE;mso-bidi-font-style:italic'><o:p></o:p></spa=
n></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'font-size=
:11.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roma=
n";
mso-ansi-language:DE;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=3Dall style=3D'mso-special-character:line-break;page-break-before:alw=
ays'>
</span></b>

<p class=3DMsoNormal style=3D'mso-pagination:no-line-numbers'><span lang=3D=
DE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-paginati=
on:widow-orphan no-line-numbers'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>ANHANG&nbsp;II</span></b><span lang=3DDE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:70.8pt;margin-bot=
tom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-pagi=
nation:
widow-orphan no-line-numbers'><span lang=3DDE style=3D'mso-bidi-font-size:1=
2.0pt;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:42.55pt;margin-bo=
ttom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;mso-pagi=
nation:
widow-orphan no-line-numbers'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>A.<span
style=3D'mso-tab-count:1'> </span>HERSTELLER DES WIRKSTOFFS BIOLOGIS=
CHEN
URSPRUNGS UND HERSTELLER, DIE FR DIE CHARGENFREIGABE VERANTWORTLICH SIND</=
span></b><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:42.55pt;margin-bo=
ttom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;mso-pagi=
nation:
widow-orphan no-line-numbers'><span lang=3DDE style=3D'mso-bidi-font-size:1=
2.0pt;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:42.55pt;margin-bo=
ttom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;mso-pagi=
nation:
widow-orphan no-line-numbers'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>B.<span
style=3D'mso-tab-count:1'> </span>BEDINGUNGEN ODER EINSCHRNKUNGEN F=
R DIE
ABGABE UND DEN GEBRAUCH</span></b><span lang=3DDE style=3D'mso-bidi-font-si=
ze:12.0pt;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:42.55pt;margin-bo=
ttom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;mso-pagi=
nation:
widow-orphan no-line-numbers'><span lang=3DDE style=3D'mso-bidi-font-size:1=
2.0pt;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:42.55pt;margin-bo=
ttom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;mso-hyph=
enate:
none;tab-stops:-.5in 28.35pt'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>C.<span
style=3D'mso-tab-count:1'> </span>SONSTIGE BEDINGUNGEN UND AUFLAGEN =
DER
GENEHMIGUNG FR DAS INVERKEHRBRINGEN<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:42.55pt;margin-bo=
ttom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;mso-hyph=
enate:
none;tab-stops:-.5in 28.35pt'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:42.55pt;margin-bo=
ttom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;mso-hyph=
enate:
none;tab-stops:-.5in 28.35pt'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>D.<span
style=3D'mso-tab-count:1'> </span>BEDINGUNGEN ODER EINSCHRNKUNGEN F=
R DIE
SICHERE UND WIRKSAME ANWENDUNG DES ARZNEIMITTELS <o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:70.5pt;margin-bot=
tom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;mso-hyphe=
nate:
none;tab-stops:-.5in 28.35pt'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></b></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'font-size=
:11.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roma=
n";
mso-ansi-language:DE;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=3Dall style=3D'page-break-before:always'>
</span></b>

<p class=3DTitleB style=3D'page-break-after:avoid'><span lang=3DDE style=3D=
'mso-ansi-language:
DE;mso-no-proof:no'>A.<span style=3D'mso-tab-count:1'> </span></span><=
span
lang=3DDE style=3D'mso-ansi-language:DE'>HERSTELLER DES WIRKSTOFFS BIOLOGIS=
CHEN
URSPRUNGS UND HERSTELLER, DIE FR DIE CHARGENFREIGABE VERANTWORTLICH SIND<o=
:p></o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><u><span lang=3DDE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Name und Anschrift=
 des
Herstellers des Wirkstoffs biologischen Ursprungs</span></u><u><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</u></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt;mso-list:skip;tab-stops:=
.5in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-bidi-=
font-weight:
bold'>Teva Biotech GmbH<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt;mso-list:skip;tab-stops:=
.5in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-bidi-=
font-weight:
bold'>Dornierstrae 10<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt;mso-list:skip;tab-stops:=
.5in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-bidi-=
font-weight:
bold'>D-89079 Ulm<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt;tab-stops:.5in'><span la=
ng=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Deutschland<o:p></=
o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt'><span lang=3DDE style=
=3D'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><u><span lang=3DDE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Name und Anschrift=
 der
Hersteller, die fr die Chargenfreigabe verantwortlich sind</span></u><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt;mso-list:skip;tab-stops:=
.5in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-bidi-=
font-weight:
bold'>Teva Biotech GmbH<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt;mso-list:skip;tab-stops:=
.5in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-bidi-=
font-weight:
bold'>Dornierstrae 10<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt;mso-list:skip;tab-stops:=
.5in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-bidi-=
font-weight:
bold'>D-89079 Ulm<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt;tab-stops:.5in'><span la=
ng=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Deutschland<o:p></=
o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt'><span lang=3DDE style=
=3D'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt'><span lang=3DDE style=
=3D'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>Teva Pharmaceuticals Europe B.V.<o:p></o:p></s=
pan></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt'><span lang=3DDE style=
=3D'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>Swensweg 5<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt'><span lang=3DDE style=
=3D'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>NL-2031 GA Haarlem<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt'><span lang=3DDE style=
=3D'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>Niederlande<span style=3D'mso-no-proof:yes'><o=
:p></o:p></span></span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt'><span lang=3DDE style=
=3D'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt'><span lang=3DDE style=
=3D'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE;mso-no-proof:yes'>Merckle GmbH<o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt'><span lang=3DDE style=
=3D'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE;mso-no-proof:yes'>Graf-Arco-Strae 3<o:p></o:p>=
</span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt'><span lang=3DDE style=
=3D'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE;mso-no-proof:yes'>89079 Ulm, <o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt;tab-stops:.5in'><span la=
ng=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Deutschland<o:p></=
o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt'><span lang=3DDE style=
=3D'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.05pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
12.0pt;mso-ansi-language:DE'>In der Druckversion der Packungsbeilage des
Arzneimittels mssen Name und Anschrift des Herstellers, der fr die Freiga=
be
der betreffenden Charge verantwortlich ist, angegeben werden.</span><span
lang=3DDE style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt'><span lang=3DDE style=
=3D'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt'><span lang=3DDE style=
=3D'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DTitleB style=3D'page-break-after:avoid'><a name=3D"OLE_LINK2"><s=
pan
lang=3DDE style=3D'mso-ansi-language:DE;mso-no-proof:no'>B.</span></a><span
lang=3DDE style=3D'mso-ansi-language:DE;mso-no-proof:no'><span style=3D'mso=
-tab-count:
1'> </span></span><span lang=3DDE style=3D'mso-ansi-language:DE'>BEDIN=
GUNGEN
ODER EINSCHRNKUNGEN FR DIE ABGABE UND DEN GEBRAUCH<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-right:-.05pt;mso-list:skip'><span lang=
=3DDE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Arzneimittel auf
eingeschrnkte rztliche Verschreibung (siehe Anhang&nbsp;I: Zusammenfassung
der Merkmale des Arzneimittels, Abschnitt&nbsp;4.2).</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt;mso-list:skip'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt;mso-list:skip'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DTitleB style=3D'page-break-after:avoid'><span lang=3DDE style=3D=
'mso-ansi-language:
DE;mso-no-proof:no'>C.<span style=3D'mso-tab-count:1'> </span></span><=
span
lang=3DDE style=3D'mso-ansi-language:DE'>SONSTIGE BEDINGUNGEN UND AUFLAGEN =
DER
GENEHMIGUNG FR DAS INVERKEHRBRINGEN<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;page=
-break-after:
avoid;mso-list:l21 level1 lfo4'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b style=3D'mso-bidi-font-weight:normal'><sp=
an
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Regelm=
ig
aktualisierte Unbedenklichkeitsberichte</span></b><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-right:28.35pt;mso-pagination:widow-orp=
han no-line-numbers;
tab-stops:0in 28.35pt'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;
mso-ansi-language:DE'>Die Anforderungen an die Einreichung von regelmig
aktualisierten Unbedenklichkeitsberichten fr dieses Arzneimittel sind in d=
er
nach Artikel&nbsp;107&nbsp;c Absatz&nbsp;7 der Richtlinie&nbsp;2001/83/EG
vorgesehenen und im europischen Internetportal fr Arzneimittel
verffentlichten Liste der in der Union festgelegten Stichtage (EURD-Liste)=
 
und allen knftigen Aktualisierungen  festgelegt.<i style=3D'mso-bidi-font=
-style:
normal'><o:p></o:p></i></span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt'><span lang=3DDE style=
=3D'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt'><span lang=3DDE style=
=3D'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DTitleB style=3D'page-break-after:avoid'><span lang=3DDE style=3D=
'mso-ansi-language:
DE;mso-no-proof:no'>D.<span style=3D'mso-tab-count:1'> </span></span><=
span
lang=3DDE style=3D'mso-ansi-language:DE'>BEDINGUNGEN ODER EINSCHRNKUNGEN F=
R DIE
SICHERE UND WIRKSAME ANWENDUNG DES ARZNEIMITTELS<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan no-line-numbers;page-break-after:avoid'><b><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></b></p>

<p class=3DMsoNormal style=3D'margin-left:.5in;text-indent:-.5in;mso-pagina=
tion:
widow-orphan no-line-numbers;page-break-after:avoid;mso-list:l20 level1 lfo=
12;
tab-stops:28.35pt list .5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:12.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b style=3D'mso-bidi-font-weight:normal'><sp=
an
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Risikoma=
nagement-Plan
(RMP)<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-left:.5in;mso-pagination:widow-orphan =
no-line-numbers;
page-break-after:avoid'><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DDE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></b></p>

<p class=3DMsoNormal style=3D'margin-right:28.35pt;mso-pagination:widow-orp=
han no-line-numbers;
tab-stops:0in 28.35pt'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;
mso-ansi-language:DE'>Der Inhaber der Genehmigung fr das Inverkehrbringen
fhrt die notwendigen, im vereinbarten RMP beschriebenen und in Modul&nbsp;=
1.8.2
der Zulassung dargelegten Pharmakovigilanzaktivitten und Manahmen sowie a=
lle
knftigen vereinbarten Aktualisierungen des RMP durch.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:28.35pt'><span lang=3DDE style=
=3D'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.05pt;mso-pagination:widow-orph=
an no-line-numbers'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Ein
aktualisierter RMP ist einzureichen:<i style=3D'mso-bidi-font-style:normal'=
><o:p></o:p></i></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-.05pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-14.15pt;line-hei=
ght:
13.0pt;mso-line-height-rule:exactly;mso-pagination:widow-orphan no-line-num=
bers;
mso-list:l11 level1 lfo13'><![if !supportLists]><span lang=3DDE style=3D'ms=
o-bidi-font-size:
12.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-fami=
ly:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></sp=
an></span><![endif]><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>nach Auf=
forderung
durch die Europische Arzneimittel-Agentur;<i style=3D'mso-bidi-font-style:=
normal'><o:p></o:p></i></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-.05pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-14.15pt;line-hei=
ght:
13.0pt;mso-line-height-rule:exactly;mso-pagination:widow-orphan no-line-num=
bers;
mso-list:l11 level1 lfo13'><![if !supportLists]><span lang=3DDE style=3D'ms=
o-bidi-font-size:
12.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-fami=
ly:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></sp=
an></span><![endif]><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>jedes Ma=
l wenn
das Risikomanagement-System gendert wird, insbesondere infolge neuer
eingegangener Informationen, die zu einer wesentlichen nderung des
Nutzen-Risiko-Verhltnisses fhren knnen oder infolge des Erreichens eines
wichtigen Meilensteins (in Bezug auf Pharmakovigilanz oder Risikominimierun=
g).<o:p></o:p></span></p>

<b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'font-size=
:11.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roma=
n";
mso-ansi-language:DE;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=3Dall style=3D'mso-special-character:line-break;page-break-before:alw=
ays'>
</span></b>

<p class=3DMsoNormal style=3D'margin-right:-.05pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-paginati=
on:widow-orphan no-line-numbers;
mso-outline-level:1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
DE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>ANHANG&nbsp;III<o:=
p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-paginati=
on:widow-orphan no-line-numbers'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-paginati=
on:widow-orphan no-line-numbers;
mso-outline-level:1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
DE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>ETIKETTIERUNG UND
PACKUNGSBEILAGE<o:p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><b style=3D=
'mso-bidi-font-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'><o:p>&nbsp;</o:p></span></b></p>

<span lang=3DDE style=3D'font-size:11.0pt;font-family:"Times New Roman",ser=
if;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:DE;mso-fareast-=
language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'mso-special-charact=
er:line-break;
page-break-before:always'>
</span>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DTitleA><span lang=3DDE style=3D'mso-ansi-language:DE'>A. ETIKETT=
IERUNG<o:p></o:p></span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<span lang=3DDE style=3D'font-size:11.0pt;font-family:"Times New Roman",ser=
if;
mso-fareast-font-family:"Times New Roman";color:black;mso-color-alt:windowt=
ext;
mso-ansi-language:DE;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br
clear=3Dall style=3D'page-break-before:always'>
</span>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=3DMsoNormal style=3D'background:white;border:none;mso-border-alt:s=
olid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;color:black;mso-=
color-alt:
windowtext;mso-ansi-language:DE'>ANGABEN AUF DER USSEREN UMHLLUNG</span><=
/b><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;back=
ground:
white;mso-shading:transparent;border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-bidi-font-weigh=
t:
bold'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'background:white;mso-shading:transparent;bord=
er:none;
mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-alt:1.0pt 4.0p=
t 1.0pt 4.0pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'>UMKARTON</span></b><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;mso-ansi-language:DE;mso-bidi-font-weight:bold'><o:p></o:p></span></=
p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>1.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>BEZEICHNUNG
DES ARZNEIMITTELS</span></b><span lang=3DDE style=3D'mso-bidi-font-size:11.=
0pt;
mso-ansi-language:DE'><o:p></o:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Ovaleap 300&nbsp;I.E./0,5&nbsp;ml =
Injektionslsung<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
mso-ansi-language:DE'>Follitropin&nbsp;alfa</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>2.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>WIRKSTOFF(E)</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal><i style=3D'mso-bidi-font-style:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></i></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Jede Patrone enthlt 300&nbsp;I.E.=
 (entspricht
22&nbsp;Mikrogramm) Follitropin alfa in 0,5&nbsp;ml Lsung. Jeder ml Lsung
enthlt 600&nbsp;I.E. (entspricht 44&nbsp;Mikrogramm) Follitropin alfa.</sp=
an><span
lang=3DDE style=3D'font-size:10.0pt;mso-bidi-font-size:11.0pt;color:black;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>3.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>SONSTIGE
BESTANDTEILE</span></b><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
mso-ansi-language:DE'><o:p></o:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>Sonstige Bestandteile: Natriumdihydrogenphosphat-Dihydrat, Natriumhydro=
xid
(2&nbsp;M) (zur pH-Einstellung), Mannitol, Methionin, Polysorbat 20, Benzyl=
alkohol,
Benzalkoniumchlorid, Wasser fr Injektionszwecke.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>4.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>DARREICHUNGSFORM
UND INHALT</span></b><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p></o:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
background:lightgrey;mso-highlight:lightgrey;mso-ansi-language:DE'>Injektio=
nslsung</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'><o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>1&nbsp;Patrone mit 0,5&nbsp;ml Ls=
ung und
10&nbsp;Injektionsnadeln<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>5.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;text-transform:u=
ppercase;
mso-ansi-language:DE'>Hinweise zur</span></b><b style=3D'mso-bidi-font-weig=
ht:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>
UND ART(EN) DER ANWENDUNG</span></b><span lang=3DDE style=3D'mso-bidi-font-=
size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Nur zur
Anwendung mit dem Ovaleap-Pen.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>Packungsbeilage beachten.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'><o:p>&=
nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-fareast-languag=
e:
DE'>Subkutane Anwendung<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>6.<span
style=3D'mso-tab-count:1'> </span></span></b><a name=3D"OLE_LINK3"><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>WARNHINWEIS, DASS DAS ARZNEIMITTEL FR KINDER =
</span></b></a><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>UNZUGNGLICH AUFZUBEWAHREN IST</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan no-line-numbers;
mso-outline-level:1'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso=
-ansi-language:
DE'>Arzneimittel fr Kinder unzugnglich aufbewahren.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>7.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>WEITERE
WARNHINWEISE, FALLS ERFORDERLICH</span></b><span lang=3DDE style=3D'mso-bid=
i-font-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></p>

</div>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan lines-together;page-break-after:avoid;mso-outline-level:1;
border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-al=
t:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>8.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>VERFALLDATUM</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

</div>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
mso-ansi-language:DE'>Verwendbar bis<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;tab-stops:.5in'><span =
lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Die im=
 Pen
befindliche Patrone kann ber einen Zeitraum von hchstens 28&nbsp;Tagen bei
einer Temperatur nicht ber 25&nbsp;C aufbewahrt werden.<o:p></o:p></span>=
</p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;page=
-break-after:
avoid;mso-outline-level:1;border:none;mso-border-alt:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>9.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>BESONDERE
VORSICHTSMASSNAHMEN FR DIE AUFBEWAHRUNG</span></b><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Im Khlschrank lagern.<o:p></o:p><=
/span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Nicht einfrieren.<o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Die Patrone im Umkarton aufbewahre=
n,
um den Inhalt vor Licht zu schtzen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>Kann vor dem ffnen bis zu 3&nbsp;Monate lang bei einer Temperatur nicht
ber <span style=3D'color:black'>25&nbsp;C aufbewahrt werden. Muss entsorgt
werden, wenn es nicht innerhalb der 3&nbsp;Monate verwendet wurde.<o:p></o:=
p></span></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>10.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>GEGEBENENFALLS
BESONDERE VORSICHTSMASSNAHMEN FR DIE BESEITIGUNG VON NICHT VERWENDETEM
ARZNEIMITTEL ODER DAVON STAMMENDEN ABFALLMATERIALIEN</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>11.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>NAME
UND ANSCHRIFT DES PHARMAZEUTISCHEN UNTERNEHMERS</span></b><b style=3D'mso-b=
idi-font-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>Theramex Ireland Limited<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DEN-GB style=3D'm=
so-bidi-font-family:
Verdana;color:black'>3<sup>rd</sup> Floor, </span><span lang=3DNL
style=3D'mso-ansi-language:NL'>Kilmore House,<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>Park Lane, Spencer Dock,<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>Dublin 1<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>D01 YE64<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
mso-ansi-language:DE;mso-no-proof:yes'>Irland</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>12.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>ZULASSUNGSNUMMER(N)</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>EU/1/13/871/001<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>13.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;text-transform:u=
ppercase;
mso-ansi-language:DE'>Chargenbezeichnung</span></b><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>Ch.-B.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>14.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>VERKAUFSABGRENZUNG</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

</div>

<p class=3DMsoNormal><i style=3D'mso-bidi-font-style:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></i></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:2.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>15.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>HINWEISE
FR DEN GEBRAUCH</span></b><span lang=3DDE style=3D'mso-bidi-font-size:11.0=
pt;
mso-ansi-language:DE'><o:p></o:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=3DMsoNormal style=3D'page-break-after:avoid;border:none;mso-border=
-alt:
solid windowtext .5pt;padding:0in;mso-padding-alt:1.0pt 4.0pt 0in 4.0pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'>16.<span style=3D'mso-tab-count:1'> </span=
></span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>ANGABEN IN BLINDENSCHRIFT</span></b><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

</div>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
mso-ansi-language:DE'>Ovaleap 300&nbsp;I.E./0,5&nbsp;ml<o:p></o:p></span></=
p>

<p class=3DMsoNormal><span lang=3DDE style=3D'background:#CCCCCC;mso-ansi-l=
anguage:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;bac=
kground:
#CCCCCC;mso-ansi-language:DE;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:-.15pt;margin-right:0in'>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-al=
t:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-ansi-language:DE;mso-no-proof:yes'>17.<span style=3D'mso-tab-c=
ount:
1'> </span>INDIVIDUELLES ERKENNUNGSMERKMAL  2D-BARCODE</span></b><i
style=3D'mso-bidi-font-style:normal'><span lang=3DDE style=3D'mso-ansi-lang=
uage:DE;
mso-no-proof:yes'><o:p></o:p></span></i></p>

</div>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
ansi-language:
DE;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'background:lightgrey;mso-high=
light:
lightgrey;mso-ansi-language:DE;mso-no-proof:yes'>2D-Barcode mit individuell=
em
Erkennungsmerkmal.</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
background:#CCCCCC;mso-ansi-language:DE;mso-no-proof:yes'><o:p></o:p></span=
></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;bac=
kground:
#CCCCCC;mso-ansi-language:DE;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
ansi-language:
DE;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;page=
-break-after:
avoid;mso-outline-level:1;border:none;mso-border-alt:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-ansi-language:DE;mso-no-proof:yes'>18.=
<span
style=3D'mso-tab-count:1'> </span>INDIVIDUELLES ERKENNUNGSMERKMAL  VOM
MENSCHEN LESBARES FORMAT</span></b><i style=3D'mso-bidi-font-style:normal'>=
<span
lang=3DDE style=3D'mso-ansi-language:DE;mso-no-proof:yes'><o:p></o:p></span=
></i></p>

</div>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
ansi-language:
DE;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>PC:<o:p=
></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>SN:</sp=
an><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-ansi-language:
DE'>NN:<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<span lang=3DDE style=3D'font-size:11.0pt;font-family:"Times New Roman",ser=
if;
mso-fareast-font-family:"Times New Roman";color:black;mso-color-alt:windowt=
ext;
background:#CCCCCC;mso-ansi-language:DE;mso-fareast-language:EN-US;mso-bidi=
-language:
AR-SA'><br clear=3Dall style=3D'page-break-before:always'>
</span>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=3DMsoNormal style=3D'background:white;border:none;mso-border-alt:s=
olid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;color:black;mso-=
color-alt:
windowtext;mso-ansi-language:DE'>ANGABEN AUF DER USSEREN UMHLLUNG</span><=
/b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'background:white;border:none;mso-border-alt:s=
olid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'background:white;mso-shading:transparent;bord=
er:none;
mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-alt:1.0pt 4.0p=
t 1.0pt 4.0pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'>UMKARTON</span></b><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;mso-ansi-language:DE;mso-bidi-font-weight:bold'><o:p></o:p></span></=
p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>1.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>BEZEICHNUNG
DES ARZNEIMITTELS</span></b><span lang=3DDE style=3D'mso-bidi-font-size:11.=
0pt;
mso-ansi-language:DE'><o:p></o:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Ovaleap 450&nbsp;I.E./0,75&nbsp;ml=
 Injektionslsung<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
mso-ansi-language:DE'>Follitropin&nbsp;alfa</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>2.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>WIRKSTOFF(E)</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'> <o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal><i style=3D'mso-bidi-font-style:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></i></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
mso-ansi-language:DE'>Jede Patrone enthlt 450&nbsp;I.E. (entspricht
33&nbsp;Mikrogramm) Follitropin alfa in 0,75&nbsp;ml Lsung. Jeder ml Lsung
enthlt 600&nbsp;I.E. (entspricht 44&nbsp;Mikrogramm) Follitropin alfa.<o:p=
></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>3.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>SONSTIGE
BESTANDTEILE</span></b><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
mso-ansi-language:DE'><o:p></o:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>Sonstige Bestandteile: Natriumdihydrogenphosphat-Dihydrat, Natriumhydro=
xid
(2&nbsp;M) (zur pH-Einstellung), Mannitol, Methionin, Polysorbat 20,
Benzylalkohol, Benzalkoniumchlorid, Wasser fr Injektionszwecke.<o:p></o:p>=
</span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>4.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>DARREICHUNGSFORM
UND INHALT</span></b><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p></o:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
background:lightgrey;mso-highlight:lightgrey;mso-ansi-language:DE'>Injektio=
nslsung</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'><o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>1&nbsp;Patrone mit 0,75&nbsp;ml L=
sung
und 10&nbsp;Injektionsnadeln<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>5.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;text-transform:u=
ppercase;
mso-ansi-language:DE'>Hinweise zur</span></b><b style=3D'mso-bidi-font-weig=
ht:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>
UND ART(EN) DER ANWENDUNG</span></b><span lang=3DDE style=3D'mso-bidi-font-=
size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Nur zur
Anwendung mit dem Ovaleap-Pen.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;bac=
kground:
lightgrey;mso-highlight:lightgrey;mso-ansi-language:DE'><o:p>&nbsp;</o:p></=
span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>Packungsbeilage beachten.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-fareast-languag=
e:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-fareast-languag=
e:
DE'>Subkutane Anwendung<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>6.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>WARNHINWEIS,
DASS DAS ARZNEIMITTEL FR KINDER UNZUGNGLICH AUFZUBEWAHREN IST</span></b><=
span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan no-line-numbers;
mso-outline-level:1'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso=
-ansi-language:
DE'>Arzneimittel fr Kinder unzugnglich aufbewahren.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>7.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>WEITERE
WARNHINWEISE, FALLS ERFORDERLICH</span></b><span lang=3DDE style=3D'mso-bid=
i-font-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></p>

</div>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan lines-together;page-break-after:avoid;mso-outline-level:1;
border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-al=
t:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>8.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>VERFALLDATUM</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

</div>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
mso-ansi-language:DE'>Verwendbar bis<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;tab-stops:.5in'><span =
lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Die im=
 Pen
befindliche Patrone kann ber einen Zeitraum von hchstens 28&nbsp;Tagen bei
einer Temperatur nicht ber 25&nbsp;C aufbewahrt werden.<o:p></o:p></span>=
</p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;page=
-break-after:
avoid;mso-outline-level:1;border:none;mso-border-alt:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>9.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>BESONDERE
VORSICHTSMASSNAHMEN FR DIE AUFBEWAHRUNG</span></b><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Im Khlschrank lagern.<o:p></o:p><=
/span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Nicht einfrieren.<o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Die Patrone im Umkarton aufbewahre=
n,
um den Inhalt vor Licht zu schtzen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>Kann vor dem ffnen bis zu 3&nbsp;Monate lang bei einer Temperatur nicht
ber <span style=3D'color:black'>25&nbsp;C aufbewahrt werden. Muss entsorgt
werden, wenn es nicht innerhalb der 3&nbsp;Monate verwendet wurde.<o:p></o:=
p></span></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>10.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>GEGEBENENFALLS
BESONDERE VORSICHTSMASSNAHMEN FR DIE BESEITIGUNG VON NICHT VERWENDETEM
ARZNEIMITTEL ODER DAVON STAMMENDEN ABFALLMATERIALIEN</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>11.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>NAME
UND ANSCHRIFT DES PHARMAZEUTISCHEN UNTERNEHMERS</span></b><b style=3D'mso-b=
idi-font-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>Theramex Ireland Limited<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DEN-GB style=3D'm=
so-bidi-font-family:
Verdana;color:black'>3<sup>rd</sup> Floor, </span><span lang=3DNL
style=3D'mso-ansi-language:NL'>Kilmore House,<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>Park Lane, Spencer Dock,<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>Dublin 1<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>D01 YE64<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
mso-ansi-language:DE;mso-no-proof:yes'>Irland</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>12.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>ZULASSUNGSNUMMER(N)</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>EU/1/13/871/002<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>13.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;text-transform:u=
ppercase;
mso-ansi-language:DE'>Chargenbezeichnung</span></b><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>Ch.-B.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>14.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>VERKAUFSABGRENZUNG</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

</div>

<p class=3DMsoNormal><i style=3D'mso-bidi-font-style:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></i></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:2.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>15.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>HINWEISE
FR DEN GEBRAUCH</span></b><span lang=3DDE style=3D'mso-bidi-font-size:11.0=
pt;
mso-ansi-language:DE'><o:p></o:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=3DMsoNormal style=3D'page-break-after:avoid;border:none;mso-border=
-alt:
solid windowtext .5pt;padding:0in;mso-padding-alt:1.0pt 4.0pt 0in 4.0pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'>16.<span style=3D'mso-tab-count:1'> </span=
></span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>ANGABEN IN BLINDENSCHRIFT</span></b><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

</div>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
mso-ansi-language:DE'>Ovaleap 450&nbsp;I.E./0,75&nbsp;ml<o:p></o:p></span><=
/p>

<p class=3DMsoNormal><span lang=3DDE style=3D'background:#CCCCCC;mso-ansi-l=
anguage:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;bac=
kground:
#CCCCCC;mso-ansi-language:DE;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:-.15pt;margin-right:0in'>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-al=
t:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-ansi-language:DE;mso-no-proof:yes'>17.<span style=3D'mso-tab-c=
ount:
1'> </span>INDIVIDUELLES ERKENNUNGSMERKMAL  2D-BARCODE</span></b><i
style=3D'mso-bidi-font-style:normal'><span lang=3DDE style=3D'mso-ansi-lang=
uage:DE;
mso-no-proof:yes'><o:p></o:p></span></i></p>

</div>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
ansi-language:
DE;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'background:lightgrey;mso-high=
light:
lightgrey;mso-ansi-language:DE;mso-no-proof:yes'>2D-Barcode mit individuell=
em
Erkennungsmerkmal.</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
background:#CCCCCC;mso-ansi-language:DE;mso-no-proof:yes'><o:p></o:p></span=
></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;bac=
kground:
#CCCCCC;mso-ansi-language:DE;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
ansi-language:
DE;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;page=
-break-after:
avoid;mso-outline-level:1;border:none;mso-border-alt:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-ansi-language:DE;mso-no-proof:yes'>18.=
<span
style=3D'mso-tab-count:1'> </span>INDIVIDUELLES ERKENNUNGSMERKMAL  VOM
MENSCHEN LESBARES FORMAT</span></b><i style=3D'mso-bidi-font-style:normal'>=
<span
lang=3DDE style=3D'mso-ansi-language:DE;mso-no-proof:yes'><o:p></o:p></span=
></i></p>

</div>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
ansi-language:
DE;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>PC:<o:p=
></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>SN:</sp=
an><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-ansi-language:
DE'>NN:<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
page-break-after:avoid;mso-layout-grid-align:none;text-autospace:none'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;background:#CCCCCC;mso-ansi-la=
nguage:
DE'><o:p>&nbsp;</o:p></span></p>

<span lang=3DDE style=3D'font-size:11.0pt;font-family:"Times New Roman",ser=
if;
mso-fareast-font-family:"Times New Roman";color:black;mso-color-alt:windowt=
ext;
background:#CCCCCC;mso-ansi-language:DE;mso-fareast-language:EN-US;mso-bidi=
-language:
AR-SA'><br clear=3Dall style=3D'page-break-before:always'>
</span>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=3DMsoNormal style=3D'background:white;border:none;mso-border-alt:s=
olid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;color:black;mso-=
color-alt:
windowtext;mso-ansi-language:DE'>ANGABEN AUF DER USSEREN UMHLLUNG</span><=
/b><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;back=
ground:
white;mso-shading:transparent;border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-bidi-font-weigh=
t:
bold'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'background:white;mso-shading:transparent;bord=
er:none;
mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-alt:1.0pt 4.0p=
t 1.0pt 4.0pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'>UMKARTON</span></b><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;mso-ansi-language:DE;mso-bidi-font-weight:bold'><o:p></o:p></span></=
p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>1.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>BEZEICHNUNG
DES ARZNEIMITTELS</span></b><span lang=3DDE style=3D'mso-bidi-font-size:11.=
0pt;
mso-ansi-language:DE'><o:p></o:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Ovaleap 900&nbsp;I.E./1,5&nbsp;ml =
Injektionslsung<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
mso-ansi-language:DE'>Follitropin&nbsp;alfa</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>2.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>WIRKSTOFF(E)</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'> <o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal><i style=3D'mso-bidi-font-style:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></i></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
mso-ansi-language:DE'>Jede Patrone enthlt 900&nbsp;I.E. (entspricht
66&nbsp;Mikrogramm) Follitropin alfa in 1,5&nbsp;ml Lsung. Jeder ml Lsung
enthlt 600&nbsp;I.E. (entspricht 44&nbsp;Mikrogramm) Follitropin alfa.<o:p=
></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>3.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>SONSTIGE
BESTANDTEILE</span></b><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
mso-ansi-language:DE'><o:p></o:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>Sonstige Bestandteile: Natriumdihydrogenphosphat-Dihydrat, Natriumhydro=
xid
(2&nbsp;M) (zur pH-Einstellung), Mannitol, Methionin, Polysorbat 20,
Benzylalkohol, Benzalkoniumchlorid, Wasser fr Injektionszwecke.<o:p></o:p>=
</span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>4.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>DARREICHUNGSFORM
UND INHALT</span></b><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p></o:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
background:lightgrey;mso-highlight:lightgrey;mso-ansi-language:DE'>Injektio=
nslsung</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'><o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>1&nbsp;Patrone mit 1,5&nbsp;ml Ls=
ung und
20&nbsp;Injektionsnadeln<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>5.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;text-transform:u=
ppercase;
mso-ansi-language:DE'>Hinweise zur</span></b><b style=3D'mso-bidi-font-weig=
ht:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>
UND ART(EN) DER ANWENDUNG</span></b><span lang=3DDE style=3D'mso-bidi-font-=
size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Nur zur
Anwendung mit dem Ovaleap-Pen.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;bac=
kground:
lightgrey;mso-highlight:lightgrey;mso-ansi-language:DE'><o:p>&nbsp;</o:p></=
span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>Packungsbeilage beachten.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-fareast-languag=
e:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-fareast-languag=
e:
DE'>Subkutane Anwendung<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>6.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>WARNHINWEIS,
DASS DAS ARZNEIMITTEL FR KINDER UNZUGNGLICH AUFZUBEWAHREN IST</span></b><=
span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan no-line-numbers;
mso-outline-level:1'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso=
-ansi-language:
DE'>Arzneimittel fr Kinder unzugnglich aufbewahren.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>7.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>WEITERE
WARNHINWEISE, FALLS ERFORDERLICH</span></b><span lang=3DDE style=3D'mso-bid=
i-font-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></p>

</div>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'tab-stops:28.35pt 37.45pt'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan lines-together;page-break-after:avoid;mso-outline-level:1;
border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-al=
t:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>8.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>VERFALLDATUM</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

</div>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
mso-ansi-language:DE'>Verwendbar bis<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;tab-stops:.5in'><span =
lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Die im=
 Pen
befindliche Patrone kann ber einen Zeitraum von hchstens 28&nbsp;Tagen bei
einer Temperatur nicht ber 25&nbsp;C aufbewahrt werden.<o:p></o:p></span>=
</p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;page=
-break-after:
avoid;mso-outline-level:1;border:none;mso-border-alt:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>9.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>BESONDERE
VORSICHTSMASSNAHMEN FR DIE AUFBEWAHRUNG</span></b><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Im Khlschrank lagern.<o:p></o:p><=
/span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Nicht einfrieren.<o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Die Patrone im Umkarton aufbewahre=
n,
um den Inhalt vor Licht zu schtzen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>Kann vor dem ffnen bis zu 3&nbsp;Monate lang bei einer Temperatur nicht
ber <span style=3D'color:black'>25&nbsp;C aufbewahrt werden. Muss entsorgt
werden, wenn es nicht innerhalb der 3&nbsp;Monate verwendet wurde.<o:p></o:=
p></span></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
outline-level:
1;border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-=
alt:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>10.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>GEGEBENENFALLS
BESONDERE VORSICHTSMASSNAHMEN FR DIE BESEITIGUNG VON NICHT VERWENDETEM
ARZNEIMITTEL ODER DAVON STAMMENDEN ABFALLMATERIALIEN</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>11.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>NAME
UND ANSCHRIFT DES PHARMAZEUTISCHEN UNTERNEHMERS</span></b><b style=3D'mso-b=
idi-font-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>Theramex Ireland Limited<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DEN-GB style=3D'm=
so-bidi-font-family:
Verdana;color:black'>3<sup>rd</sup> Floor, </span><span lang=3DNL
style=3D'mso-ansi-language:NL'>Kilmore House,<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>Park Lane, Spencer Dock,<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>Dublin 1<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>D01 YE64<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
mso-ansi-language:DE;mso-no-proof:yes'>Irland</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>12.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>ZULASSUNGSNUMMER(N)</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:1'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>EU/1/13/871/003<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>13.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;text-transform:u=
ppercase;
mso-ansi-language:DE'>Chargenbezeichnung</span></b><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>Ch.-B.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>14.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>VERKAUFSABGRENZUNG</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

</div>

<p class=3DMsoNormal><i style=3D'mso-bidi-font-style:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></i></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:2.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>15.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-font-=
weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>HINWEISE
FR DEN GEBRAUCH</span></b><span lang=3DDE style=3D'mso-bidi-font-size:11.0=
pt;
mso-ansi-language:DE'><o:p></o:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=3DMsoNormal style=3D'page-break-after:avoid;border:none;mso-border=
-alt:
solid windowtext .5pt;padding:0in;mso-padding-alt:1.0pt 4.0pt 0in 4.0pt'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'>16.<span style=3D'mso-tab-count:1'> </span=
></span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>ANGABEN IN BLINDENSCHRIFT</span></b><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

</div>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
mso-ansi-language:DE'>Ovaleap 900&nbsp;I.E./1,5&nbsp;ml<o:p></o:p></span></=
p>

<p class=3DMsoNormal><span lang=3DDE style=3D'background:#CCCCCC;mso-ansi-l=
anguage:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;bac=
kground:
#CCCCCC;mso-ansi-language:DE;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
margin-left:-.15pt;margin-right:0in'>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:1;
border:none;mso-border-alt:solid windowtext .5pt;padding:0in;mso-padding-al=
t:
1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lan=
g=3DDE
style=3D'mso-ansi-language:DE;mso-no-proof:yes'>17.<span style=3D'mso-tab-c=
ount:
1'> </span>INDIVIDUELLES ERKENNUNGSMERKMAL  2D-BARCODE</span></b><i
style=3D'mso-bidi-font-style:normal'><span lang=3DDE style=3D'mso-ansi-lang=
uage:DE;
mso-no-proof:yes'><o:p></o:p></span></i></p>

</div>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
ansi-language:
DE;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'background:lightgrey;mso-high=
light:
lightgrey;mso-ansi-language:DE;mso-no-proof:yes'>2D-Barcode mit individuell=
em
Erkennungsmerkmal.</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
background:#CCCCCC;mso-ansi-language:DE;mso-no-proof:yes'><o:p></o:p></span=
></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;bac=
kground:
#CCCCCC;mso-ansi-language:DE;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
ansi-language:
DE;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;page=
-break-after:
avoid;mso-outline-level:1;border:none;mso-border-alt:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-ansi-language:DE;mso-no-proof:yes'>18.=
<span
style=3D'mso-tab-count:1'> </span>INDIVIDUELLES ERKENNUNGSMERKMAL  VOM
MENSCHEN LESBARES FORMAT</span></b><i style=3D'mso-bidi-font-style:normal'>=
<span
lang=3DDE style=3D'mso-ansi-language:DE;mso-no-proof:yes'><o:p></o:p></span=
></i></p>

</div>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
ansi-language:
DE;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>PC:<o:p=
></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>SN:</sp=
an><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-ansi-language:
DE'>NN:<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
page-break-after:avoid;mso-layout-grid-align:none;text-autospace:none'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'><o:p>&nbsp;</o:p></span></p>

<span lang=3DDE style=3D'font-size:11.0pt;font-family:"Times New Roman",ser=
if;
mso-fareast-font-family:"Times New Roman";color:black;mso-color-alt:windowt=
ext;
background:#CCCCCC;mso-ansi-language:DE;mso-fareast-language:EN-US;mso-bidi=
-language:
AR-SA'><br clear=3Dall style=3D'page-break-before:always'>
</span>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>MINDESTANGABEN
AUF KLEINEN BEHLTNISSEN</span></b><b style=3D'mso-bidi-font-weight:normal'=
><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></b></p>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>PATRONE<o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>1.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>BEZEICHNUNG
DES ARZNEIMITTELS SOWIE ART(EN) DER ANWENDUNG</span></b><b style=3D'mso-bid=
i-font-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt'><sp=
an
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Ovaleap 300&nbsp;I.E./0,5&nbsp;ml
Injektion<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
mso-ansi-language:DE'>Follitropin&nbsp;alfa</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>s.c.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>2.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;text-transform:u=
ppercase;
mso-ansi-language:DE'>Hinweise</span></b><b style=3D'mso-bidi-font-weight:n=
ormal'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'> <span
style=3D'text-transform:uppercase'>zur</span> ANWENDUNG</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>3.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>VERFALLDATUM</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>Verw. bis<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>4.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;text-transform:u=
ppercase;
mso-ansi-language:DE'>Chargenbezeichnung</span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>Ch.-B.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>5.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>INHALT
NACH GEWICHT, VOLUMEN ODER EINHEITEN</span></b><b style=3D'mso-bidi-font-we=
ight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>0,5&nbsp;ml<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>6.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>WEITERE
ANGABEN</span></b><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</b></p>

</div>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<span lang=3DDE style=3D'font-size:11.0pt;font-family:"Times New Roman",ser=
if;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:DE;mso-fareast-=
language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>MINDESTANGABEN
AUF KLEINEN BEHLTNISSEN</span></b><b style=3D'mso-bidi-font-weight:normal'=
><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></b></p>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>PATRONE</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>1.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>BEZEICHNUNG
DES ARZNEIMITTELS SOWIE ART(EN) DER ANWENDUNG</span></b><b style=3D'mso-bid=
i-font-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt'><sp=
an
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Ovaleap 450&nbsp;I.E./0,75&nbsp;ml
Injektion<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
mso-ansi-language:DE'>Follitropin&nbsp;alfa</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>s.c.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>2.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;text-transform:u=
ppercase;
mso-ansi-language:DE'>Hinweise</span></b><b style=3D'mso-bidi-font-weight:n=
ormal'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'> <span
style=3D'text-transform:uppercase'>zur</span> ANWENDUNG</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>3.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>VERFALLDATUM</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>Verw. bis<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>4.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;text-transform:u=
ppercase;
mso-ansi-language:DE'>Chargenbezeichnung</span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>Ch.-B.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>5.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>INHALT
NACH GEWICHT, VOLUMEN ODER EINHEITEN</span></b><b style=3D'mso-bidi-font-we=
ight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>0,75&nbsp;ml<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>6.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>WEITERE
ANGABEN</span></b><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</b></p>

</div>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<span lang=3DDE style=3D'font-size:11.0pt;font-family:"Times New Roman",ser=
if;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:DE;mso-fareast-=
language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>MINDESTANGABEN
AUF KLEINEN BEHLTNISSEN</span></b><b style=3D'mso-bidi-font-weight:normal'=
><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></b></p>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'border:none;mso-border-alt:solid windowtext .=
5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>PATRONE</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>1.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>BEZEICHNUNG
DES ARZNEIMITTELS SOWIE ART(EN) DER ANWENDUNG</span></b><b style=3D'mso-bid=
i-font-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt'><sp=
an
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'text-align:justify;text-justify:inter-ideogra=
ph;
mso-layout-grid-align:none;text-autospace:none'><span lang=3DDE style=3D'ms=
o-bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Ovaleap 900&nbsp;I.E./1,5&nbsp;ml =
Injektion<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
mso-ansi-language:DE'>Follitropin&nbsp;alfa</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>s.c.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>2.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;text-transform:u=
ppercase;
mso-ansi-language:DE'>Hinweise</span></b><b style=3D'mso-bidi-font-weight:n=
ormal'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'> <span
style=3D'text-transform:uppercase'>zur</span> ANWENDUNG</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>3.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>VERFALLDATUM</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'>Verw. bis<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>4.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;text-transform:u=
ppercase;
mso-ansi-language:DE'>Chargenbezeichnung</span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>Ch.-B.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>5.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>INHALT
NACH GEWICHT, VOLUMEN ODER EINHEITEN</span></b><b style=3D'mso-bidi-font-we=
ight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'><o:p></o:p></span></b></p>

</div>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>1,5&nbsp;ml<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<div style=3D'mso-element:para-border-div;border:solid windowtext 1.0pt;
mso-border-alt:solid windowtext .5pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=3DMsoNormal style=3D'mso-outline-level:1;border:none;mso-border-al=
t:solid windowtext .5pt;
padding:0in;mso-padding-alt:1.0pt 4.0pt 1.0pt 4.0pt'><b style=3D'mso-bidi-f=
ont-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-languag=
e:DE'>6.<span
style=3D'mso-tab-count:1'> </span></span></b><b style=3D'mso-bidi-fon=
t-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>WEITERE
ANGABEN</span></b><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</b></p>

</div>

<p class=3DMsoNormal style=3D'margin-right:5.65pt'><span lang=3DDE style=3D=
'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<span lang=3DDE style=3D'font-size:11.0pt;font-family:"Times New Roman",ser=
if;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:DE;mso-fareast-=
language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'mso-special-charact=
er:line-break;
page-break-before:always'>
</span>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><b style=3D=
'mso-bidi-font-weight:
normal'><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p>&nbsp;</o:p></s=
pan></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DTitleA><span lang=3DDE style=3D'mso-ansi-language:DE'>B. PACKUNG=
SBEILAGE<o:p></o:p></span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-an=
si-language:
DE'><o:p>&nbsp;</o:p></span></b></p>

<span lang=3DDE style=3D'font-size:11.0pt;font-family:"Times New Roman",ser=
if;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:DE;mso-fareast-=
language:
EN-US;mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:a=
lways'>
</span>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1;tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE;mso-no-proof:yes'>G=
ebrauchsinformation:
Information fr Anwender</span></b><b style=3D'mso-bidi-font-weight:normal'=
><span
lang=3DDE style=3D'mso-ansi-language:DE'> </span></b><span lang=3DDE
style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-list:ski=
p;
tab-stops:.5in;background:white'><span lang=3DDE style=3D'mso-ansi-language=
:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1;tab-stops:28.35pt 49.65pt'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DDE style=3D'mso-ansi-language:DE'>Ovaleap 300&nbsp;I.E./0,5&nbsp;ml =
Injektionslsung<o:p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1;tab-stops:28.35pt 49.65pt'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DDE style=3D'mso-ansi-language:DE'>Ovaleap 450&nbsp;I.E./0,75&nbsp;ml=
 Injektionslsung<o:p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-outline-=
level:
1;tab-stops:28.35pt 49.65pt'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DDE style=3D'mso-ansi-language:DE'>Ovaleap 900&nbsp;I.E./1,5&nbsp;ml =
Injektionslsung<o:p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-list:ski=
p;
tab-stops:.5in'><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p>&nbsp;<=
/o:p></span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center;mso-list:ski=
p;
tab-stops:.5in'><span lang=3DDE style=3D'mso-ansi-language:DE'>Follitropin =
alfa<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>Lesen Sie die gesamte Packungsbeilage sorgflt=
ig
durch, bevor Sie mit der Anwendung dieses Arzneimittels beginnen, denn sie
enthlt wichtige Informationen.</span></b><span lang=3DDE style=3D'mso-bidi=
-font-size:
12.0pt;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-.1pt;margin-bott=
om:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:l10=
 level1 lfo1;
tab-stops:.5in'><![if !supportLists]><span lang=3DDE style=3D'mso-ansi-lang=
uage:
DE'><span style=3D'mso-list:Ignore'>-<span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Heben
Sie die Packungsbeilage auf. Vielleicht mchten Sie diese spter nochmals
lesen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-.1pt;margin-bott=
om:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:l10=
 level1 lfo1;
tab-stops:.5in'><![if !supportLists]><span lang=3DDE style=3D'mso-ansi-lang=
uage:
DE'><span style=3D'mso-list:Ignore'>-<span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Wenn
Sie weitere Fragen haben, wenden Sie sich an Ihren Arzt, Apotheker oder das
medizinische Fachpersonal.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-.1pt;margin-bott=
om:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:l10=
 level1 lfo1;
tab-stops:.5in'><![if !supportLists]><span lang=3DDE style=3D'mso-ansi-lang=
uage:
DE'><span style=3D'mso-list:Ignore'>-<span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Dieses
Arzneimittel wurde Ihnen persnlich verschrieben. Geben Sie es nicht an Dri=
tte
weiter. Es kann anderen Menschen schaden, auch wenn diese die gleichen
Beschwerden haben wie Sie.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-.1pt;margin-bott=
om:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:l10=
 level1 lfo1;
tab-stops:.5in'><![if !supportLists]><span lang=3DDE style=3D'mso-ansi-lang=
uage:
DE'><span style=3D'mso-list:Ignore'>-<span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Wenn
Sie Nebenwirkungen bemerken, wenden Sie sich an Ihren Arzt, Apotheker oder =
das
medizinische Fachpersonal. Dies gilt auch fr Nebenwirkungen, die nicht in
dieser Packungsbeilage angegeben sind.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;tab-stops:.5in'><span lang=
=3DDE
style=3D'mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;tab-stops:.5in'><span lang=
=3DDE
style=3D'mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-outline-level:
1;mso-list:skip;tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><s=
pan
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Was in d=
ieser
Packungsbeilage steht<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-outline-level:
1;mso-list:skip;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size=
:12.0pt;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-1.45pt;mso-list:skip;tab-stops:=
21.3pt 28.35pt'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>1.<span
style=3D'mso-tab-count:1'> </span>Was ist </span><span lang=3DDE
style=3D'mso-ansi-language:DE'>Ovaleap</span><span lang=3DDE style=3D'mso-b=
idi-font-size:
12.0pt;mso-ansi-language:DE'> und wofr wird es angewendet?<o:p></o:p></spa=
n></p>

<p class=3DMsoNormal style=3D'margin-right:-1.45pt;mso-list:skip;tab-stops:=
21.3pt 28.35pt'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>2.<span
style=3D'mso-tab-count:1'> </span>Was sollten Sie vor der Anwendung von =
</span><span
lang=3DDE style=3D'mso-ansi-language:DE'>Ovaleap</span><span lang=3DDE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'> beachten?<o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-1.45pt;mso-list:skip;tab-stops:=
21.3pt 28.35pt'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>3.<span
style=3D'mso-tab-count:1'> </span>Wie ist </span><span lang=3DDE
style=3D'mso-ansi-language:DE'>Ovaleap</span><span lang=3DDE style=3D'mso-b=
idi-font-size:
12.0pt;mso-ansi-language:DE'> anzuwenden?<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-1.45pt;mso-list:skip;tab-stops:=
21.3pt 28.35pt'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>4.<span
style=3D'mso-tab-count:1'> </span>Welche Nebenwirkungen sind mglich?<o:=
p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.45pt;margin-bo=
ttom:
0in;margin-left:28.5pt;margin-bottom:.0001pt;text-indent:-28.5pt;mso-list:l=
19 level1 lfo14;
tab-stops:21.3pt list 35.45pt;layout-grid-mode:char'><![if !supportLists]><=
span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'>5.<span style=3D'font:7.0pt "Times New Roman"'>&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
12.0pt;
mso-ansi-language:DE'>Wie ist </span><span lang=3DDE style=3D'mso-ansi-lang=
uage:
DE'>Ovaleap</span><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-an=
si-language:
DE'> aufzubewahren?<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-1.45pt;tab-stops:21.3pt 28.35pt=
'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>6.<span
style=3D'mso-tab-count:1'> </span>Inhalt der Packung und weitere Informa=
tionen<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'>1.<span style=3D'mso-tab-count:1'> </spa=
n></span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>Was ist </span></b><b style=3D'mso-bidi-font-w=
eight:
normal'><span lang=3DDE style=3D'mso-ansi-language:DE'>Ovaleap</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'> und wofr wird es angewendet?</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-list:skip;tab-stop=
s:.5in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;tab=
-stops:
.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso=
-bidi-font-size:
11.0pt;mso-ansi-language:DE'>Was ist Ovaleap?<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;tab-stops:.5in'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Dieses Arzneimitte=
l enthlt
den Wirkstoff Follitropin alfa, das nahezu identisch ist mit dem natrlich =
im
Krper gebildeten Hormon Follikel-stimulierendes Hormon (FSH). FSH ist ei=
n </span><span
lang=3DDE style=3D'mso-ansi-language:DE'>Gonadotropin, d.&nbsp;h. es gehrt=
 zu
einer Gruppe von Hormonen, die eine wichtige Rolle bei der Fruchtbarkeit und
Fortpflanzung des Menschen spielen. Bei Frauen wird FSH fr das Wachstum und
die Reifung der Eizellen enthaltenden Blschen (Follikel) in den Eierstcken
bentigt</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-=
language:
DE'>. Bei Mnnern wird FSH fr die Spermienbildung bentigt.<o:p></o:p></sp=
an></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;tab-stops:.5in'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;tab=
-stops:
.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso=
-bidi-font-size:
11.0pt;mso-ansi-language:DE'>Wofr wird Ovaleap angewendet?<o:p></o:p></spa=
n></b></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;tab=
-stops:
.5in'><u><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-langua=
ge:DE'><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;tab=
-stops:
.5in'><u><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-langua=
ge:DE'>Bei
erwachsenen Frauen wird Ovaleap angewendet,<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l23 level1 lfo5;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>um
den Eisprung (Freisetzung einer reifen Eizelle aus einem Follikel) bei Frau=
en
herbeizufhren, die keinen Eisprung haben und auf eine Behandlung mit einem
Arzneimittel namens Clomifencitrat nicht angesprochen haben.</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l23 level1 lfo5;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>um
die Entwicklung von Follikeln bei Frauen auszulsen, die sich einer Technik=
 der
assistierten Reproduktion (Verfahren, die Ihnen helfen knnen, schwanger zu
werden), wie <i style=3D'mso-bidi-font-style:normal'>In-vitro</i>-Fertilis=
ation,
Intratubarer Gametentransfer oder Intratubarer Zygotentransfer,
unterziehen. </span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-=
ansi-language:
DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l23 level1 lfo5;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>um in
Kombination mit einem Arzneimittel namens Lutropin alfa (eine Form eines
anderen Gonadotropins, dem Luteinisierenden Hormon oder LH) einen Eisprung
bei Frauen herbeizufhren, die keinen Eisprung haben, weil ihr Krper zu we=
nig
FSH und LH produziert. </span><span lang=3DDE style=3D'mso-bidi-font-size:1=
1.0pt;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p>&n=
bsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><u><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Bei erwachsenen M=
nnern
wird Ovaleap angewendet,</span></u><u><span lang=3DDE style=3D'mso-ansi-lan=
guage:
DE'><o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l17 level1 lfo6'><![if !supportLists]><span lang=3DDE style=3D'font-family:=
Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-languag=
e:
DE'><span style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>um in
Kombination mit einem anderen Arzneimittel namens humanes Choriongonadotro=
pin
(hCG) die Spermienproduktion bei Mnnern anzuregen, die aufgrund einer zu
geringen Konzentration bestimmter Hormone unfruchtbar sind.<o:p></o:p></spa=
n></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;tab-stops:.5in'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;background:yellow;mso-highlight:yellow;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;tab-stops:.5in'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;background:yellow;mso-highlight:yellow;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-1.4pt;page-break-after:avoid;
mso-list:skip;tab-stops:21.3pt 28.35pt'><b style=3D'mso-bidi-font-weight:no=
rmal'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>2.<span
style=3D'mso-tab-count:1'> </span>Was sollten Sie vor der Anwendung von =
</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-ansi-lan=
guage:
DE'>Ovaleap</span></b><b style=3D'mso-bidi-font-weight:normal'><span lang=
=3DDE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'> beachten?<o:p></o=
:p></span></b></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;mso-outline-level:1;mso-list:skip;tab-stops:.5in'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DDE style=3D'mso-bidi-font=
-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></i></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;mso-outline-level:1;mso-list:skip;tab-stops:.5in'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'>Ovaleap</span></b><b style=3D'mso-bidi-font-we=
ight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>
darf nicht angewendet werden,</span></b><span lang=3DDE style=3D'mso-bidi-f=
ont-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l17 level1 lfo6;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
12.0pt;
mso-ansi-language:DE'>wenn Sie allergisch gegen </span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Follitropin alfa, =
follikelstimulierendes
Hormon (FSH) </span><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-=
ansi-language:
DE'>oder einen der in Abschnitt&nbsp;6. genannten sonstigen Bestandteile di=
eses
Arzneimittels sind.</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l17 level1 lfo6;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>wenn
bei Ihnen ein Tumor im Hypothalamus oder in der Hypophyse diagnostiziert wu=
rde,
(Regionen des Gehirns). </span><span lang=3DDE style=3D'mso-bidi-font-size:=
11.0pt;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l17 level1 lfo6;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>als <b><i
style=3D'mso-bidi-font-style:normal'>Frau </i></b><span style=3D'mso-bidi-f=
ont-weight:
bold'>wenn Sie</span></span><span lang=3DDE style=3D'mso-bidi-font-size:11.=
0pt;
mso-ansi-language:DE'>:<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:56.7pt;tab-stops:.5in'><span lang=
=3DDE
style=3D'mso-ansi-language:DE'>- an vergrerten Eierstcken oder </span><s=
pan
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;font-family:"TimesNewRomanPSMT=
",serif;
mso-fareast-font-family:SimSun;mso-bidi-font-family:TimesNewRomanPSMT;
mso-ansi-language:DE;mso-fareast-language:DE'>Eierstockzysten</span><span
lang=3DDE style=3D'mso-ansi-language:DE'> (mit Flssigkeit gefllte Hohlru=
me im
Gewebe der Eierstcke) unbekannter Ursache leiden</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>.<o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'margin-left:56.7pt;tab-stops:.5in'><span lang=
=3DDE
style=3D'mso-ansi-language:DE'>- vaginale Blutungen unbekannter Ursache hab=
en.</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:56.7pt;tab-stops:.5in'><span lang=
=3DDE
style=3D'mso-ansi-language:DE'>- an Eierstock-, Gebrmutter- oder Brustkrebs
erkrankt sind.</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:56.7pt;tab-stops:.5in'><span lang=
=3DDE
style=3D'mso-ansi-language:DE'>- an einem Zustand leiden, der eine normale
Schwangerschaft unmglich macht, wie zum Beispiel vorzeitige Wechseljahre
(Ovarialinsuffizienz), fibrse Gebrmuttertumoren oder missgebildete
Fortpflanzungsorgane.</span><span lang=3DDE style=3D'mso-bidi-font-size:11.=
0pt;
mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l18 level1 lfo7'><![if !supportLists]><span lang=3DDE style=3D'font-family:=
Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-languag=
e:
DE'><span style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>als <b><i
style=3D'mso-bidi-font-style:normal'>Mann</i></b><span style=3D'mso-bidi-fo=
nt-weight:
bold'> wenn Sie</span>:<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:56.7pt;tab-stops:.5in'><span lang=
=3DDE
style=3D'mso-ansi-language:DE'>- an einer Unterfunktion der Hoden leiden, d=
ie
nicht behandelt werden kann.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p>&n=
bsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>Wenn ei=
ner dieser
Punkte auf Sie zutrifft, drfen Sie dieses Arzneimittel nicht anwenden. Wenn
Sie sich nicht sicher sind, sprechen Sie mit Ihrem Arzt oder Apotheker, bev=
or
Sie dieses Arzneimittel anwenden.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
DE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Warnhinweise und V=
orsichtsmanahmen</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Bevor die
Behandlung begonnen wird, sollten Ihre Fruchtbarkeit und die Fruchtbarkeit
Ihres Partners/Ihrer Partnerin von einem Arzt beurteilt werden, der ber
Erfahrung mit der Behandlung von Fruchtbarkeitsstrungen verfgt.<o:p></o:p=
></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><u><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Porphyrie<o:p></o:=
p></span></u></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-ansi-language:DE'>Wenn Sie oder ein Mitglied Ihrer Familie an
Porphyrie leiden, informieren Sie bitte Ihren Arzt vor Beginn der Behandlun=
g.
Dabei handelt es sich um eine Erkrankung, die von den Eltern auf die Kinder
vererbt werden kann</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
mso-ansi-language:DE'> und mit der </span><span lang=3DDE style=3D'mso-ansi=
-language:
DE'>Unfhigkeit einhergeht, Porphyrine (organische Verbindungen) abzubauen.=
 </span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-ansi-language:DE'>Informieren Sie sofort Ihren Arzt, wenn</spa=
n><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l18 level1 lfo7;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Sie
bemerken, dass Ihre Haut verletzlich wird und schnell zur Blasenbildung nei=
gt
(besonders an Stellen, die hufig der Sonne ausgesetzt sind) und/oder</span=
><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'> <o:p></=
o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l18 level1 lfo7;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Sie Magen-,
Arm- oder Beinschmerzen haben.</span><span lang=3DDE style=3D'mso-bidi-font=
-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-ansi-language:DE'>Wenn es bei Ihnen zu den oben genannten Symp=
tomen
kommt, wird Ihnen Ihr Arzt gegebenenfalls empfehlen, die Behandlung abzuset=
zen.
</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language=
:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-list:skip;tab-stop=
s:.5in'><u
style=3D'text-underline:black'><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Ovarielles
berstimulationssyndrom (OHSS)</span></u><u><span lang=3DDE style=3D'mso-bi=
di-font-size:
11.0pt;mso-ansi-language:DE'> <o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-ansi-language:DE'>Als Frau sind Sie durch dieses Arzneimittel =
einem erhhten
Risiko fr das Entstehen eines OHSS ausgesetzt. In diesem Fall kommt es zu
einer berentwicklung der Follikel und es entstehen groe Zysten</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>.<o:p></=
o:p></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Bitte sprechen Sie=
 unverzglich
mit Ihrem Arzt, wenn<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l18 level1 lfo7;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
11.0pt;
mso-ansi-language:DE'>Sie Schmerzen im unteren Bereich des Abdomens (Bauch)=
 bekommen,<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l18 level1 lfo7;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
11.0pt;
mso-ansi-language:DE'>Sie rasch an Gewicht zunehmen,<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l18 level1 lfo7;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
11.0pt;
mso-ansi-language:DE'>Sie an belkeit oder Erbrechen leiden,<o:p></o:p></sp=
an></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l18 level1 lfo7;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
11.0pt;
mso-ansi-language:DE'>Sie Probleme beim Atmen haben.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-ansi-language:DE'>Wenn es bei Ihnen zu den oben genannten Symp=
tomen
kommt, wird der Arzt Ihnen mglicherweise die Anweisung geben, das Arzneimi=
ttel
abzusetzen (siehe auch Abschnitt&nbsp;4, Schwerwiegende Nebenwirkungen bei
Frauen). </span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ans=
i-language:
DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-ansi-language:DE'>Wenn Sie keinen Eisprung haben und sich an d=
ie
empfohlene Dosierung und den Zeitplan halten, ist das Auftreten eines OHSS
weniger wahrscheinlich. Eine Ovaleap&#8209;Behandlung fhrt selten zu einem
schweren OHSS, wenn das Arzneimittel zur Einleitung der endgltigen
Follikelreifung (humanes Choriongonadotropin, hCG) nicht gegeben wird. Wenn
sich bei Ihnen die Entwicklung eines OHSS abzeichnet, wird Ihnen Ihr Arzt
mglicherweise in diesem Behandlungszyklus kein hCG geben. Sie werden
angewiesen, fr mindestens 4&nbsp;Tage Geschlechtsverkehr zu vermeiden oder
eine Barrieremethode als Verhtungsmittel zu benutzen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-list:skip;tab-stop=
s:.5in'><u
style=3D'text-underline:black'><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Mehrlingsschwangerschaften</span></u><u><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'> <o:p></=
o:p></span></u></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Wenn Sie </span><s=
pan
lang=3DDE style=3D'mso-ansi-language:DE'>dieses Arzneimittel</span><span la=
ng=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'> anwenden, besteht=
 ein
hheres Risiko, mehr als ein Kind zu erwarten, als bei einer natrlichen
Empfngnis</span><span lang=3DDE style=3D'mso-ansi-language:DE'> </span><sp=
an
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>(d.&nbsp=
;h.
Mehrlingsschwangerschaft, typischerweise Zwillinge). Eine
Mehrlingsschwangerschaft kann fr Sie und Ihre Babys zu medizinischen
Komplikationen fhren. Sie knnen das Risiko fr eine Mehrlingsschwangersch=
aft
senken, wenn Sie </span><span lang=3DDE style=3D'mso-ansi-language:DE'>dies=
es
Arzneimittel</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-a=
nsi-language:
DE'> in der richtigen Dosierung zu den richtigen Zeitpunkten anwenden. Das
Risiko von Mehrlingsschwangerschaften nach Anwendung von Techniken der
assistierten Reproduktion steht in Zusammenhang mit Ihrem Alter sowie der
Qualitt und Anzahl befruchteter Eizellen oder Embryonen, die Ihnen eingese=
tzt
werden.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-list:skip;tab-stop=
s:.5in'><u><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Fehlgebu=
rt<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-ansi-language:DE'>Die Wahrscheinlichkeit einer Fehlgeburt ist
berdurchschnittlich hoch, wenn Sie sich Techniken der assistierten
Reproduktion unterziehen oder Ihre Eierstcke stimuliert werden, um Eizelle=
n zu
produzieren.</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-a=
nsi-language:
DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-list:skip;tab-stop=
s:.5in'><u><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Ektope
Schwangerschaft<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Die Wahrscheinlich=
keit
einer Schwangerschaft auerhalb der Gebrmutter (ektope Schwangerschaft) is=
t </span><span
lang=3DDE style=3D'mso-ansi-language:DE'>berdurchschnittlich hoch,</span><=
span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'> </span>=
<span
lang=3DDE style=3D'mso-ansi-language:DE'>wenn Sie sich Techniken der assist=
ierten
Reproduktion unterziehen und Ihre Eileiter geschdigt sind.</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE;mso-bidi-font-style:italic;mso-no-p=
roof:
yes'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><u><span lang=3DDE style=3D'm=
so-bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE;mso-no-proof:yes'>Geburtsfehler<span
style=3D'mso-bidi-font-style:italic'><o:p></o:p></span></span></u></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE;mso-no-proof:yes'>Bei einer Empfng=
nis
mit Hilfe von Techniken der assistierten Reproduktion kann fr einen Sugli=
ng
ein gegenber einer natrlichen Empfngnis leicht erhhtes Risiko von Gebur=
tsfehlern
bestehen. Diese knnten mit Mehrfachschwangerschaften oder Eigenschaften der
Eltern wie dem Alter der Mutter und Eigenschaften der Spermien in Zusammenh=
ang
stehen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-list:skip;tab-stop=
s:.5in'><u
style=3D'text-underline:black'><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Strung
der Blutgerinnung (thromboembolische Ereignisse)</span></u><u><span lang=3D=
DE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</u></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Wenn Sie jemals ein
Blutgerinnsel im Bein oder in der Lunge, einen Herzinfarkt oder Schlaganfall
hatten, oder wenn in Ihrer Familie ein derartiges Ereignis aufgetreten ist,=
 informieren
Sie Ihren Arzt. Das Risiko fr ein Auftreten oder eine Verschlimmerung dies=
er
Probleme knnte im Zuge einer Behandlung mit Ovaleap erhht sein.<o:p></o:p=
></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:2.9pt;margin-bott=
om:0in;
margin-left:5.9pt;margin-bottom:.0001pt'><span lang=3DDE style=3D'mso-ansi-=
language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-list:skip;tab-stop=
s:.5in'><u
style=3D'text-underline:black'><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Mnner
mit zu viel FSH im Blut</span></u><u><span lang=3DDE style=3D'mso-bidi-font=
-size:
11.0pt;mso-ansi-language:DE'> <o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Bei Mnnern deuten
erhhte Blutwerte von natrlichem FSH auf eine Hodenschdigung hin. Wenn di=
eses
Problem bei Ihnen vorliegt, bleibt eine Behandlung mit </span><span lang=3D=
DE
style=3D'mso-ansi-language:DE'>diesem Arzneimittel</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'> fr gewhnlich
wirkungslos. Wenn Ihr Arzt beschliet, eine Behandlung mit Ovaleap zu
versuchen, wird er zur Therapieberwachung 4 bis 6&nbsp;Monate nach
Behandlungsbeginn eine Spermaanalyse durchfhren.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-list:skip;tab-stop=
s:.5in'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>Kinder und Jugendliche<o:p></o:p></span></b></=
p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-ansi-language:DE'>Dieses Arzneimittel</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'> </span><span lang=
=3DDE
style=3D'mso-ansi-language:DE'>ist fr eine Anwendung bei Kindern und
Jugendlichen unter </span><span lang=3DDE style=3D'mso-bidi-font-size:11.0p=
t;
mso-ansi-language:DE'>18&nbsp;Jahren nicht angezeigt.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><b><span lang=
=3DDE
style=3D'mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
DE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Anwendung von </sp=
an></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'>Ovaleap</span></b><b style=3D'mso-bidi-font-we=
ight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>
zusammen mit anderen Arzneimitteln</span></b><span lang=3DDE style=3D'mso-b=
idi-font-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Informie=
ren Sie
Ihren Arzt oder Apotheker, wenn Sie andere Arzneimittel anwenden, krzlich
andere Arzneimittel angewendet haben oder beabsichtigen andere Arzneimittel
anzuwenden.</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-an=
si-language:
DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l12 level1 lfo8;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Wenn
Sie </span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-lang=
uage:
DE'>Ovaleap </span><span lang=3DDE style=3D'mso-ansi-language:DE'>zusammen =
mit
anderen Arzneimitteln zur Frderung des Eisprungs anwenden, z.&nbsp;B. huma=
nes
Choriongonadotropin (hCG) oder Clomifencitrat, kann sich die Wirkung auf die
Follikel (Eiblschen) verstrken</span><span lang=3DDE style=3D'mso-bidi-fo=
nt-size:
11.0pt;mso-ansi-language:DE'>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l12 level1 lfo8;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Wenn
Sie </span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-lang=
uage:
DE'>Ovaleap </span><span lang=3DDE style=3D'mso-ansi-language:DE'>zusammen =
mit
einem Agonisten oder Antagonisten des Gonadotropin-Releasing-Hormons (GnR=
H)
anwenden (diese Arzneimittel verringern die Konzentration Ihrer Sexualhormo=
ne
und verhindern den Eisprung), bentigen Sie mglicherweise eine hhere Dosi=
s </span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Ovaleap<=
/span><span
lang=3DDE style=3D'mso-ansi-language:DE'>, damit Follikel (Eiblschen) prod=
uziert
werden</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-la=
nguage:
DE'>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;background:yellow;mso-highligh=
t:yellow;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
DE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Schwangerschaft und
Stillzeit</span></b><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</b></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-ansi-language:DE'>Sie sollten dieses Arzneimittel</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'> </span>=
<span
lang=3DDE style=3D'mso-ansi-language:DE'>nicht anwenden, wenn Sie schwanger=
 sind
oder stillen.</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-=
ansi-language:
DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-outline-level:1;mso-li=
st:skip;
tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></b></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
DE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Verkehrstchtigkei=
t und
Fhigkeit zum Bedienen von Maschinen</span></b><span lang=3DDE style=3D'mso=
-bidi-font-size:
12.0pt;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Dieses
Arzneimittel beeintrchtig nicht Ihre Fhigkeit, ein Fahrzeug zu steuern und
Maschinen zu bedienen. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
DE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Ovaleap enthlt Na=
trium,
Benzalkoniumchlorid und Benzylalkohol<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Dieses Arzneimittel enthlt weniger
als 1&nbsp;mmol Natrium (23&nbsp;mg) pro Dosis, </span><span lang=3DDE
style=3D'mso-ansi-language:DE'>d.h., es ist nahezu natriumfrei. </span><s=
pan
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-fo=
nt-size:
11.0pt;mso-ansi-language:DE;mso-no-proof:yes'>Dieses </span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Arzneimittel enth=
lt
auch <span style=3D'mso-no-proof:yes'>0,02&nbsp;mg Benzalkoniumchlorid pro =
ml und
</span></span><span lang=3DDE style=3D'mso-ansi-language:DE'>10,0&nbsp;mg
Benzylalkohol pro ml. Wenn Sie an einer Leber- oder Nierenerkrankung leiden=
 und
wenn Sie schwanger sind oder stillen, fragen Sie Ihren Arzt oder Apotheker =
um
Rat, da groe Mengen Benzylalkohol sich in Ihrem Krper anreichern und
Nebenwirkungen verursachen knnen (so genannte &quot;metabolische
Azidose&quot;).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:.5in'><span lang=3DDE style=3D'mso-ansi-la=
nguage:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-1.45pt;page-break-after:avoid;
mso-list:skip;tab-stops:21.3pt 28.35pt'><b style=3D'mso-bidi-font-weight:no=
rmal'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>3.<span
style=3D'mso-tab-count:1'> </span>Wie ist </span></b><b style=3D'mso-bid=
i-font-weight:
normal'><span lang=3DDE style=3D'mso-ansi-language:DE'>Ovaleap</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'> anzuwenden?<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><i style=3D'mso-bidi-font-style:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></i></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso=
-ansi-language:
DE'>Wenden Sie dieses Arzneimittel immer genau nach Absprache mit Ihrem Arzt
oder Apotheker an. Fragen Sie bei Ihrem Arzt oder Apotheker nach, wenn Sie =
sich
nicht sicher sind.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso=
-ansi-language:
DE'>Dieses Arzneimittel wird in Form einer Injektion in das Gewebe unter die
Haut (subkutane Injektion) gegeben. Ihr Arzt oder </span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>das medizinische
Fachpersonal </span><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-=
ansi-language:
DE'>wird Ihnen zeigen, wie Sie das Arzneimittel injizieren mssen. Wenn Sie
sich dieses Arzneimittel selbst geben, lesen und befolgen Sie bitte sorgfl=
tig
die </span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-lan=
guage:
DE'>Anleitung zur Anwendung auf dem Pen.</span><span lang=3DDE style=3D'ms=
o-bidi-font-size:
12.0pt;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
DE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Empfohlene Dosis</=
span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></b></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>Ihr Arz=
t wird
bestimmen, in welcher Dosierung und wie oft Sie das Arzneimittel anwenden
sollen. Die folgenden Dosierungen sind in Internationalen Einheiten (I.E.)
angegeben.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p>&n=
bsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><u><span lang=3DDE
style=3D'mso-ansi-language:DE'>Frauen<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span lang=3DDE
style=3D'mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid'><u><span lang=3DDE style=3D'mso-ansi-language:DE'>W=
enn Sie
keinen Eisprung und unregelmige oder keine Regelblutungen (Menstruation)
haben<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
pagination:
widow-orphan lines-together;page-break-after:avoid;mso-list:l15 level1 lfo9=
'><![if !supportLists]><span
lang=3DDE style=3D'font-family:Symbol;mso-fareast-font-family:Symbol;mso-bi=
di-font-family:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Dieses
Arzneimittel wird blicherweise tglich angewendet.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l15 level1 lfo9'><![if !supportLists]><span lang=3DDE style=3D'font-family:=
Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-languag=
e:
DE'><span style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Wenn
Sie unregelmige Regelblutungen haben, sollte die Behandlung mit diesem
Arzneimittel innerhalb der ersten 7&nbsp;Tage des Menstruationszyklus begin=
nen.
Wenn Sie keine Regelblutungen haben, knnen Sie jederzeit mit der Anwendung=
 des
Arzneimittels beginnen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l15 level1 lfo9'><![if !supportLists]><span lang=3DDE style=3D'font-family:=
Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-languag=
e:
DE'><span style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Gewhnlich
wird mit einer Arzneimitteldosis von 75 bis 150&nbsp;I.E. tglich begonnen.=
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l15 level1 lfo9'><![if !supportLists]><span lang=3DDE style=3D'font-family:=
Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-languag=
e:
DE'><span style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Ihre
Dosis dieses Arzneimittels kann alle 7 oder 14&nbsp;Tage um 37,5 bis 75&nbs=
p;I.E.
gesteigert werden, bis die Behandlung die gewnschte Wirkung zeigt.<o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l15 level1 lfo9'><![if !supportLists]><span lang=3DDE style=3D'font-family:=
Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-languag=
e:
DE'><span style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Die
maximale Tagesdosis dieses Arzneimittels liegt blicherweise nicht hher als
225&nbsp;I.E.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l15 level1 lfo9'><![if !supportLists]><span lang=3DDE style=3D'font-family:=
Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-languag=
e:
DE'><span style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Nach
erfolgreichem Ansprechen erhalten Sie hCG oder rekombinantes hCG&quot; (r&=
#8209;hCG,
ein hCG, das durch eine spezielle DNA-Technik in einem Laboratorium hergest=
ellt
wird). Dafr werden 24 bis 48&nbsp;Stunden nach Ihrer letzten Ovaleap-Injek=
tion
einmalig 250&nbsp;Mikrogramm r&#8209;hCG oder 5.000 bis 10.000&nbsp;I.E. hCG
injiziert. Die beste Zeit fr Geschlechtsverkehr ist am Tag der hCG-Injekti=
on
und am darauf folgenden Tag. Alternativ kann eine intrauterine Insemination
(Einbringen von Spermien in die Gebrmutter) durchgefhrt werden.<o:p></o:p=
></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p>&n=
bsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>Falls I=
hr Arzt
nach 4&#8209;wchiger Behandlung keinen Erfolg feststellt, muss dieser
Behandlungszyklus mit Ovaleap abgebrochen werden. Im folgenden Zyklus wird
Ihnen Ihr Arzt dieses Arzneimittel in einer hheren Anfangsdosis verschreib=
en.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p>&n=
bsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>Wenn Ih=
r Krper
zu stark reagiert, wird die Behandlung beendet und Sie erhalten kein hCG [s=
iehe
auch Abschnitt&nbsp;2 unter Ovarielles berstimulationssyndrom (OHSS)]. Im
nchsten Behandlungszyklus wird Ihnen Ihr Arzt Ovaleap in einer niedrigeren
Dosierung verschreiben. <o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'background:yellow;mso-highlig=
ht:yellow;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><u><span lang=3DDE
style=3D'mso-ansi-language:DE'>Wenn sich bei Ihnen vor einer Anwendung von
Techniken der assistierten Reproduktion mehrere Eizellen zur Entnahme
entwickeln mssen<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l13 level1 lfo10'><![if !supportLists]><span lang=3DDE style=3D'font-family=
:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-languag=
e:
DE'><span style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>blicherweise
wird am 2. oder 3.&nbsp;Zyklustag mit einer tglichen Arzneimitteldosis von=
 150
bis 225&nbsp;I.E. begonnen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l13 level1 lfo10'><![if !supportLists]><span lang=3DDE style=3D'font-family=
:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-languag=
e:
DE'><span style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Abhngig
von Ihrem Ansprechen kann die Dosierung erhht werden. Die maximale Tagesdo=
sis
betrgt 450&nbsp;I.E.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l13 level1 lfo10'><![if !supportLists]><span lang=3DDE style=3D'font-family=
:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-languag=
e:
DE'><span style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Die
Behandlung wird fortgefhrt, bis sich Ihre Eizellen ausreichend entwickelt
haben. Dies dauert in der Regel etwa 10&nbsp;Tage, kann aber schon am 5. od=
er
auch erst am 20.&nbsp;Tag erfolgt sein. Ihr Arzt wird den Zeitpunkt mittels
Blut- und/oder Ultraschalluntersuchungen feststellen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l13 level1 lfo10'><![if !supportLists]><span lang=3DDE style=3D'font-family=
:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-languag=
e:
DE'><span style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Wenn
sich Ihre Eizellen ausreichend entwickelt haben, erhalten Sie hCG oder r&#8=
209;hCG.
Dafr werden 24 bis 48&nbsp;Stunden nach der letzten Ovaleap-Injektion einm=
alig
250&nbsp;Mikrogramm r-hCG oder 5.000 bis 10.000 I.E. hCG injiziert. Auf die=
se
Weise werden Ihre Eizellen fr die Entnahme vorbereitet.<o:p></o:p></span><=
/p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt'><sp=
an
lang=3DDE style=3D'mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>In ande=
ren Fllen
wird Ihr Arzt vielleicht zuerst einen Eisprung mit einem
Gonadotropin-Releasing-Hormon-(GnRH-)Agonisten oder -Antagonisten verhinder=
n.
Dann wird mit der Gabe von Ovaleap etwa 2&nbsp;Wochen nach Beginn der
Behandlung mit einem Agonisten begonnen. Ovaleap und der GnRH-Agonist werden
dann so lange angewendet, bis sich Ihre Follikel (Eiblschen) ausreichend
entwickelt haben.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'background:yellow;mso-highlig=
ht:yellow;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><u><span lang=3DDE
style=3D'mso-ansi-language:DE'>Wenn Sie keinen Eisprung und keine Regelblut=
ung
haben und bei Ihnen sehr niedrige Konzentrationen der Hormone FSH und LH
festgestellt worden sind<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l13 level1 lfo10'><![if !supportLists]><span lang=3DDE style=3D'font-family=
:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-languag=
e:
DE'><span style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>blicherweise
wird mit einer Dosis von 75 bis 150&nbsp;I.E. Ovaleap zusammen mit 75&nbsp;=
I.E.
Lutropin alfa begonnen. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l13 level1 lfo10'><![if !supportLists]><span lang=3DDE style=3D'font-family=
:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-languag=
e:
DE'><span style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Sie
werden diese beiden Arzneimittel tglich ber einen Zeitraum von bis zu 5&n=
bsp;Wochen
anwenden.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l13 level1 lfo10'><![if !supportLists]><span lang=3DDE style=3D'font-family=
:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-languag=
e:
DE'><span style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Ihre
Ovaleap-Dosis kann alle 7 oder 14&nbsp;Tage um 37,5 bis 75&nbsp;I.E. gestei=
gert
werden, bis die Behandlung die gewnschte Wirkung zeigt.<o:p></o:p></span><=
/p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l13 level1 lfo10'><![if !supportLists]><span lang=3DDE style=3D'font-family=
:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-languag=
e:
DE'><span style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Wenn
sich die gewnschte Wirkung zeigt, erhalten Sie hCG oder r&#8209;hCG. Dafr
werden 24 bis 48&nbsp;Stunden nach der letzten Injektion von Ovaleap und
Lutropin alfa einmalig 250&nbsp;Mikrogramm r&#8209;hCG oder 5.000 bis 10.00=
0&nbsp;I.E.
hCG injiziert. Die beste Zeit fr Geschlechtsverkehr ist am Tag der
hCG-Injektion und am darauf folgenden Tag. Alternativ kann eine intrauterine
Insemination (Einbringen von Spermien in die Gebrmutter) durchgefhrt werd=
en.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt'><sp=
an
lang=3DDE style=3D'mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>Falls I=
hr Arzt
nach 5-wchiger Behandlung keinen Erfolg feststellt, muss dieser
Behandlungszyklus abgebrochen werden. Im folgenden Zyklus wird Ihnen Ihr Ar=
zt dieses
Arzneimittel in einer hheren Anfangsdosis verschreiben.<o:p></o:p></span><=
/p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p>&n=
bsp;</o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-ansi-language:DE'>Wenn Ih=
r Krper
zu stark reagiert, wird die Behandlung mit Ovaleap beendet und Sie erhalten
kein hCG [siehe auch Abschnitt&nbsp;2 unter Ovarielles berstimulationssyn=
drom
(OHSS)]. Im nchsten Behandlungszyklus wird Ihnen Ihr Arzt Ovaleap in einer
niedrigeren Dosierung als zuvor verschreiben.<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'background:yellow;mso-highlig=
ht:yellow;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><u><span lang=3DDE
style=3D'mso-ansi-language:DE'>Mnner<o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l13 level1 lfo10'><![if !supportLists]><span lang=3DDE style=3D'font-family=
:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-languag=
e:
DE'><span style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Die
bliche Dosis dieses Arzneimittels ist 150&nbsp;I.E. zusammen mit hCG.<o:p>=
</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l13 level1 lfo10'><![if !supportLists]><span lang=3DDE style=3D'font-family=
:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-languag=
e:
DE'><span style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Sie
werden diese beiden Arzneimittel dreimal pro Woche ber einen Zeitraum von
mindestens 4&nbsp;Monaten anwenden.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l13 level1 lfo10'><![if !supportLists]><span lang=3DDE style=3D'font-family=
:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-ansi-languag=
e:
DE'><span style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New R=
oman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Wenn
Sie nach 4&nbsp;Monaten noch nicht auf die Behandlung angesprochen haben,
schlgt Ihnen Ihr Arzt vielleicht vor, die Behandlung mit diesen beiden
Arzneimitteln fr weitere 18&nbsp;Monate oder lnger fortzusetzen.<o:p></o:=
p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-list:skip;tab-stop=
s:.5in'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'>Wie werden die Injektionen gegeben?<o:p></o:p>=
</span></b></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Dieses Arzneimitte=
l wird
</span><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language=
:DE'>in
Form einer Injektion </span><span lang=3DDE style=3D'mso-bidi-font-size:11.=
0pt;
mso-ansi-language:DE'>mit Hilfe des Ovaleap-Pens </span><span lang=3DDE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>in das Gewebe unte=
r die
Haut (subkutane Injektion) </span><span lang=3DDE style=3D'mso-bidi-font-si=
ze:11.0pt;
mso-ansi-language:DE'>gegeben. Bei dem Ovaleap-Pen handelt es sich um ein
Hilfsmittel (einen Pen) fr die Gabe von Injektionen in das Gewebe unter =
die
Haut.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Ihr Arzt=
 schlgt
Ihnen mglicherweise vor, dass Sie lernen, sich dieses Arzneimittel selbst =
zu injizieren.
Ihr Arzt oder das medizinische Fachpersonal wird Ihnen erklren, wie Sie die
Injektionen durchfhren und Sie finden auch entsprechende Hinweise in der g=
esonderten
Anleitung zur Anwendung des Pens. Versuchen Sie nicht, dieses Arzneimittel =
selbst
anzuwenden, bevor Sie nicht von Ihrem Arzt oder dem medizinischen Fachperso=
nal
entsprechend geschult wurden. Die allererste Injektion </span><span lang=3D=
DE
style=3D'mso-ansi-language:DE'>dieses Arzneimittels</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'> sollte nur in Geg=
enwart
eines Arztes oder des medizinischen Fachpersonals gegeben werden.<o:p></o:p=
></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Die Oval=
eap-Injektionslsung
in Patronen wurde fr die Anwendung mit dem Ovaleap&#8209;Pen entwickelt. S=
ie
mssen sich genau an die gesonderte Anleitung zur Anwendung des Ovaleap-Pens
halten. Die Hinweise zur Anwendung des Pens liegen dem Ovaleap-Pen bei. Eine
sachgerechte Behandlung Ihrer Erkrankung setzt jedoch eine enge und konstan=
te
Zusammenarbeit mit Ihrem Arzt voraus.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Verwende=
te
Nadeln sind sofort nach der Injektion zu entsorgen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
DE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Wenn Sie eine gr=
ere
Menge von </span></b><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
DE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Ovaleap </span></b=
><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'>angewendet haben, als Sie sollten</span></b><s=
pan
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-outline-level:1;mso-li=
st:skip;
tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi=
-language:
DE'>Die Auswirkungen einer Anwendung zu groer Mengen von Ovaleap sind nicht
bekannt. Dennoch knnte eine berdosierung zu einem ovariellen
berstimulationssyndrom (OHSS) fhren, welches im Abschnitt&nbsp;4 unter
Schwerwiegende Nebenwirkungen bei Frauen beschrieben ist. Ein OHSS tritt
jedoch nur dann ein, wenn auch hCG gegeben wird [</span><span lang=3DDE
style=3D'mso-ansi-language:DE'>siehe auch Abschnitt&nbsp;2 unter Ovarielles
berstimulationssyndrom (OHSS)]</span><span lang=3DDE style=3D'mso-bidi-fo=
nt-size:
11.0pt;mso-ansi-language:DE'>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-outline-level:1;mso-li=
st:skip;
tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi=
-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
DE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Wenn Sie die Anwen=
dung
von </span></b><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Ovaleap</span></b>=
<b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
12.0pt;mso-ansi-language:DE'> vergessen haben</span></b><span lang=3DDE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Wenden S=
ie nicht
die doppelte Menge an, wenn Sie die vorherige Anwendung vergessen haben. </=
span><span
lang=3DDE style=3D'mso-ansi-language:DE'>Kontaktieren Sie bitte Ihren Arzt,=
 sobald
Sie bemerkt haben, dass Sie eine Anwendung vergessen haben. </span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;background:yellow;mso-highligh=
t:yellow;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-1.45pt;mso-list:skip;tab-stops:=
.5in'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Wenn Sie=
 weitere
Fragen zur Anwendung dieses Arzneimittels haben, wenden Sie sich an Ihren A=
rzt,
Apotheker oder das medizinische Fachpersonal.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
DE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>4.<span
style=3D'mso-tab-count:1'> </span>Welche Nebenwirkungen sind mglic=
h?</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-list:skip;tab-stop=
s:.5in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-1.45pt;page-break-after:avoid;
mso-list:skip;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:1=
2.0pt;
mso-ansi-language:DE'>Wie alle Arzneimittel kann auch dieses Arzneimittel
Nebenwirkungen haben, die aber nicht bei jedem auftreten mssen.<o:p></o:p>=
</span></p>

<p class=3DMsoNormal style=3D'margin-right:-1.45pt;page-break-after:avoid;
mso-list:skip;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:1=
1.0pt;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-1.45pt;page-break-after:avoid;
mso-list:skip;tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Bedeuten=
de
Nebenwirkungen<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-right:-1.45pt;page-break-after:avoid;
mso-list:skip;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:1=
1.0pt;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-1.45pt;page-break-after:avoid;
mso-list:skip;tab-stops:.5in'><u><span lang=3DDE style=3D'mso-bidi-font-siz=
e:11.0pt;
mso-ansi-language:DE'>Schwerwiegende Nebenwirkungen bei Mnnern und Frauen<=
o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Allergische
Reaktionen wie Hautausschlag, erhabene juckende Hautbereiche sowie
schwerwiegende allergische Reaktionen mit Schwche, Blutdruckabfall,
Atemproblemen und Gesichtsschwellung wurden sehr selten gemeldet </span><sp=
an
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>(kann we=
niger
als 1&nbsp;Behandelten von 10.000 betreffen). Wenn Sie vermuten, dass bei I=
hnen
eine solche Reaktion vorliegt, mssen Sie die Injektion von Ovaleap beenden=
 und<span
style=3D'font-variant:small-caps'> </span>unverzglich rztliche Hilfe in
Anspruch nehmen. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-1.45pt;mso-list:skip;tab-stops:=
.5in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-1.45pt;page-break-after:avoid;
mso-list:skip;tab-stops:.5in'><u><span lang=3DDE style=3D'mso-bidi-font-siz=
e:11.0pt;
mso-ansi-language:DE'>Schwerwiegende Nebenwirkungen bei Frauen<o:p></o:p></=
span></u></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
11.0pt;
mso-ansi-language:DE'>Unterbauchschmerzen mit belkeit oder Erbrechen knne=
n Zeichen
eines ovariellen berstimulationssyndroms sein (OHSS). Dies kann ein Anzeic=
hen
dafr sein, dass die Eierstcke auf die Behandlung berreagieren und sich g=
roe
Ovarialzysten gebildet haben [</span><span lang=3DDE style=3D'mso-ansi-lang=
uage:
DE'>siehe auch Abschnitt&nbsp;2 unter Ovarielles berstimulationssyndrom (=
OHSS)]</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>. Diese =
Nebenwirkung
tritt hufig auf (kann </span><span lang=3DDE style=3D'mso-ansi-language:DE=
'>1 bis
10&nbsp;Behandelte von 100 betreffen</span><span lang=3DDE style=3D'mso-bid=
i-font-size:
11.0pt;mso-ansi-language:DE'>).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
11.0pt;
mso-ansi-language:DE'>Das OHSS kann einen schweren Verlauf nehmen,</span><s=
pan
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;font-family:"TimesNewRomanPSMT=
",serif;
mso-fareast-font-family:SimSun;mso-bidi-font-family:TimesNewRomanPSMT;
mso-ansi-language:DE;mso-fareast-language:DE'> wobei es zu deutlich
vergrerten Ovarien, verminderter Urinproduktion</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>, Gewichtszunahme,=
</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;font-family:"TimesNewRomanPSMT=
",serif;
mso-fareast-font-family:SimSun;mso-bidi-font-family:TimesNewRomanPSMT;
mso-ansi-language:DE;mso-fareast-language:DE'> Atemproblemen und/oder
Flssigkeitsansammlung im Bauch- oder Brustraum kommt</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>. Hierbei handelt =
es
sich um eine gelegentliche Nebenwirkung (kann </span><span lang=3DDE
style=3D'mso-ansi-language:DE'>1 bis 10&nbsp;Behandelte von 1.000 betreffen=
</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>).<o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
11.0pt;
mso-ansi-language:DE'>Komplikationen eines OHSS wie Verdrehung der Eierstc=
ke
oder Blutgerinnselbildung knnen selten auftreten (kann </span><span lang=
=3DDE
style=3D'mso-ansi-language:DE'>1 bis 10&nbsp;Behandelte von 10.000 betreffe=
n</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>).<o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;font-family:Symbol;mso-fareast-font-fami=
ly:
Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:DE'><span
style=3D'mso-list:Ignore'><span style=3D'font:7.0pt "Times New Roman"'>&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>In
sehr seltenen Fllen knnen schwerwiegende Gerinnungsstrungen
(thromboembolische Ereignisse) manchmal auch unabhngig von einem OHSS
auftreten</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi=
-language:
DE'> (kann weniger als 1&nbsp;Behandelten von 10.000 betreffen). Dies kann
Schmerzen im Brustkorb, Atemnot, Schlaganfall oder Herzinfarkt verursachen =
[siehe
auch Abschnitt&nbsp;2 unter </span><span lang=3DDE style=3D'mso-ansi-langu=
age:
DE'>Strung der Blutgerinnung (thromboembolische Ereignisse)]</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>.<o:p></=
o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.45pt;margin-bo=
ttom:
0in;margin-left:0in;margin-bottom:.0001pt;text-indent:0in;mso-list:l16 ligh=
ter lfo11 skip;
tab-stops:list .25in'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-1.45pt;mso-list:skip;tab-stops:=
.5in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Sollte e=
ine der geschilderten
Nebenwirkungen auftreten, informieren Sie bitte unverzglich Ihren Arzt. Di=
eser
wird Sie eventuell anweisen, die Anwendung von Ovaleap abzubrechen.<o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-1.45pt;mso-list:skip;tab-stops:=
.5in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;background:yellow;mso-highligh=
t:yellow;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
DE
style=3D'mso-ansi-language:DE'>Weitere Nebenwirkungen bei Frauen<o:p></o:p>=
</span></b></p>

<p class=3DMsoNormal style=3D'margin-right:-1.45pt;page-break-after:avoid;
mso-list:skip;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:1=
1.0pt;
background:yellow;mso-highlight:yellow;mso-ansi-language:DE'><o:p>&nbsp;</o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><u><span lang=3DDE style=3D'mso-ansi-language:DE'>Sehr=
 hufig</span></u><span
lang=3DDE style=3D'mso-ansi-language:DE'> (</span><span lang=3DDE style=3D'=
mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>kann mehr als 1&nbsp;Behandelten von 10 betref=
fen)</span><u><span
lang=3DDE style=3D'mso-ansi-language:DE'><o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-fa=
mily:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Lokale
Reaktionen an der Injektionsstelle, z. B. Schmerzen, Rtung, Bluterguss,
Schwellung und/oder Reizung<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-fa=
mily:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Kopfschmerzen<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-fa=
mily:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Mit
Flssigkeit gefllte Hohlrume im Gewebe der Eierstcke (Eierstockzysten)<o=
:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><u><span lang=3DDE style=3D'mso-ansi-language:DE'>Huf=
ig</span></u><span
lang=3DDE style=3D'mso-ansi-language:DE'> (</span><span lang=3DDE style=3D'=
mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>kann 1 bis 10&nbsp;Behandelte von 100 betreffe=
n)</span><u><span
lang=3DDE style=3D'mso-ansi-language:DE'><o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-fa=
mily:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Magenschmerzen
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-fa=
mily:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Vllegefhl<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-fa=
mily:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Unterleibskrmpfe<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-fa=
mily:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>belkeit<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-fa=
mily:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Erbrechen<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-fa=
mily:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Durchfall<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><u><span lang=3DDE style=3D'mso-ansi-language:DE'>Sehr=
 selten</span></u><span
lang=3DDE style=3D'mso-ansi-language:DE'> (</span><span lang=3DDE style=3D'=
mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>kann weniger als 1&nbsp;Behandelten von 10.000
betreffen)</span><u><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p></o=
:p></span></u></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-fa=
mily:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
11.0pt;
font-family:"TimesNewRomanPSMT",serif;mso-fareast-font-family:SimSun;
mso-bidi-font-family:TimesNewRomanPSMT;mso-ansi-language:DE;mso-fareast-lan=
guage:
DE'>Unter Umstnden kann sich Ihr Asthma verschlimmern.</span><span lang=3D=
DE
style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-.1pt;margin-bott=
om:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:ski=
p;
tab-stops:.5in'><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p>&nbsp;<=
/o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
DE
style=3D'mso-ansi-language:DE'>Weitere Nebenwirkungen bei Mnnern<o:p></o:p=
></span></b></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p>&n=
bsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><u><span lang=3DDE style=3D'mso-ansi-language:DE'>Sehr=
 hufig</span></u><span
lang=3DDE style=3D'mso-ansi-language:DE'> (</span><span lang=3DDE style=3D'=
mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>kann mehr als 1&nbsp;Behandelten von 10 betref=
fen)</span><u><span
lang=3DDE style=3D'mso-ansi-language:DE'><o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-fa=
mily:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Lokale
Reaktionen an der Injektionsstelle, z. B. Schmerzen, Rtung, Bluterguss,
Schwellung und/oder Reizung <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><u><span lang=3DDE style=3D'mso-ansi-language:DE'>Huf=
ig</span></u><span
lang=3DDE style=3D'mso-ansi-language:DE'> (</span><span lang=3DDE style=3D'=
mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>kann 1 bis 10&nbsp;Behandelte von 100 betreffe=
n)</span><u><span
lang=3DDE style=3D'mso-ansi-language:DE'><o:p></o:p></span></u></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-fa=
mily:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
11.0pt;
font-family:"TimesNewRomanPSMT",serif;mso-fareast-font-family:SimSun;
mso-bidi-font-family:TimesNewRomanPSMT;mso-ansi-language:DE;mso-fareast-lan=
guage:
DE'>Anschwellen der Venen im Hodenbereich</span><span lang=3DDE style=3D'ms=
o-ansi-language:
DE'> (Varikozele) <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-fa=
mily:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Vergrerung
der Brustdrsen<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-fa=
mily:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Akne<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-fa=
mily:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-ansi-language:D=
E'>Gewichtszunahme<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><u><span lang=3DDE style=3D'mso-ansi-language:DE'>Sehr=
 selten</span></u><span
lang=3DDE style=3D'mso-ansi-language:DE'> (</span><span lang=3DDE style=3D'=
mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'>kann weniger als 1&nbsp;Behandelten von 10.000
betreffen)</span><u><span lang=3DDE style=3D'mso-ansi-language:DE'><o:p></o=
:p></span></u></p>

<p class=3DMsoNormal style=3D'margin-top:0in;margin-right:-1.4pt;margin-bot=
tom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;mso-list:
l16 level1 lfo11;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-fa=
mily:
Symbol;mso-ansi-language:DE'><span style=3D'mso-list:Ignore'><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
11.0pt;
font-family:"TimesNewRomanPSMT",serif;mso-fareast-font-family:SimSun;
mso-bidi-font-family:TimesNewRomanPSMT;mso-ansi-language:DE;mso-fareast-lan=
guage:
DE'>Unter Umstnden kann sich Ihr Asthma verschlimmern.</span><span lang=3D=
DE
style=3D'mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE;mso-no-proof:yes'>Meldung von Nebenwirkungen</s=
pan></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-no-pr=
oof:
yes'>Wenn Sie Nebenwirkungen bemerken, wenden Sie sich an Ihren Arzt, Apoth=
eker
oder das medizinische Fachpersonal.</span><span lang=3DDE style=3D'mso-bidi=
-font-size:
11.0pt;color:red;mso-ansi-language:DE'> </span><span lang=3DDE style=3D'mso=
-bidi-font-size:
11.0pt;mso-ansi-language:DE;mso-no-proof:yes'>Dies gilt auch fr
Nebenwirkungen, die nicht in dieser Packungsbeilage angegeben sind.</span><=
span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'> <span
style=3D'mso-no-proof:yes'>Sie knnen Nebenwirkungen auch direkt ber <span
style=3D'background:lightgrey;mso-highlight:lightgrey'>das in </span></span=
></span><span
lang=3DEN-GB><a
href=3D"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_fo=
rm/2013/03/WC500139752.doc"><span
lang=3DDE style=3D'background:lightgrey;mso-highlight:lightgrey;mso-ansi-la=
nguage:
DE'>Anhang&nbsp;V</span></a></span><span lang=3DDE style=3D'mso-bidi-font-s=
ize:
11.0pt;background:lightgrey;mso-highlight:lightgrey;mso-ansi-language:DE;
mso-no-proof:yes'> aufgefhrte nationale Meldesystem</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-no-proof:yes'>
anzeigen.</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi=
-language:
DE'> <span style=3D'mso-no-proof:yes'>Indem Sie Nebenwirkungen melden, knn=
en Sie
dazu beitragen, dass mehr Informationen ber die Sicherheit dieses
Arzneimittels zur Verfgung gestellt werden.<o:p></o:p></span></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
DE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>5.<span
style=3D'mso-tab-count:1'> </span>Wie ist Ovaleap aufzubewahren?<o:=
p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso=
-ansi-language:
DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso=
-ansi-language:
DE'>Bewahren Sie dieses Arzneimittel fr Kinder unzugnglich auf.<o:p></o:p=
></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Sie drf=
en
dieses Arzneimittel nach dem auf dem Etikett nach Verw. bis und dem Umkar=
ton
nach Verwendbar bis angegebenen Verfalldatum nicht mehr verwenden. Das
Verfalldatum bezieht sich auf den letzten Tag des angegebenen Monats.<o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Im Khlschrank lagern (2&nbsp;C&#=
8209;8&nbsp;C).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Nicht einfrieren.<o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Die Patrone im Umkarton aufbewahre=
n,
um den Inhalt vor Licht zu schtzen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Ungeffnet und innerhalb der Dauer=
 der
Haltbarkeit knnen Sie dieses Arzneimittel aus dem Khlschrank nehmen und o=
hne
erneute Khlung bis zu 3&nbsp;Monate aufbewahren. Nicht ber 25&nbsp;C lag=
ern.
Ist das Arzneimittel nach 3&nbsp;Monaten nicht verwendet worden, mssen Sie=
 es verwerfen.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Nach dem ffnen kann die im Pen ei=
ngelegte
Patrone hchstens 28&nbsp;Tage aufbewahrt werden. Nicht ber 25&nbsp;C lag=
ern.
</span><span lang=3DDE style=3D'mso-ansi-language:DE'>Notieren Sie sich das=
 Datum
der ersten Anwendung in dem Patiententagebuch, das dem Ovaleap-Pen beiliegt=
.</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:=
DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;color:black;mso-ansi-language:DE'>Die Kappe des Ovaleap-Pens muss na=
ch
jeder Injektion wieder auf den Pen aufgesetzt werden, um den Inhalt der Pat=
rone
vor Licht zu schtzen. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-ansi-language:DE'>Sie drfen dieses Arzneimittel nic=
ht
verwenden, wenn Sie Folgendes bemerken: Es erscheint trbe oder enthlt
Schwebstoffe</span><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-a=
nsi-language:
DE'>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Entsorge=
n Sie
Arzneimittel nicht im Abwasser. Fragen Sie Ihren Apotheker, wie das
Arzneimittel zu entsorgen ist, wenn Sie es nicht mehr verwenden. Sie tragen
damit zum Schutz der Umwelt bei.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
DE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>6.<span
style=3D'mso-tab-count:1'> </span>Inhalt der Packung und weitere
Informationen<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-list:skip;tab-stop=
s:.5in'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
DE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Was Ovaleap enthl=
t</span></b><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l10 level1 lfo2;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><span style=3D'mso=
-list:
Ignore'>-<span style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
11.0pt;
mso-ansi-language:DE'>Der Wirkstoff ist: Follitropin alfa.<o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Ovaleap 300&nbsp;I=
.E./0,5&nbsp;ml:
Jede Patrone enthlt 300&nbsp;I.E. (entspricht 22&nbsp;Mikrogramm) Follitro=
pin
alfa in 0,5&nbsp;ml Lsung.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Ovaleap 450&nbsp;I=
.E./0,75&nbsp;ml:
Jede Patrone enthlt 450&nbsp;I.E. (entspricht 33&nbsp;Mikrogramm) Follitro=
pin
alfa in 0,75&nbsp;ml Lsung.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Ovaleap 900&nbsp;I=
.E./1,5&nbsp;ml:
Jede Patrone enthlt 900&nbsp;I.E. (entspricht 66&nbsp;Mikrogramm) Follitro=
pin
alfa in 1,5&nbsp;ml Lsung.<span style=3D'color:black'><o:p></o:p></span></=
span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-ansi-language:DE'>Jeder =
ml
Lsung enthlt 600&nbsp;I.E. (entspricht 44&nbsp;Mikrogramm) Follitropin al=
fa.</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;text-indent:-28.35pt;mso-=
list:
l10 level1 lfo2;tab-stops:.5in'><![if !supportLists]><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><span style=3D'mso=
-list:
Ignore'>-<span style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nb=
sp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DDE style=3D'mso-bidi-font-size:=
11.0pt;
mso-ansi-language:DE'>Die sonstigen Bestandteile sind: Natriumdihydrogenpho=
sphat-Dihydrat,
Natriumhydroxid (2&nbsp;M) (zur pH-Einstellung), Mannitol, Methionin, Polys=
orbat&nbsp;20,
Benzylalkohol, Benzalkoniumchlorid und Wasser fr Injektionszwecke.<o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:28.35pt;tab-stops:.5in'><span lan=
g=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'>Alle oben genannte=
n Strken
enthalten die sonstigen Bestandteile.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><b><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
mso-ansi-language:DE'>Wie Ovaleap </span></b><b style=3D'mso-bidi-font-weig=
ht:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>aussieht
und Inhalt der Packung</span></b><b><span lang=3DDE style=3D'mso-bidi-font-=
size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;mso-ansi-language:DE'>Ovaleap ist eine Injektionslsung (Injektion).=
 Ovaleap
ist eine klare und farblose Lsung.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;mso-ansi-language:DE'>Ovaleap 300&nbsp;I.E./0,5&nbsp;ml ist in Packu=
ngen
mit 1&nbsp;Patrone und 10&nbsp;Injektionsnadeln erhltlich.<br>
Ovaleap 450&nbsp;I.E./0,75&nbsp;ml ist in Packungen mit 1&nbsp;Patrone und =
10&nbsp;Injektionsnadeln
erhltlich.<br>
Ovaleap 900&nbsp;I.E./1,5&nbsp;ml ist in Packungen mit 1&nbsp;Patrone und 2=
0&nbsp;Injektionsnadeln
erhltlich.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DDE style=3D'mso-=
bidi-font-size:
11.0pt;mso-ansi-language:DE'>Es werden mglicherweise nicht alle Packungsgr=
en
in den Verkehr gebracht.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
DE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Pharmazeutischer
Unternehmer</span></b><b><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
mso-ansi-language:DE'><o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>Theramex Ireland Limited<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DEN-GB style=3D'm=
so-bidi-font-family:
Verdana;color:black'>3<sup>rd</sup> Floor, </span><span lang=3DNL
style=3D'mso-ansi-language:NL'>Kilmore House,<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>Park Lane, Spencer Dock,<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>Dublin 1<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span lang=3DNL style=3D'mso-=
ansi-language:
NL'>D01 YE64<o:p></o:p></span></p>

<p class=3DMsoNormal><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;col=
or:black;
mso-ansi-language:DE;mso-no-proof:yes'>Irland</span><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;page-break-after:avoid;mso=
-list:
skip;tab-stops:.5in'><b><span lang=3DDE style=3D'mso-bidi-font-size:11.0pt;
mso-ansi-language:DE'>Hersteller<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><a name=3D"OLE_=
LINK8"></a><a
name=3D"OLE_LINK9"><span style=3D'mso-bookmark:OLE_LINK8'><span lang=3DDE
style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE;mso-bidi-font-weigh=
t:
bold'>Teva Biotech GmbH<o:p></o:p></span></span></a></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span style=3D'=
mso-bookmark:
OLE_LINK9'><span style=3D'mso-bookmark:OLE_LINK8'><span lang=3DDE style=3D'=
mso-bidi-font-size:
11.0pt;mso-ansi-language:DE;mso-bidi-font-weight:bold'>Dornierstrae 10<o:p=
></o:p></span></span></span></p>

<p class=3DMsoNormal style=3D'mso-list:skip;tab-stops:.5in'><span style=3D'=
mso-bookmark:
OLE_LINK9'><span style=3D'mso-bookmark:OLE_LINK8'><span lang=3DDE style=3D'=
mso-bidi-font-size:
11.0pt;mso-ansi-language:DE;mso-bidi-font-weight:bold'>89079 Ulm<o:p></o:p>=
</span></span></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span style=3D'mso-bookmark:O=
LE_LINK9'><span
style=3D'mso-bookmark:OLE_LINK8'><span lang=3DDE style=3D'mso-bidi-font-siz=
e:11.0pt;
mso-ansi-language:DE'>Deutschland<o:p></o:p></span></span></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in'><span style=3D'mso-bookmark:O=
LE_LINK9'><span
style=3D'mso-bookmark:OLE_LINK8'><span lang=3DDE style=3D'mso-bidi-font-siz=
e:11.0pt;
mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></span></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in;background:silver'><span
style=3D'mso-bookmark:OLE_LINK9'><span style=3D'mso-bookmark:OLE_LINK8'><sp=
an
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-color-alt:wind=
owtext;
mso-ansi-language:DE'>Teva Pharmaceuticals Europe B.V.</span></span></span>=
<span
style=3D'mso-bookmark:OLE_LINK9'><span style=3D'mso-bookmark:OLE_LINK8'><sp=
an
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></span></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in;background:silver'><span
style=3D'mso-bookmark:OLE_LINK9'><span style=3D'mso-bookmark:OLE_LINK8'><sp=
an
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-color-alt:wind=
owtext;
mso-ansi-language:DE'>Swensweg 5</span></span></span><span style=3D'mso-boo=
kmark:
OLE_LINK9'><span style=3D'mso-bookmark:OLE_LINK8'><span lang=3DDE style=3D'=
mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></span></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in;background:silver'><span
style=3D'mso-bookmark:OLE_LINK9'><span style=3D'mso-bookmark:OLE_LINK8'><sp=
an
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-color-alt:wind=
owtext;
mso-ansi-language:DE'>2031 GA Haarlem</span></span></span><span
style=3D'mso-bookmark:OLE_LINK9'><span style=3D'mso-bookmark:OLE_LINK8'><sp=
an
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></span></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in;background:silver'><span
style=3D'mso-bookmark:OLE_LINK9'><span style=3D'mso-bookmark:OLE_LINK8'><sp=
an
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;color:black;mso-color-alt:wind=
owtext;
mso-ansi-language:DE'>Niederlande</span></span></span><span style=3D'mso-bo=
okmark:
OLE_LINK9'><span style=3D'mso-bookmark:OLE_LINK8'><span lang=3DDE style=3D'=
mso-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></span></span></p>

<span style=3D'mso-bookmark:OLE_LINK8'></span><span style=3D'mso-bookmark:O=
LE_LINK9'></span>

<p class=3DMsoNormal style=3D'margin-right:-28.4pt'><span lang=3DDE style=
=3D'mso-bidi-font-size:
11.0pt;mso-ansi-language:DE;mso-no-proof:yes'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in;background:silver'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-color-alt:windowtext;
mso-ansi-language:DE'>Merckle GmbH</span><span lang=3DDE style=3D'mso-bidi-=
font-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in;background:silver'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-color-alt:windowtext;
mso-ansi-language:DE'>Graf-Arco-Strae 3</span><span lang=3DDE style=3D'mso=
-bidi-font-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in;background:silver'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-color-alt:windowtext;
mso-ansi-language:DE'>89079 Ulm, </span><span lang=3DDE style=3D'mso-bidi-f=
ont-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:.5in;background:silver'><span lang=
=3DDE
style=3D'mso-bidi-font-size:11.0pt;color:black;mso-color-alt:windowtext;
mso-ansi-language:DE'>Deutschland</span><span lang=3DDE style=3D'mso-bidi-f=
ont-size:
11.0pt;mso-ansi-language:DE'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip;tab-stops:.5=
in'><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-outline-level:1;mso-li=
st:skip;
tab-stops:.5in'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DDE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Diese Packungsbeil=
age
wurde zuletzt berarbeitet im </span></b><b style=3D'mso-bidi-font-weight:n=
ormal'><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;font-family:"MS Mincho";mso-ha=
nsi-font-family:
"Times New Roman";mso-ansi-language:DE'>{</span></b><b style=3D'mso-bidi-fo=
nt-weight:
normal'><span lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-languag=
e:DE'>Monat&nbsp;JJJJ}.<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip'><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DDE style=3D'mso-bidi-fon=
t-size:
11.0pt;mso-ansi-language:DE'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-right:-.1pt;mso-list:skip'><span lang=
=3DDE
style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>Ausfhrliche
Informationen zu diesem Arzneimittel sind auf den Internetseiten der
Europischen Arzneimittel-Agentur </span><span lang=3DEN-GB><a
href=3D"http://www.ema.europa.eu/"><span lang=3DDE style=3D'mso-bidi-font-s=
ize:12.0pt;
mso-ansi-language:DE'>http://www.ema.europa.eu</span></a></span><span lang=
=3DDE
style=3D'mso-bidi-font-size:12.0pt;color:blue;mso-ansi-language:DE'> </span=
><span
lang=3DDE style=3D'mso-bidi-font-size:12.0pt;mso-ansi-language:DE'>verfgba=
r.</span><span
lang=3DDE style=3D'mso-bidi-font-size:11.0pt;mso-ansi-language:DE'><o:p></o=
:p></span></p>

</div>

</body>

</html>

------=_NextPart_01D75BA1.F8BC9610
Content-Location: file:///C:/C467A08E/Ovaleap_clean_files/item0001.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"utf-8"?><ct:contentTypeSchema ct:_=3D"" m=
a:_=3D"" ma:contentTypeName=3D"Document" ma:contentTypeID=3D"0x010100726F91=
DD1AE57B44B1BCEB7F1056F5D0" ma:contentTypeVersion=3D"6" ma:contentTypeDescr=
iption=3D"Create a new document." ma:contentTypeScope=3D"" ma:versionID=3D"=
80d1dd17cb0c17b7740334051d5d16b2" xmlns:ct=3D"http://schemas.microsoft.com/=
office/2006/metadata/contentType" xmlns:ma=3D"http://schemas.microsoft.com/=
office/2006/metadata/properties/metaAttributes">
<xsd:schema targetNamespace=3D"http://schemas.microsoft.com/office/2006/met=
adata/properties" ma:root=3D"true" ma:fieldsID=3D"c170dc105f61f60cf84b7b3e6=
d807e4f" ns2:_=3D"" ns3:_=3D"" xmlns:xsd=3D"http://www.w3.org/2001/XMLSchem=
a" xmlns:xs=3D"http://www.w3.org/2001/XMLSchema" xmlns:p=3D"http://schemas.=
microsoft.com/office/2006/metadata/properties" xmlns:ns2=3D"a6a35199-84b7-4=
ca5-aa1c-39e9ca4c46ff" xmlns:ns3=3D"0ac2e3cc-46bd-4320-b2ac-d7f7d167e1a9">
<xsd:import namespace=3D"a6a35199-84b7-4ca5-aa1c-39e9ca4c46ff"/>
<xsd:import namespace=3D"0ac2e3cc-46bd-4320-b2ac-d7f7d167e1a9"/>
<xsd:element name=3D"properties">
<xsd:complexType>
<xsd:sequence>
<xsd:element name=3D"documentManagement">
<xsd:complexType>
<xsd:all>
<xsd:element ref=3D"ns2:MediaServiceMetadata" minOccurs=3D"0"/>
<xsd:element ref=3D"ns2:MediaServiceFastMetadata" minOccurs=3D"0"/>
<xsd:element ref=3D"ns2:MediaServiceAutoKeyPoints" minOccurs=3D"0"/>
<xsd:element ref=3D"ns2:MediaServiceKeyPoints" minOccurs=3D"0"/>
<xsd:element ref=3D"ns3:SharedWithUsers" minOccurs=3D"0"/>
<xsd:element ref=3D"ns3:SharedWithDetails" minOccurs=3D"0"/>
</xsd:all>
</xsd:complexType>
</xsd:element>
</xsd:sequence>
</xsd:complexType>
</xsd:element>
</xsd:schema>
<xsd:schema targetNamespace=3D"a6a35199-84b7-4ca5-aa1c-39e9ca4c46ff" elemen=
tFormDefault=3D"qualified" xmlns:xsd=3D"http://www.w3.org/2001/XMLSchema" x=
mlns:xs=3D"http://www.w3.org/2001/XMLSchema" xmlns:dms=3D"http://schemas.mi=
crosoft.com/office/2006/documentManagement/types" xmlns:pc=3D"http://schema=
s.microsoft.com/office/infopath/2007/PartnerControls">
<xsd:import namespace=3D"http://schemas.microsoft.com/office/2006/documentM=
anagement/types"/>
<xsd:import namespace=3D"http://schemas.microsoft.com/office/infopath/2007/=
PartnerControls"/>
<xsd:element name=3D"MediaServiceMetadata" ma:index=3D"8" nillable=3D"true"=
 ma:displayName=3D"MediaServiceMetadata" ma:hidden=3D"true" ma:internalName=
=3D"MediaServiceMetadata" ma:readOnly=3D"true">
<xsd:simpleType>
<xsd:restriction base=3D"dms:Note"/>
</xsd:simpleType>
</xsd:element>
<xsd:element name=3D"MediaServiceFastMetadata" ma:index=3D"9" nillable=3D"t=
rue" ma:displayName=3D"MediaServiceFastMetadata" ma:hidden=3D"true" ma:inte=
rnalName=3D"MediaServiceFastMetadata" ma:readOnly=3D"true">
<xsd:simpleType>
<xsd:restriction base=3D"dms:Note"/>
</xsd:simpleType>
</xsd:element>
<xsd:element name=3D"MediaServiceAutoKeyPoints" ma:index=3D"10" nillable=3D=
"true" ma:displayName=3D"MediaServiceAutoKeyPoints" ma:hidden=3D"true" ma:i=
nternalName=3D"MediaServiceAutoKeyPoints" ma:readOnly=3D"true">
<xsd:simpleType>
<xsd:restriction base=3D"dms:Note"/>
</xsd:simpleType>
</xsd:element>
<xsd:element name=3D"MediaServiceKeyPoints" ma:index=3D"11" nillable=3D"tru=
e" ma:displayName=3D"KeyPoints" ma:internalName=3D"MediaServiceKeyPoints" m=
a:readOnly=3D"true">
<xsd:simpleType>
<xsd:restriction base=3D"dms:Note">
<xsd:maxLength value=3D"255"/>
</xsd:restriction>
</xsd:simpleType>
</xsd:element>
</xsd:schema>
<xsd:schema targetNamespace=3D"0ac2e3cc-46bd-4320-b2ac-d7f7d167e1a9" elemen=
tFormDefault=3D"qualified" xmlns:xsd=3D"http://www.w3.org/2001/XMLSchema" x=
mlns:xs=3D"http://www.w3.org/2001/XMLSchema" xmlns:dms=3D"http://schemas.mi=
crosoft.com/office/2006/documentManagement/types" xmlns:pc=3D"http://schema=
s.microsoft.com/office/infopath/2007/PartnerControls">
<xsd:import namespace=3D"http://schemas.microsoft.com/office/2006/documentM=
anagement/types"/>
<xsd:import namespace=3D"http://schemas.microsoft.com/office/infopath/2007/=
PartnerControls"/>
<xsd:element name=3D"SharedWithUsers" ma:index=3D"12" nillable=3D"true" ma:=
displayName=3D"Shared With" ma:internalName=3D"SharedWithUsers" ma:readOnly=
=3D"true">
<xsd:complexType>
<xsd:complexContent>
<xsd:extension base=3D"dms:UserMulti">
<xsd:sequence>
<xsd:element name=3D"UserInfo" minOccurs=3D"0" maxOccurs=3D"unbounded">
<xsd:complexType>
<xsd:sequence>
<xsd:element name=3D"DisplayName" type=3D"xsd:string" minOccurs=3D"0"/>
<xsd:element name=3D"AccountId" type=3D"dms:UserId" minOccurs=3D"0" nillabl=
e=3D"true"/>
<xsd:element name=3D"AccountType" type=3D"xsd:string" minOccurs=3D"0"/>
</xsd:sequence>
</xsd:complexType>
</xsd:element>
</xsd:sequence>
</xsd:extension>
</xsd:complexContent>
</xsd:complexType>
</xsd:element>
<xsd:element name=3D"SharedWithDetails" ma:index=3D"13" nillable=3D"true" m=
a:displayName=3D"Shared With Details" ma:internalName=3D"SharedWithDetails"=
 ma:readOnly=3D"true">
<xsd:simpleType>
<xsd:restriction base=3D"dms:Note">
<xsd:maxLength value=3D"255"/>
</xsd:restriction>
</xsd:simpleType>
</xsd:element>
</xsd:schema>
<xsd:schema targetNamespace=3D"http://schemas.openxmlformats.org/package/20=
06/metadata/core-properties" elementFormDefault=3D"qualified" attributeForm=
Default=3D"unqualified" blockDefault=3D"#all" xmlns=3D"http://schemas.openx=
mlformats.org/package/2006/metadata/core-properties" xmlns:xsd=3D"http://ww=
w.w3.org/2001/XMLSchema" xmlns:xsi=3D"http://www.w3.org/2001/XMLSchema-inst=
ance" xmlns:dc=3D"http://purl.org/dc/elements/1.1/" xmlns:dcterms=3D"http:/=
/purl.org/dc/terms/" xmlns:odoc=3D"http://schemas.microsoft.com/internal/ob=
d">
<xsd:import namespace=3D"http://purl.org/dc/elements/1.1/" schemaLocation=
=3D"http://dublincore.org/schemas/xmls/qdc/2003/04/02/dc.xsd"/>
<xsd:import namespace=3D"http://purl.org/dc/terms/" schemaLocation=3D"http:=
//dublincore.org/schemas/xmls/qdc/2003/04/02/dcterms.xsd"/>
<xsd:element name=3D"coreProperties" type=3D"CT_coreProperties"/>
<xsd:complexType name=3D"CT_coreProperties">
<xsd:all>
<xsd:element ref=3D"dc:creator" minOccurs=3D"0" maxOccurs=3D"1"/>
<xsd:element ref=3D"dcterms:created" minOccurs=3D"0" maxOccurs=3D"1"/>
<xsd:element ref=3D"dc:identifier" minOccurs=3D"0" maxOccurs=3D"1"/>
<xsd:element name=3D"contentType" minOccurs=3D"0" maxOccurs=3D"1" type=3D"x=
sd:string" ma:index=3D"0" ma:displayName=3D"Content Type"/>
<xsd:element ref=3D"dc:title" minOccurs=3D"0" maxOccurs=3D"1" ma:index=3D"4=
" ma:displayName=3D"Title"/>
<xsd:element ref=3D"dc:subject" minOccurs=3D"0" maxOccurs=3D"1"/>
<xsd:element ref=3D"dc:description" minOccurs=3D"0" maxOccurs=3D"1"/>
<xsd:element name=3D"keywords" minOccurs=3D"0" maxOccurs=3D"1" type=3D"xsd:=
string"/>
<xsd:element ref=3D"dc:language" minOccurs=3D"0" maxOccurs=3D"1"/>
<xsd:element name=3D"category" minOccurs=3D"0" maxOccurs=3D"1" type=3D"xsd:=
string"/>
<xsd:element name=3D"version" minOccurs=3D"0" maxOccurs=3D"1" type=3D"xsd:s=
tring"/>
<xsd:element name=3D"revision" minOccurs=3D"0" maxOccurs=3D"1" type=3D"xsd:=
string">
<xsd:annotation>
<xsd:documentation>
                        This value indicates the number of saves or revisio=
ns. The application is responsible for updating this value after each revis=
ion.
                    </xsd:documentation>
</xsd:annotation>
</xsd:element>
<xsd:element name=3D"lastModifiedBy" minOccurs=3D"0" maxOccurs=3D"1" type=
=3D"xsd:string"/>
<xsd:element ref=3D"dcterms:modified" minOccurs=3D"0" maxOccurs=3D"1"/>
<xsd:element name=3D"contentStatus" minOccurs=3D"0" maxOccurs=3D"1" type=3D=
"xsd:string"/>
</xsd:all>
</xsd:complexType>
</xsd:schema>
<xs:schema targetNamespace=3D"http://schemas.microsoft.com/office/infopath/=
2007/PartnerControls" elementFormDefault=3D"qualified" attributeFormDefault=
=3D"unqualified" xmlns:pc=3D"http://schemas.microsoft.com/office/infopath/2=
007/PartnerControls" xmlns:xs=3D"http://www.w3.org/2001/XMLSchema">
<xs:element name=3D"Person">
<xs:complexType>
<xs:sequence>
<xs:element ref=3D"pc:DisplayName" minOccurs=3D"0"></xs:element>
<xs:element ref=3D"pc:AccountId" minOccurs=3D"0"></xs:element>
<xs:element ref=3D"pc:AccountType" minOccurs=3D"0"></xs:element>
</xs:sequence>
</xs:complexType>
</xs:element>
<xs:element name=3D"DisplayName" type=3D"xs:string"></xs:element>
<xs:element name=3D"AccountId" type=3D"xs:string"></xs:element>
<xs:element name=3D"AccountType" type=3D"xs:string"></xs:element>
<xs:element name=3D"BDCAssociatedEntity">
<xs:complexType>
<xs:sequence>
<xs:element ref=3D"pc:BDCEntity" minOccurs=3D"0" maxOccurs=3D"unbounded"></=
xs:element>
</xs:sequence>
<xs:attribute ref=3D"pc:EntityNamespace"></xs:attribute>
<xs:attribute ref=3D"pc:EntityName"></xs:attribute>
<xs:attribute ref=3D"pc:SystemInstanceName"></xs:attribute>
<xs:attribute ref=3D"pc:AssociationName"></xs:attribute>
</xs:complexType>
</xs:element>
<xs:attribute name=3D"EntityNamespace" type=3D"xs:string"></xs:attribute>
<xs:attribute name=3D"EntityName" type=3D"xs:string"></xs:attribute>
<xs:attribute name=3D"SystemInstanceName" type=3D"xs:string"></xs:attribute>
<xs:attribute name=3D"AssociationName" type=3D"xs:string"></xs:attribute>
<xs:element name=3D"BDCEntity">
<xs:complexType>
<xs:sequence>
<xs:element ref=3D"pc:EntityDisplayName" minOccurs=3D"0"></xs:element>
<xs:element ref=3D"pc:EntityInstanceReference" minOccurs=3D"0"></xs:element>
<xs:element ref=3D"pc:EntityId1" minOccurs=3D"0"></xs:element>
<xs:element ref=3D"pc:EntityId2" minOccurs=3D"0"></xs:element>
<xs:element ref=3D"pc:EntityId3" minOccurs=3D"0"></xs:element>
<xs:element ref=3D"pc:EntityId4" minOccurs=3D"0"></xs:element>
<xs:element ref=3D"pc:EntityId5" minOccurs=3D"0"></xs:element>
</xs:sequence>
</xs:complexType>
</xs:element>
<xs:element name=3D"EntityDisplayName" type=3D"xs:string"></xs:element>
<xs:element name=3D"EntityInstanceReference" type=3D"xs:string"></xs:elemen=
t>
<xs:element name=3D"EntityId1" type=3D"xs:string"></xs:element>
<xs:element name=3D"EntityId2" type=3D"xs:string"></xs:element>
<xs:element name=3D"EntityId3" type=3D"xs:string"></xs:element>
<xs:element name=3D"EntityId4" type=3D"xs:string"></xs:element>
<xs:element name=3D"EntityId5" type=3D"xs:string"></xs:element>
<xs:element name=3D"Terms">
<xs:complexType>
<xs:sequence>
<xs:element ref=3D"pc:TermInfo" minOccurs=3D"0" maxOccurs=3D"unbounded"></x=
s:element>
</xs:sequence>
</xs:complexType>
</xs:element>
<xs:element name=3D"TermInfo">
<xs:complexType>
<xs:sequence>
<xs:element ref=3D"pc:TermName" minOccurs=3D"0"></xs:element>
<xs:element ref=3D"pc:TermId" minOccurs=3D"0"></xs:element>
</xs:sequence>
</xs:complexType>
</xs:element>
<xs:element name=3D"TermName" type=3D"xs:string"></xs:element>
<xs:element name=3D"TermId" type=3D"xs:string"></xs:element>
</xs:schema>
</ct:contentTypeSchema>
------=_NextPart_01D75BA1.F8BC9610
Content-Location: file:///C:/C467A08E/Ovaleap_clean_files/props002.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"no"?>
<ds:datastoreItem ds:itemID=3D"{A1CE8983-EF9F-4105-9237-E2365E87E794}" xmln=
s:ds=3D"http://schemas.openxmlformats.org/officeDocument/2006/customXml"><d=
s:schemaRefs><ds:schemaRef ds:uri=3D"http://schemas.microsoft.com/office/20=
06/metadata/contentType"/><ds:schemaRef ds:uri=3D"http://schemas.microsoft.=
com/office/2006/metadata/properties/metaAttributes"/><ds:schemaRef ds:uri=
=3D"http://www.w3.org/2001/XMLSchema"/><ds:schemaRef ds:uri=3D"http://schem=
as.microsoft.com/office/2006/metadata/properties"/><ds:schemaRef ds:uri=3D"=
a6a35199-84b7-4ca5-aa1c-39e9ca4c46ff"/><ds:schemaRef ds:uri=3D"0ac2e3cc-46b=
d-4320-b2ac-d7f7d167e1a9"/><ds:schemaRef ds:uri=3D"http://schemas.microsoft=
.com/office/2006/documentManagement/types"/><ds:schemaRef ds:uri=3D"http://=
schemas.microsoft.com/office/infopath/2007/PartnerControls"/><ds:schemaRef =
ds:uri=3D"http://schemas.openxmlformats.org/package/2006/metadata/core-prop=
erties"/><ds:schemaRef ds:uri=3D"http://purl.org/dc/elements/1.1/"/><ds:sch=
emaRef ds:uri=3D"http://purl.org/dc/terms/"/><ds:schemaRef ds:uri=3D"http:/=
/schemas.microsoft.com/internal/obd"/></ds:schemaRefs></ds:datastoreItem>
------=_NextPart_01D75BA1.F8BC9610
Content-Location: file:///C:/C467A08E/Ovaleap_clean_files/item0003.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"utf-8"?><p:properties xmlns:p=3D"http://s=
chemas.microsoft.com/office/2006/metadata/properties" xmlns:xsi=3D"http://w=
ww.w3.org/2001/XMLSchema-instance" xmlns:pc=3D"http://schemas.microsoft.com=
/office/infopath/2007/PartnerControls"><documentManagement/></p:properties>
------=_NextPart_01D75BA1.F8BC9610
Content-Location: file:///C:/C467A08E/Ovaleap_clean_files/props004.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"no"?>
<ds:datastoreItem ds:itemID=3D"{48CFDC3D-7692-4091-ADB6-F576A7640E8E}" xmln=
s:ds=3D"http://schemas.openxmlformats.org/officeDocument/2006/customXml"><d=
s:schemaRefs><ds:schemaRef ds:uri=3D"http://schemas.microsoft.com/office/20=
06/metadata/properties"/><ds:schemaRef ds:uri=3D"http://schemas.microsoft.c=
om/office/infopath/2007/PartnerControls"/></ds:schemaRefs></ds:datastoreIte=
m>
------=_NextPart_01D75BA1.F8BC9610
Content-Location: file:///C:/C467A08E/Ovaleap_clean_files/item0005.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?mso-contentType?><FormTemplates xmlns=3D"http://schemas.microsoft.com/sha=
repoint/v3/contenttype/forms"><Display>DocumentLibraryForm</Display><Edit>D=
ocumentLibraryForm</Edit><New>DocumentLibraryForm</New></FormTemplates>
------=_NextPart_01D75BA1.F8BC9610
Content-Location: file:///C:/C467A08E/Ovaleap_clean_files/props006.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"no"?>
<ds:datastoreItem ds:itemID=3D"{38ABA178-C3C2-4E03-9F80-738EA413A030}" xmln=
s:ds=3D"http://schemas.openxmlformats.org/officeDocument/2006/customXml"><d=
s:schemaRefs><ds:schemaRef ds:uri=3D"http://schemas.microsoft.com/sharepoin=
t/v3/contenttype/forms"/></ds:schemaRefs></ds:datastoreItem>
------=_NextPart_01D75BA1.F8BC9610
Content-Location: file:///C:/C467A08E/Ovaleap_clean_files/themedata.thmx
Content-Transfer-Encoding: base64
Content-Type: application/vnd.ms-officetheme
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------=_NextPart_01D75BA1.F8BC9610
Content-Location: file:///C:/C467A08E/Ovaleap_clean_files/colorschememapping.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"yes"?>
<a:clrMap xmlns:a=3D"http://schemas.openxmlformats.org/drawingml/2006/main"=
 bg1=3D"lt1" tx1=3D"dk1" bg2=3D"lt2" tx2=3D"dk2" accent1=3D"accent1" accent=
2=3D"accent2" accent3=3D"accent3" accent4=3D"accent4" accent5=3D"accent5" a=
ccent6=3D"accent6" hlink=3D"hlink" folHlink=3D"folHlink"/>
------=_NextPart_01D75BA1.F8BC9610
Content-Location: file:///C:/C467A08E/Ovaleap_clean_files/image001.png
Content-Transfer-Encoding: base64
Content-Type: image/png
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------=_NextPart_01D75BA1.F8BC9610
Content-Location: file:///C:/C467A08E/Ovaleap_clean_files/header.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="windows-1252"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-125=
2">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 15">
<meta name=3DOriginator content=3D"Microsoft Word 15">
<link id=3DMain-File rel=3DMain-File href=3D"../Ovaleap_clean.htm">
<![if IE]>
<base href=3D"file:///C:/C467A08E/Ovaleap_clean_files/header.htm"
id=3D"webarch_temp_base_tag">
<![endif]><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext=3D"edit" spidmax=3D"2049"/>
</xml><![endif]-->
</head>

<body lang=3DEN-US link=3Dblue vlink=3Dpurple>

<div style=3D'mso-element:footnote-separator' id=3Dfs>

<p class=3DMsoNormal><span lang=3DEN-GB><span style=3D'mso-special-characte=
r:footnote-separator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1 width=3D"33%">

<![endif]></span></span></p>

</div>

<div style=3D'mso-element:footnote-continuation-separator' id=3Dfcs>

<p class=3DMsoNormal><span lang=3DEN-GB><span style=3D'mso-special-characte=
r:footnote-continuation-separator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1>

<![endif]></span></span></p>

</div>

<div style=3D'mso-element:endnote-separator' id=3Des>

<p class=3DMsoNormal><span lang=3DEN-GB><span style=3D'mso-special-characte=
r:footnote-separator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1 width=3D"33%">

<![endif]></span></span></p>

</div>

<div style=3D'mso-element:endnote-continuation-separator' id=3Decs>

<p class=3DMsoNormal><span lang=3DEN-GB><span style=3D'mso-special-characte=
r:footnote-continuation-separator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1>

<![endif]></span></span></p>

</div>

<div style=3D'mso-element:footer' id=3Df1>

<p class=3DMsoFooter align=3Dcenter style=3D'margin-right:4.8pt;text-align:=
center;
tab-stops:28.35pt center 3.15in right 415.3pt 446.55pt'><!--[if supportFiel=
ds]><span
lang=3DEN-GB><span style=3D'mso-element:field-begin'></span><span
style=3D'mso-spacerun:yes'></span>EQ </span><![endif]--><!--[if supportFie=
lds]><span
lang=3DEN-GB><span style=3D'mso-element:field-end'></span></span><![endif]-=
-><!--[if supportFields]><span
class=3DMsoPageNumber><span lang=3DEN-GB style=3D'font-family:"Arial",sans-=
serif'><span
style=3D'mso-element:field-begin'></span>PAGE<span style=3D'mso-spacerun:ye=
s'>
</span><span style=3D'mso-element:field-separator'></span></span></span><![=
endif]--><span
class=3DMsoPageNumber><span lang=3DEN-GB style=3D'font-family:"Arial",sans-=
serif'>4</span></span><!--[if supportFields]><span
class=3DMsoPageNumber><span lang=3DEN-GB style=3D'font-family:"Arial",sans-=
serif'><span
style=3D'mso-element:field-end'></span></span></span><![endif]--></p>

</div>

<div style=3D'mso-element:footer' id=3Dff1>

<p class=3DMsoFooter align=3Dcenter style=3D'margin-right:4.8pt;text-align:=
center;
tab-stops:28.35pt center 3.15in right 415.3pt 446.55pt'><!--[if supportFiel=
ds]><span
lang=3DEN-GB><span style=3D'mso-element:field-begin'></span><span
style=3D'mso-spacerun:yes'></span>EQ </span><![endif]--><!--[if supportFie=
lds]><span
lang=3DEN-GB><span style=3D'mso-element:field-end'></span></span><![endif]-=
-><!--[if supportFields]><span
class=3DMsoPageNumber><span lang=3DEN-GB style=3D'font-family:"Arial",sans-=
serif'><span
style=3D'mso-element:field-begin'></span>PAGE<span style=3D'mso-spacerun:ye=
s'>
</span><span style=3D'mso-element:field-separator'></span></span></span><![=
endif]--><span
class=3DMsoPageNumber><span lang=3DEN-GB style=3D'font-family:"Arial",sans-=
serif'>1</span></span><!--[if supportFields]><span
class=3DMsoPageNumber><span lang=3DEN-GB style=3D'font-family:"Arial",sans-=
serif'><span
style=3D'mso-element:field-end'></span></span></span><![endif]--></p>

</div>

</body>

</html>

------=_NextPart_01D75BA1.F8BC9610
Content-Location: file:///C:/C467A08E/Ovaleap_clean_files/filelist.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml; charset="utf-8"

<xml xmlns:o=3D"urn:schemas-microsoft-com:office:office">
 <o:MainFile HRef=3D"../Ovaleap_clean.htm"/>
 <o:File HRef=3D"item0001.xml"/>
 <o:File HRef=3D"props002.xml"/>
 <o:File HRef=3D"item0003.xml"/>
 <o:File HRef=3D"props004.xml"/>
 <o:File HRef=3D"item0005.xml"/>
 <o:File HRef=3D"props006.xml"/>
 <o:File HRef=3D"themedata.thmx"/>
 <o:File HRef=3D"colorschememapping.xml"/>
 <o:File HRef=3D"image001.png"/>
 <o:File HRef=3D"header.htm"/>
 <o:File HRef=3D"filelist.xml"/>
</xml>
------=_NextPart_01D75BA1.F8BC9610--
